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RÉSUMÉ 
TRF2: A new target for telomere dysregulation in human lymphoid cells 
Par 
Joannie St-Germain du Programme de Microbiologie 
Me ́moire pre ́sente ́ à la Faculte ́ de me ́decine et des sciences de la sante ́ en vue de l’obtention 
du diplo ̂me de mai ̂tre ès sciences (M.Sc) en microbiologie, Faculte ́ de me ́decine et sciences 
de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, JIH 5N4 
 LMP1 est une protéine oncogène qui est observée dans les cellules tumorales dans le 
lymphome de Hodgkin associé au virus d'Epstein-Barr (EBV). LMP1 est responsable de 
l'interaction et / ou de l'interférence avec plusieurs voies de signalisation. Certaines de ces voies 
finiront par affecter l'activité transcriptionnelle de nombreux gènes en activant et en réprimant 
leurs promoteurs. Dans les cellules de lymphome hodgkinien EBV-négatives et EBV-positives, 
des expériences antérieures ont découverts des fusions-extrémitées chromosomiques, des 
translocations, des duplications chromosomiques et un dysfonctionnement des télomères. Le 
complexe Shelterin, composé des six sous-unités TRF1, TRF2, RAP1, TIN2, POT1 et TPP1, est 
associé à la formation de la structure de la boucle T-loop au niveau des télomères, formant ainsi 
un embout pour les chromosomes. Notre laboratoire a montré que l'expression de LMP1 induit 
une régulation négative des composants de Shelterin TRF1, TRF2 et POT1 au niveau 
transcriptionnel. Dans le complexe Shelterin, le TRF2 s'est avéré être la principale protéine 
affectée par l'induction de LMP1. Il a été montré que lorsque la protéine TRF2 conduite par myc 
est réintégrée dans une lignée cellulaire exprimant la protéine oncogène LMP1, cette LMP1 n'a 
plus d'effet sur sa régulation. Mon projet de maîtrise visait à comprendre comment LMP1 régule 
TRF2 au niveau de son promoteur. Notre hypothèse est que LMP1 interfère avec TRF2 au 
niveau du promoteur puisque les niveaux d'ARN de TRF2 sont réversibles lorsque LMP1 est 
supprimée. Plusieurs constructions de promoteurs de TRF2 fusionnées avec un gène rapporteur 
GFP ont été introduites dans une lignée cellulaire LMP1-tet-OFF et le niveau d'expression du 
gène rapporteur a été analysé par Western blot. Par cartographie appropriée de la région 
promotrice, un fragment de 30 pb du promoteur TRF2 a été identifié jouant un rôle central dans 
sa régulation. En utilisant la sequence du promoteur de 30 pb, une sonde radiomarquée a été 
créer. Un EMSA a été réalisé avec des extraits nucléaires provenant de cellules qui ont été 
induites ou non induites par LMP1. Les résultats révèlent des bandes distinctes et spécifiques 
pour des extraits nucléaires induits par LMP1 et non induits par LMP1 in vitro. Un séquençage 
de l'ARN avec un extrait cellulaire total a été réalisé pour obtenir des données sur les gènes qui 
sont régulés à la baisse et régulés à la hausse en présence de LMP1. Cela a été fait pour 
déterminer la composition dynamique cellulaire en l'absence et la présence de LMP1. Avec ces 
nouvelles données, une région spécifique sur le promoteur de TRF2 pour la régulation a été 
analysée par chromatographie d'affinité d'ADN et spectrométrie de masse. La découverte de 
protéines régulatrices du promoteur TRF2 aura un grand impact sur la compréhension des 
mécanismes régulateurs en jeu pour l'abondance de TRF2 in vivo. 
Mots Clés: TRF2, LMP1, Promoteur, régulation négative 
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SUMMARY 
 
 LMP1 is an oncogenic protein that is observed in tumor cells of Epstein-Barr virus 
(EBV)-associated Hodgkin’s lymphoma. LMP1 is responsible for interacting and/or interfering 
with multiple signaling pathways. At least some of those pathways will eventually affect 
transcriptional activity on many genes by activating and repressing their promoters. In EBV-
negative as well as EBV-positive Hodgkin lymphoma cells, previous experiments uncovered 
chromosomal end-fusions, translocations, chromosomal duplications and telomere dysfunction. 
The Shelterin complex, consisting of the six subunits TRF1, TRF2, RAP1, TIN2, POT1 and 
TPP1, is associated with the formation of the T-loop structure at telomeres, thus forming an end 
cap for chromosomes. Our lab showed that expression of LMP1 induces a downregulation of the 
Shelterin components TRF1, TRF2 and POT1 at the transcriptional level. In the Shelterin 
complex, TRF2 was found to be the major protein affected by the induction of LMP1.  
 
 It was shown that when a myc-driven TRF2 is reintegrated into a cell line expressing 
LMP1 oncogenic protein, that LMP1 had no longer effect on its regulation. My master’s project 
focused on understanding how LMP1 regulates the TRF2 at its promoter level. Our hypothesis is 
that LMP1 interferes with TRF2 at the promoter level since TRF2 RNA levels are reversible 
when LMP1 is suppressed. Several TRF2 promoter constructs fused with a GFP reporter gene 
were introduced into a LMP1-tet-OFF cell line and reporter gene expression level were 
monitored using Western blot. In that way, a LMP1-induced transcriptional shutdown could be 
documented. By appropriate mapping of the promoter region, a 30bp fragment of the TRF2 
promoter was identified to play a pivotal role in this regulation. Using this 30bp as a dsDNA 
radio-labelled probe, EMSA was performed with nuclear extracts from cells that were induced or 
uninduced to express LMP1. The results reveal distinct and specific bands for LMP1-induced 
and LMP1-uninduced nuclear extracts in vitro. An RNA seq on the total cell extract was 
performed to obtain data of the genes that are downregulated and upregulated in the prescence of 
LMP1. This was done to determine the cellular dynamic composition in the absence and 
presence of LMP1-induction. These new data outline a specific region on the promoter of TRF2 
for regulation that was analyzed by DNA affinity chromatography and mass spectrometry. The 
finding of regulator proteins of the TRF2 promoter will have great impact in understanding the 
regulatory mechanisms at play for TRF2 abundance in vivo.  
 
Keywords: TRF2, LMP1, GFP, Promoter Regulation, Downregulation 
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Introduction 
 
 The goal of this study is to understand the impact of LMP1 on telomeres, more 
specifically, the telomeric protein TRF2, in the context of Hodgkin Lymphoma (HL). The study 
will focus on TRF2’s promoter, and the regulation thereof in the context of a virus-associated 
cancer. 
 
Importance of Telomere Function and the Shelterin Complex 
 
Telomeres are unique structures found at the physical ends of linear eukaryotic 
chromosomes, which have multiple functions in preserving chromosomal stability, including 
protecting the ends of chromosomes from degradation and end to end fusion (Bailey & 
Murname, 2006). Telomeric functions depend on three important factors: telomeric DNA, the 
shelterin complex and telomerase. In humans and mice, the telomeric ends are composed of 2-30 
kb of double-stranded TTAGGG repeats with the termini carrying a long 75-200 nt single-
stranded overhang (Figure 1). The telomeric DNA is protected by the shelterin complex, which is 
comprised of several specific proteins that either bind telomeric DNA directly or are associated 
with telomeric chromatin (Maciejowski & de Lange, 2017). More specifically, the shelterin 
complex consists of the proteins TRF1, TRF2, POT1, TINT1/PTOP/PIPI (TPPI), RAP1, and 
TIN2 (Figure 1) (Palm & de Lange, 2008).  
 
 
Figure 1: Telomeric structure.  
A protein complex called shelterin forms the constitutive telomere architecture that is required 
for vital telomere function. The shelterin complex consists of six proteins, TRF1, TRF2, TIN2, 
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Rap1, TPP1 and POT1. TRF1 and TRF2 directly bind double strand telomeric DNA with high 
affinity, TIN2 binds both TRF1 and TRF2 to stabilize their association; Rap1 interacts with 
TRF2 and improves its selective binding to telomeric DNA while POT1 binds single strand 
telomere DNA. The 3’ single strand overhang facilitates T-loop formation (Adapted from 
Maciejowski & de Lange, 2017).  
 
The shelterin complex is recruited to the telomeres through TRF1 and TRF2 binding to 
the double-strand telomeric DNA and TIN2 that serves as a linker between the two homodimers. 
POT1 binds to the single stranded DNA and is linked to TRF1 and TRF2 through TPP1, which is 
associated with TIN2 (Maciejowski & de Lange, 2017).  
The six components of the shelterin complex are responsible for formation of the t-loop 
structure (Griffith et al., 1999) which protects telomeres by repressing the DNA damage 
response (DDR) and repair pathways: the ATM kinase signaling pathway and non-homologous 
end joining (NHEJ) (Benarroch-Popivker et al., 2016). T-loops are formed through strand 
invasion of the single-stranded (ss) 3’ telomeric overhang into the double-stranded (ds) part of 
the telomere, thereby forming a three-way junction at the base of the t-loop (Schmutz, Timashev, 
Patel & de Lange, 2017). This way, a telomeric DNA end is shielded from the DDR factors. The 
3’ overhang required for the t-loop formation is made by exonucleolytic degradation of the 5’ 
ends of the telomeres, which therefore, shortens telomeres by about 50 bp per cell division (de 
Lange, 2005). Telomere shortening can be counteracted by telomerase which adds telomeric 
repeats at the end of the chromosome (Greider & Blackburn, 1987). Telomerase is a reverse 
transcriptase that synthesizes telomeric DNA using the integral RNA as the template and the 
3’end of the telomere as the primer (Chan & Blackburn, 2002). Human telomerase is composed 
of a catalytic subunit TERT, an RNA component TERC and multiple accessory factors required 
for the activity of telomerase and its recruitment to telomeres (Cohen et al., 2007). During human 
development, telomerase will become deactivated through the downregulation of TERT (Holysz, 
Lipinska, Paszel-Jaworska & Rubis, 2013). As a result; somatic cells will undergo telomere 
shortening after each cellular division (Maciejowski & de Lange, 2017). This process of 
telomeric shortening will lead to the loss of telomeric DNA, chromosomal deprotection and 
activation of DDR pathways, which in turn leads to cell cycle arrest, senescence or apoptosis 
(Oeseburg, de Boer, van Gilst & van der Harst, 2009). Unlike normal cells, cancer cells will be 
under constant stress such as oncogenic stress, genomic instability and activation of apoptosis 
pathways. However, these cells escape apoptosis via genetic inactivation of certain pro-apoptotic 
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genes such as inactivation of BH3-only or caspase genes (Boyd et al., 1995). As a result, many 
cancer cells accumulate chromosomal abnormalities that are the direct result of telomere 
dysfunction due to inhibition of apoptosis (Mai & Garini, 2005).  
TRF2 is the main shelterin component required for proper configuration of the telomeric 
t-loop, repression of DNA damage repair mechanisms at telomeres, and hence, protection of 
telomeres from fusions during cellular division. Deletion of the TRF2 protein has been shown to 
lead to chromosomal end fusion, DNA bridges, lagging chromosomes and giant, dicentric 
chromosomes during metaphase and anaphase (Figure 2) (van Steensel, Smogorzewska & de 
Lange, 1998; de Lange, 2005). This shows the importance that the shelterin complex plays in 
telomeric integrity and genome stability overall. 
 
Figure 2: Cellular effects of TRF2 mutations. 
a) Metaphase chromosomal spread, b) Metaphase chromosomal spread with removal of TRF2 by 
shRNA displaying DNA fusion, c) and d) Anaphase cells displaying TRF2 mutant missing its 
Myb domain induced bridges and lagging chromosomal in which the DNA was stained with 
DAPI (Adapted from van Steensel et al., 1998, Rai, Chen, Lei & Chang, 2016) 
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Telomere Integrity and Cancer 
 
 Due to the lack of telomerase activity in somatic cells, telomeres will shorten with each 
cellular division (Watson, 1972). This is a consequence of the telomeric end replication problem. 
In eukaryotes, DNA replication occurs via the leading and lagging strand synthesis. The leading 
strand is replicated in a continuous fashion by extension of a single RNA primer. The opposite 
lagging strand is replicated in short sections called Okazaki fragments and therefore requires 
multiple RNA primers. (Badaracco, Bianchi, Valsasnini, Magn & Plevani, 1985; Frick & 
Richardson, 2001). These primers are subsequently substituted with DNA due to the extension of 
the downstream Okazaki fragment (Balakrishman & Bambara, 2013). When the terminal RNA 
primer at the telomeric 3’ end is removed, it cannot be replaced by DNA resulting in a short 3’-
overhang. This process will be repeated in every consecutive round of replication, leading to the 
decrease in telomere length. Eventually, telomeres will become too short for shelterin proteins to 
bind, causing a loss of telomere protection and activation of DDR signaling pathway (Harley, 
Futcher & Greider, 1990). The DDR will in turn trigger activation of tumor suppressor 
mechanisms such as ATM, NHEJ, p53 and p16, driving cells into G1 arrest and inducing 
senescence or apoptosis (Figure 3) (d’Adda di Fagagna et al., 2003). Therefore, these tumor 
suppressor mechanisms are in place to eliminate and prevent the growth of cancerous cells (Yao 
& Dai, 2014).   
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Figure 3: Telomeric integrity and role of the shelterin complex during cellular divisions. 
Telomeres are bound by the shelterin complex and with each cellular division, telomeres get 
shorter. If telomeres get too short, the shelterin complex will not bind, causing telomeric 
deprotection and activating the DDR pathway forcing the cells into senescence or apoptosis 
(Adapted from Jacobs, 2013). 
 
There is a dynamic relationship between telomeres and genomic stability. The genome is 
susceptible to exogenous, endogenous and multiple other cellular processes that can compromise 
its integrity (Jackson & Bartek, 2009). Important mechanisms have been put into place to protect 
the genome from damage and instability (Nair, Shoaib & Sorensen, 2017). DDR mechanisms are 
the first responses to any genomic damage and tight regulation of these mechanisms is required 
(Ciccia & Elledge, 2010). Defects in DDR pathways such as a loss of function of p53, ataxia 
telangiectasia (ATM), or Rad3-related (ATR) kinases are associated with tumor initiation as well 
as tumor progression and metastasis (Broutas & Lieberman, 2014). Genomic and telomeric 
instability both interact closely in tumorigenesis. TRF2 mediates t-loop formation and 
maintenance, thus sequestering DDR pathways and protecting the telomeric ends from being 
processed by the NHEJ. When it comes to telomeric end deprotection due to short telomeres, the 
ATM-dependent pathway will become activated, inducing NHEJ and generating telomeric end 
fusions. However, functional DDR will drive cells into apoptosis, thus stopping propagation of 
genetically unstable cells.  On the other hand, in the absence of the  DDR pathway, cells will not 
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be forced into senescence or apoptosis but instead, will continue into division, initiating 
chromosomal instability (Figure 4) manifested by chromosomal translocations, duplications, 
chromosome loss, endomitosis and polyploidization (Davoli & de Lange, 2012). Pre-malignant 
cancer cells need to acquire a telomere maintenance mechanism during neoplastic transformation 
and for proliferation (Yakoob, Hu, Fan & Zhang, 1999). Telomerase reactivation may occur in 
late tumorigenesis as a result of ongoing genetic instability. It was recently found that a single 
nucleotide somatic mutation in the proximal promoter of telomerase reverse transcriptase 
(TERT) was enough for telomerase reactivation (Horn et al., 2013). This discovery emphasized 
the importance of promoter mutation in the progression of genomic instability in cancer 
development.  
The cell depends on the ability of the DDR checkpoint to induce cell cycle arrest when critically 
short telomere length is reached. The effectiveness of DDR can either inhibit or promote cancer. 
Therefore, short telomeres are the earliest detectable hallmark of cancer. One form of cancer in 
which short telomeres are noticeable in its early stage is Hodgkin lymphoma (Jacobs, 2013). 
 
Figure 4: Model of cancer initiation. 
Cancer development caused by mutation in the DDR pathway when short telomeres are present. 
Short telomeres will progress with each cellular division, causing chromosomal instability and 
genomic instability. Telomerase will be reactivated during late tumorigenesis. 
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Hodgkin’s Lymphoma
Senescence/Apoptosisx
Single nucleotide change
in TERT promoter
>85% Cancers have telomerase 
reactivation
DDR
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Hodgkin Lymphoma (HL)  
 
Lymphomas are a group of blood cancers that develop in the lymphatic system.  Malignant cells 
accumulate in the lymphatic system, eventually causing enlargement of the lymph nodes (Ganti, 
Albershardt, Iritani & Ruddell, 2015).  There are two types of lymphomas: the classic Hodgkin 
lymphomas (cHL) and the Non-Hodgkin-Lymphomas (NHL). The latter are divided into B-NHL 
and T-NHL (Swerdlow et al. 2016). The Hodgkin lymphomas are characterized by the 
mononuclear Hodgkin (H) cells and the diagnostic binucleated or multinucleated Reed-Sternberg 
(RS) cells. H and RS cells are often summarized as HRS cells. HRS cells do not express the 
majority of proteins proper to B-cell immunoblasts. A typical characteristic of both are Hodgkin 
mononucleated cells and multinucleated Reed-Sternberg cells, but contrary to non-Hodgkin 
lymphoma, cHL does not express the majority of proteins proper to B-cell immunoglobulins. 
Instead, they display different molecules not normally expressed by B cells (Gobbi, Ferreri, 
Ponzoni & Levis, 2013). Interestingly, in cHL several transcription factors are deregulated, but 
not in nHL. The mononucleated and multinucleated cells lack transcription factors such as 
OCT2, BOB.1 and PU.1, which are required for activation of the promoter or enhancers of 
immunoglobulin genes. These differences between the immunophenotypes and gene expression 
clearly puts Hodgkin lymphoma in a different category of lymphomas (Stein & Bob, 2009). 
Cellular Origin of B cells including HRS cells 
 
B cells are lymphocyte cells that play a crucial role in the immune system response. The 
main function of B lymphocytes is to produce specific antibodies. Their production and 
development begins by stimulation by exogenous factors such as bacteria or viruses that activate 
the production of hematopoietic stem cells in the bone marrow (Tobon, Izquierdo & Canas, 
2013). Once exiting the marrow, all B cells are morphologically similar and also referred to as 
immature B cells (Gathings, Lawton & Cooper, 1977). Immunoglobulins play a critical part in 
the immune system by recognizing and binding to particular antigens. Antibodies are a form of 
immunoglobulin secreted by B cells to bind, neutralize, and send a signal to activate other 
defenses like macrophages to destroy foreign invaders (LeBien & Tedder, 2008). These 
immature B cells only become activated once the immunoglobulin binds to an antigen. This 
antigen binding induces B cell-activation, proliferation and differentiation in secondary 
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lymphoid tissues. These dynamic changes in gene expression and immunoglobulin mutation 
happen in the germinal center follicles of secondary lymphoid organs (Küppers, 2009). The B 
cells then undergo rapid proliferation to generate a large number of cells. Subsequently, 
immunoglobulins undergo somatic hypermutation to generate high-affinity antibodies unique to 
the antigen of the foreign invaders. This biological process also has a program that eliminates B 
cells not expressing the correct antibody and forces them into apoptosis (Figure 5). Only B cells 
harboring favorable mutations with specific antibodies will undergo class-switch recombination 
and differentiate to become plasma cells or memory B cells. A large number of genes are 
involved in the regulation of proliferation, differentiation and apoptosis, and can occasionally 
become dysregulated by errors during antibody gene modifications, thus causing genomic 
alterations. A series of checkpoints normally control the B-cells’ selection for unfavorable 
mutations resulting in cellular apoptosis. In some cases, unfavorable B cells avoid apoptosis 
because of genetic modifications or due to the presence of the Epstein-Barr virus (EBV), thus 
resulting in oncogenic transformation, resulting in cancers such as Burkitt Lymphoma and 
Hodgkin Lymphoma (Klein & Dalla-Favera, 2008). In cHL the 5-year survival rate of patients 
that will become long-term survivors is 85%, but 15% of patients will die from a rapid 
reoccurrence of the disease or become resistant to drug-therapy (et al., 2011). HL is diagnosed by 
the presence of multinucleated Reed-Sternberg cells (Shanbhag & Ambinder 2018). With a 
better understanding of the processes involved in the formation of the Reed-Sternberg cells, we 
think new drug treatments for treating Hodgkin’s lymphoma may emerge.  
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Figure 5: Origin of Hodgkin and Reed-Sternberg cells.  
In the germinal center, the antigen-activated B-cells enter proliferation and somatic 
hypermutation. The somatic hypermutation will diversify B cell immunoglobulin receptors to 
adapt to the foreign invader, creating rearrangements in the immunoglobulin gene. The B-cells 
then go through antibody class switching recombination. This will allow the cells to have 
antigenic specificity with antibodies of different subtypes. The B-cells that have obtained a 
favorable rearrangement will continue to differentiate into plasma cells or memory B cells. 
Hodgkin and Reed-Sternberg cells (HRS) are cells that have acquired unfavorable 
rearrangements and should have undergone apoptosis, but because of genetic alterations or the 
presence of Epstein –Barr virus (EBV) derived proteins, they have survived (Adapted from Klein 
& Dalla-Favera, 2008). 
 
 
Origin of Reed-Sternberg cells 
 
HL is characterized by the presence of the mononuclear H cells, and bi or multinucleated 
Reed-Sternberg cells (HRS cells). It has been shown that HL cells have a large number of 
chromosomes with aberrations, genetic alterations, and chromosomal deletions (Knecht et al., 
2008). A multitude of translocations have been identified in HRS cells and their nuclear 
architecture becomes progressively more disorganized as the number of nuclei increases. As well 
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as chromosomal disorganization, HRS also have an increased number of centrosomes, defective 
spindle formation, and genomic instability. The hallmark of HRS tumor cells is telomeric 
dysfunction (Knecht, Sawan, Lichtensztejn, Z., Lichtensztejn, D. & Mai, 2010). It is the main 
mechanism through which mononucleated Hodgkin cells become multinucleated Reed-Sternberg 
cells, in which the Hodgkin cells increase the disruption of their telomeres, genomic DNA and 
dynamically progress towards becoming Reed-Sternberg cells. These multinucleated cells are 
formed by endomitosis, a process in which the cells duplicate their chromosomes but this is not 
followed by cellular division. This phenomenon is associated with disturbed cytokinesis and 
jumping translocations due to severe telomere dysfunction. Hans Knecht et al. 2008, provided a 
3D telomere analysis diagram on the transition of H to RS cells, providing a direct graphical 
demonstration for how an H cell becomes an RS cell (Figure 6). This 3D nuclear approach 
allowed the visualization of telomeric organization as the cells underwent transformation from an 
H to an RS cell. The mononucleated Hodgkin cells already have distinctive short telomeres, and 
telomere aggregates. As the cells undergo endomitosis, they will produce binucleated Reed-
Sternberg cells, with more telomeric dysfunction such as telomeric aggregates, even shorter 
telomeres and some losses of telomeric signal (Knecht et al., 2008). This progression continues 
until the cell reaches the end stage multinucleated Reed-Sternberg cell, in which the cell no 
longer duplicates its genome, possibly due to extreme telomeric dysfunction and genomic 
instability (Knecht et al., 2010). Reed-Sternberg cells indeed show little proliferative capacity, 
thus demonstrating that Hodgkin cells could be the main cells with proliferative ability and the 
main reason for the generation of these Reed-Sternberg cells (Rengstl et al., 2013). Interestingly, 
in about 40-50% of cases of HL, patient biopsies of their H and RS cells have been found to 
express the Epstein Barr virus-encoded LMP1 oncoprotein (Knecht et al., 1993). 
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Figure 6: Correlation of telomere dysfunction and of RS-cell formation.  
The model illustrates the evolution from a mononuclear H cell to a multinuclear RS cell. 3D 
reconstructed representative nuclei and their telomeres. A mononuclear H cell may either 
progress to a telomere-poor, binucleated RS cell or to a binucleated RS cell with a ‘ghost’ 
nucleus probably telomere-poor end-stage cells, or progress to a still telomere-rich, 
binucleated RS cell or large twisted H cell capable of further nuclear duplications. This may 
result in a trinuclear or tetranuclear RS cell.  Depending on the 3D configuration of telomeres 
and the number of telomere aggregates, these RS cells may or may not be able to perform 
further nuclear division, resulting in multinucleated end-stage RS cells (Adapted from Knecht 
et al., 2008). 
 
 
Pathogenic role of Epstein-Barr Virus and its trans-membrane protein called “Latent Membrane 
Protein 1” (LMP1) 
 
Epstein-Barr virus (EBV) is a gamma-herpesvirus that establishes life-long sero-
positivity and infects 90% or more of the world’s population. Most people become infected at 
some point in their childhood, with a generally asymptomatic primary infection that can become 
symptomatic in their adolescence or adulthood, causing infectious mononucleosis (Hau & Tsao, 
2017). Rarely, the disease incites a range of malignancies including nasopharyngeal carcinoma, 
lymphoproliferation disorders and Burkitt lymphoma (Kutok & Wang, 2006). In about 40% of 
cases of classical HL, the HRS cells are infected with the Epstein-Barr virus, thus indicating an 
importance of EBV in HL pathogenesis. EBV has a 170kb double-stranded DNA genome that 
forms an episome in the infected host cell, and exists as an extrachromosomal DNA wrapped 
Mononucleated 
Hodgkin Cells Binuclear Reed- 
Sternberg cells  Tetranuclear Reed- 
Sternberg cells  
End Stage Multinucleated 
Reed- Sternberg cells  
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with histones. EBV will infect epithelial cells as well as B-lymphocytes (Riley et al., 2012). 
EBV does not usually replicate in B-lymphocytes, but instead establishes a latent infection, 
which is characterized by the limited expression of a subset of virus latent genes (Babcock, 
Hochberg & Thorley-Lawson, 2000). These subsets of individualized latent genes are the three 
main viral proteins called: EBNA1 (EBV nuclear antigen), LMP1 and LMP2A (Hau & Tsao, 
2017). EBNA1 is a mandatory protein responsible for the replication of the viral genome and 
may have additional roles (Gahn & Sugden, 1995). LMP2A mimics an Ig receptor and recruits 
cytoplasmic kinases (Mancao & Hammerschmidt 2007). LMP1 is the main viral protein required 
for B cell immortalization and promotes the formation of Reed-Sternberg cells as shown by 
Knecht et al. 1999 (Figure 7). 
 
 
Figure 7: Histology of cells transfected with LMP1. 
Impact of LMP1 expression in myelomonocytic HD-MyZ cells. A) represents cells that have 
been transfected with LMP1, showing evidence of multinucleated cells or cells larger than the 
normal surrounding cells. B) Immunostaining showing LMP1 expression C) Transfection cells 
with an empty vector D) Transfection with another viral protein EBNA1 with immunostaining 
revealing no change of cell morphology. Concluding that LMP1 is the viral protein of EBV 
causative of the multinucleated cells (Adapted from Knecht et al., 1999). 
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LMP1 is the major transforming protein of EBV and also plays a crucial role in the 
pleiotropic effects on cellular phenotypes and in the maintenance of EBV-induced tumours 
(Ahsan, Kanda, Nagashima & Takada, 2005). It is the first protein being produced during EBV 
latency establishment (Dawson, Tramountanis, Eliopolis & Young, 2002). Functionally, LMP1 
resembles CD40, a member of the TNFR family, and can partially substitute for CD40 in 
vivo, providing both growth and differentiation responses in B cells (Brauninger et al., 2005). 
The LMP1 protein is a trans-membrane protein of 63 kDa and can be subdivided into three 
domains: (a) an N-terminal cytoplasmic tail (amino acids 1–23) which tethers and orientates 
the LMP1 protein to the plasma membrane; (b) six hydrophobic transmembrane loops that are 
involved in self-aggregation and oligomerization (amino acids 24–186); (c) a long C-terminal 
cytoplasmic region (amino acids 187–386) that possesses most of the molecule's signaling 
activity (Uchida et al., 1999). Two functional domains referred to as C-terminal activation 
regions 1 and 2 (CTAR1 and CTAR2) have been identified for their ability to activate the NF-
κB transcription factor pathway (Eliopoulos, 1999). This effect contributes to the many 
phenotypic consequences of LMP1 expression including the induction of various apoptosis 
inhibition pathways and cytokine genes (Figure 8) (Huen, Henderson, Croom-Carter & Rowe, 
1995). LMP1 contributes to 25% of transcriptional changes in HL cells transferase (Vockerodt 
et al., 2014). It will also modulate the expression of key tumor suppressor genes such as p53 
and contributes to cell survival by activating several pathways such as NF-kappa B (NF-kB), 
JAK/STAT, and P13L/AKT pathways (Hoesel & Schmidt, 2013; Vaysberg, Lambert, Krams & 
Martinez, 2009). It is also involved in the loss of expression in mitotic spindle formation, 
disorganizes interphase microtubules, promotes chromosome breaks, promotes cells survival 
and B cell immortalization and is involved in promoter regulation through methylation by 
DNA methyl transferase (Vockerodt, Cader, Shannon-Lowe & Murray, 2014).  Therefore, 
LMP1 contributes to cellular dysregulation and tumorigenesis. 
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Figure 8: LMP1 structure and targeted pathway.  
Expression in EBV-positive cases, contributing to NF-kB activation as it mimics an activated 
CD40 receptor which supports survival of the deregulated B lymphoma cells (Adapted from 
Brauninger et al., 2005). 
 
Epstein-Barr virus positive Hodgkin Lymphoma  
 
 The EBV-negative and EBV-positive HRS cells show a distinct somatic mutation pattern 
underlining that the EBV infection happened in a B-cell in the germinal center (Thorley-Lawson 
& Gross, 2004).  The EBV-positive HRS cells show a similar phenotype: B cell nuclear division 
becomes impossible with telomeric loss, telomeric shortening, end to end fusions and telomere-
poor or telomere-free ‘ghost’ nuclei (Knecht et al., 2010). LMP1 expression was shown to be 
associated with multinuclearity in which many of the cells resembled RS cells (Figure 9) 
(Lajoie et al., 2015). 
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Figure 9: LMP1 expression in BJAB tTa LMP1 cell line. 
A) cells without LMP1 are showing a stable percentage of bi or multinuclearity and B) cells 
expressing LMP1 showing a distinctive increase pattern of bi and multinuclearity, C) a graph 
representing the increase of multinuclearity over a period of 21 days (Adapted from Lajoie et al., 
2015). 
 
RS cells are characterized by telomeric disorganization, short telomeres and loss of total 
telomeres and same morphology can be observed in RS cells associated with LMP1. This led to 
the hypothesis that LMP1 indirectly interferes with the shelterin complex, thereby initiating the 
telomeric disruption and assisting in the formation of H and RS cells. To determine if LMP1 
expression favored the formation of multinucleated cells, Lajoie et al., 2015 used a system a tet-
off inducible LMP1 in a stable BJAB tTa LMP1 cell line lacking chromosomal translocations. 
LMP1-expressing and LMP1-suppressed BJAB tTa cells, as well as the parental BJAB tTa cell 
line not harboring the LMP1 oncogene, were analyzed over a period of 21 days for formation of 
multinucleated cells, (Figure 9 C) and the expression of key proteins of the shelterin complex at 
the transcriptional, translational, and topographic protein level. The results show that the 
telomeres and the shelterin complex are responsive to the expression of the LMP1 oncogene 
(Figure 10). 
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Figure 10: Quantitative reverse-transcriptase polymerase chain reaction analysis of the 
TRF2 mRNA upon LMP1 expression and suppression.  
The TRF2 mRNA levels (in relative units) at days 1, 3, 7, and 14 were normalized with 
expression of 3 housekeeping genes to the LMP1-suppressed cells at each time point. Yellow 
bars represent TRF2 levels when LMP1 is expressed. Burgundy bars represent TRF2 levels after 
the expression on LMP1 was suppressed at day 3 and the blue bar when level of LMP1 
suppressed at day 7 (Adapted from Lajoie et al., 2015). 
 
The results also show that LMP1 exerts profound effects on shelterin protein expression, in 
particular the TRF1, TRF2, and POT1 proteins. TRF2 levels were the most affected when LMP1 
was induced in the cells. Continuous LMP1 expression results in downregulation at the 
transcriptional level and is associated with a highly significant formation of multinucleated RS-
like cells (Lajoie et al. 2015). Given that it was previously shown that deletion of TRF2 leads to 
chromosomal end fusions, bridges, and lagging chromosomes (van Steensel et al., 1998), it was 
suspected that it might be one of the key players for producing the multinucleated cells. To test 
this hypothesis, a myc-TRF2 driven by a CMV promoter was introduced into the BJABJ-tTA 
LMP1 cell line with and without the induction of LMP1 to verify if the multinucleation would 
still proceed. The independent expression of CMV-myc-TRF2 blocked the formation of 
multinucleated RS (Figure 11) thus showing that LMP1 appears to mimic the signaling pathway 
involved in the pathogenesis of the EBV-negative HL. Importantly, LMP1 induced changes in 
the expression of several shelterin proteins that act as gatekeepers for correct DNA replication 
telomeric integrity. These findings may eventually lead to the unraveling of the molecular 
pathogenesis of EBV-associated HL (Lajoie et al., 2015). 
 
mRNA levels (RU) 
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Figure 11: LMP1 increases multinucleation but expression of mycTRF2 eradicates 
multinuclearity in the presence of LMP1  
Count of multinucleated cells in BJAB tTA and BJAB tTA LMP1 in the presence or absence of 
tetracycline over a period of 10 days (Adapted from Lajoie et al, 2015). 
 
Hypothesis and Objectives 
 
 The ability of EBV viral proteins such as LMP1 to induce phenotypic changes when 
expressed individually in human B–cells lines implies that these viral proteins are key effectors 
in the immortalization process and changes of gene expression. No differences in clinical 
presentation are found between EBV negative and positive forms of HL, suggesting a common 
mechanism in pathogenesis. TRF2 appears to be a major target of LMP1 but is not the sole 
downstream effector of telomere dysfunction in this setting, therefore the hypothesis of this 
project is that LMP1 indirectly interferes with TRF2 at the promoter/gene level, since TRF2 
levels are reversible upon removal of LMP1 (Figure 10, Figure 12). The objective of this project 
is to firstly determine if LMP1 indirectly interferes with the TRF2 promoter since LMP1 did not 
affect the regulation of pCMV-TRF2 when transfected into the BJAB tTa induced with LMP1. 
Secondly, we hope to identify a smaller region within the TRF2 promoter in which potential 
inhibitors or missing activators are affecting TRF2 levels. 
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Figure 12: Schematic representation of LMP1 possibly interfering with TRF2 at its 
promoter region.  
The hypothesis is that LMP1 indirectly downregulates TRF2 at the promoter, and when LMP1 is 
removed or stopped by the addition of Tetracycline, TRF2 basal levels are restored.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TRF2
Normal Basal TRF2 
LMP1
TRF2
Downregulation of TRF2
Removal of LMP1 (+Tet) restoresbasal
TRF2 levels
LMP1-induction (-Tet) produces a cascade 
of pathways leading to TRF2 
downregulation 
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Materials and Methods 
 
 
Cell Lines 
 
The cell lines BJAB tTA and BJAB tTA LMP1 were obtained from Martin Rowe (Floettmann, 
Ward, Rickinson & Rowe, 1996). The BJAB cell line is an EBV-negative B lymphoma that 
shares many characteristics with typical Burkitt lymphoma except that it lacks the chromosomal 
translocation that is a marker for Burkitt Lymphoma diagnosis (Menezes, Leibold, Klein & 
Clements, 1975). Both cell lines have been integrated with a Tet-off system. The Tet-off system 
was made by adding a C-terminal portion of VP16 fused to the tetR-gene and is flanked 
upstream by a PCMV and downstream by the SV40 poly(A) site. This tetR with the activation 
domain VP16 from HSV (Herpes simplex virus) generates a specific transactivator by binding to 
tetO sequences. Transactivation is prevented by the addition of the antibiotic tetracycline. When 
bound to TetO-placed upstream promoters, tTA (tetracycline-controlled transactivator) activates 
transcription (Gossen & Bujard, 1992). 
 
BJAB tTA is the parental cell line of BJAB tTA LMP1, integrated with the plasmid pUHD15-1 
that has been modified by insertion of a hygromycin-resistance gene to give rise to pJEF-3, 
which expresses the tTA system. The tTA system is derived from fusion of two genes: tetR and a 
VP16 transactivator that is continuously expressed from a cytomegalovirus immediate-
early enhancer (CMV/IE) promoter on the pJEF3 plasmid. The TET repressor (tetR) protein is a 
transcription repressor from Escherichia coli (E. coli) and the vP16 domain transforms the tetR 
repressor into an activator (Floettmann et al., 1996). This will allow us control the gene 
expression by the addition or removal of Tetracycline. BJAB tTA LMP1 is the BJAB tTA cell 
line that has been integrated with not only pJEF-3 but also a plasmid called pJEF-6 containing a 
transactivator response element (TRE) that is located in front of the cytomegalovirus promoter 
(PCMV) that controls the expression of the gene producing the LMP1 protein to produce stable 
clones requiring binding of tTA to a 5’regulatory region containing promoter (Kim et al., 2009). 
(Figure 13) 
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Figure 13: Tet-Off system.  
The tTA binds specifically to the tet-Off (tetO) operator sequences upstream of the CMV 
promoter (P CMV). The tetO/P CMV represents the tetracycline response element (TRE) (Lajoie 
et al., 2015) 
 
 
Manipulation of cell lines 
 
Passage of Suspension Cultures 
 
Replacement of growth medium is carried out every 3 days by directly diluting the cells in the 
culture flask for further growth or withdrawing a portion of the cells and diluting the remaining 
cells down to a seeding density appropriate for the cell line. This keeps the cell density in the 
range of continuous growth until used for a transfection experiment. Transfection requires 4 
million cells per sample. Cells are always incubated at 37°C and 5% CO2. 
 
Cryopreservation of Mammalian cells 
 
Mammalian cells are cryopreserved to avoid loss by contamination, to minimize genetic change, 
and to avoid aging or transformation of cell lines. Cells are counted in order to have 2 million 
cells per vial. The cells are centrifuged at 600 rpm for 5 minutes to pellet cells. Supernatant is 
then removed and the pellet is washed twice with 1X PBS. The cells are then resuspended in 
freezing medium composed of 90% RPMI-1640 and 10% DMSO and aliquoted into cryogenic 
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storage vials. The vials are placed at -20°C for 2-3 hours then placed at -80°C overnight before 
being transferred into a liquid nitrogen tank for storage (Freshney, 1994). 
 
Thawing frozen Mammalian cells 
 
Cell vials are removed from the liquid nitrogen, placed in a 37°C water bath for 15 minutes until 
thawed, and spun at 600 rpm for 5 minutes. The supernatant is removed and cells are 
resuspended in pre-heated medium (RPMI-1640 with FBS) and transferred into a 75ml vented 
cap flask (Freshney, 1994). 
 
DNA Extraction Protocol 
 
Cells were centrifuged 4000rpm/5min/4°C and the supernatant was removed. The pellet was 
rinsed twice with 1X PBS and was centrifuged at 4000rpm/5min/4°C. The pellet was 
resuspended in 100ul of Dit buffer (10mM Tris pH8.0+0.1% Polyoxyethylene 10 lauryl ether 
(decaethylene glycol)) to lyse cells. Proteinase K was added to a ratio of 1/100 (stock 10 mg/ml, 
final concentration of 100 μg/ml). The mix was incubated at 65°C for 2 hours to digest proteins. 
It was then incubated at 95°C for 15 minutes to inactivate the Proteinase K. The genomic DNA 
was stored at -20°C for future use.  
 
Plasmid Construction 
 
 Using plasmids pGL3 and eGFP-N1, the luciferase and eGFP gene were isolated by 
digesting with XbaI and HindIII and purifying on 0.8% agarose gel. The vector fragment from 
pGL3 and eGFP insert fragment were ligated together and transformed into DH5α E. coli. This 
created plasmid JSTG-GFP (Figure 14) with a multi-cloning site for future promoter insertion 
and an ampicillin resistance gene (AMP). Primers to amplify the candidate promoter region of 
TRF2 were designed using NCBI reference NM_005652.4. The TRF2 promoter sequence was 
extracted and used to design specific primers using primer blast. The primers were checked 
against the whole human genome for specificity to the TRF2 promoter (see Table 7 for primers). 
The JSTG-GFP vector was digested with XhoI and HindIII to be able to ligate with the PCR 
product. All forward primers contained an XhoI restriction enzyme sequence and all reverse 
primers contained a HindIII sequence in order to facilitate ligation with the JSTG-GFP vector. 
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Figure 14: pJSTG-GFP plasmid construct.  
A multi-cloning site and eGFP gene were integrated into a plasmid with the AMP gene using 
enzymes XbaI and HindIII.  
 
 
PCR Mix: 
2 μl of 10μM Forward primer 
2 μl of 10μM Reverse primer  
10 μl of 5X Q5 Buffer (NEB) 
1 μl of 10 mM dNTPs  
1.0 μl of Q5 polymerase (NEB)  
1 μl DNA (~20 ng genomic DNA or 10 ng plasmid DNA)  
33.0μl of ddH2O  
50 μl total volume  
 
The following PCR conditions were used for all the reactions: 
Step 1: 95°C for 2 minutes 
Step 2: 95°C for 30 seconds  
Step 3: 59°C for 30 seconds 
Step 4: 72°C for 3 minutes  
Repeat step from 2 to 4 for 30x 
Step 5: 72°C for 10 minutes 
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Plasmid Construct Names Length of TRF2 Promoter (bp) 
TRF2-p2566 2566 
TRF2-p1307 1307 
TRF2-p1157 1157 
TRF2-p974 974 
TRF2-p821 821 
TRF2-p737 737 
TRF2-p680 680 
TRF2-p614 614 
TRF2-p484 484 
TRF2-p400 400 
TRF2-p300 300 
TRF2-p250 250 
TRF2-p200 200 
TRF2-p150 150 
TRF2-p140 140 
TRF2-p125 125 
TRF2-p115 115 
TRF2-p100 100 
TRF2-p50 50 
TRF2-PLGFP GFP-PL 
Table 1: Name of plasmid construct with respective promoter length. 
 
 
Electrophoresis Gel 
 
PCR reactions were loaded on a 1X TAE 1% agarose gel and run at 100 V for 60 min. 1kb+ 
DNA ladder (Invitrogen) was loaded as a DNA marker. The gel was placed in an ethidium 
bromide bath for 30-60 seconds then run for 15 minutes and visualized using a UV 
transilluminator and photographed with digital software.  
 
Ligation 
 
A T4 DNA ligase kit (New England Biolabs, product M0202S) was used according to 
manufacturer’s instructions for ligation to either clone an insert into a vector or circularize a 
vector after cloning. The samples were incubated for 30 min at RT. The reaction mixture was 
then stored at 4°C or used right away for transformation into E. coli. 
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Ligation of insert DNA into plasmid vector DNA 
Reagents Amount(μl) 
Insert (3:1) Varies 
Vector 10-100 ng 
T4 Ligation Buffer (10x) 4μl 
T4 DNA Ligase (1U/μl) 1 
Water Add to make 20 μl 
Total 20 μl 
Table 2: Reagents and volume used for ligation of insert with vector. 
 
Recircularization of linear DNA 
Reagents Amount(ul) 
Vector 10-50 ng 
T4 Ligation Buffer (10x) 10 μl 
T4 DNA Ligase (1U/μl) 1 μl 
Water To 50 μl 
Total 50 μl 
Table 3: Reagents and volume used for circularization ligation. 
 
Enzyme Digestion 
 
All enzymes are obtained from NEB. All enzyme digestion reactions were incubated at 37°C for 
1 hour. 
 
Digestion Mix 
1 µg DNA (purified plasmid DNA, PCR amplicons, vector plasmid) 
1 µl of each Restriction Enzyme  
5 µl of 10x Buffer 
x µl dH2O (to bring total volume to 30µL) 
 
Klenow Treatment 
 
This protocol blunts ends by 3’overhang removal or fill-in 3’ resected (5’ overhang) ends using 
DNA polymerase I, Large (Klenow) Fragment.  Using 30ng purified digested plasmid, 2U 
Klenow, 1x buffer, 5mM dNTP, and water were mixed and incubated for 20 minutes at room 
temperature. The reaction was stopped by adding EDTA to a final concentration of 10mM and 
heating for 15 minutes at 75°C (NEB, 2015). 
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Bacteria Transformation 
 
Bacterial transformation was performed using E. coli DH5α competent cells stored at -80°C and 
defrosted on ice. 50 μl was transformed with 5 μl of ligation product, pipetting up-and-down 
gently to mix, and incubated for 15 minutes on ice. The samples were heat shocked in a 42°C 
water bath for 90 seconds and then placed on ice for 2 minutes. 950 μl of LB broth was added 
and bacteria were incubated at 37°C for 1 hour with agitation. The bacteria were centrifuged for 
2 min at 12000 rpm, 950ul of the supernatant was removed and bacteria was resuspended in the 
remaining 50 μl of LB and spread onto LB-agar plates containing a selection antibiotic such as 
ampicillin (100mg/ml). The plates incubated overnight at 37°C.  Single colonies were selected 
and grown in 2 ml of LB + ampicillin overnight at 37°C. Plasmids were extracted using EZ-10 
spin column plasmid DNA mini-prep kit (Biobasic) and aliquots were frozen at -20°C to be 
thawed at 4°C as needed for downstream applications.  
 
BJAB tTA/LMP1 Transfection 
 
Human suspension cell lines BJAB tTA/BJAB tTA LMP1 were transfected with a plasmid 
containing a portion of the TRF2-promoter linked to a GFP gene (Table 7) using either 
electroporation method or the nucleofection kit (Lonza 10064-154). The day before the 
transfection, the cells were washed twice with PBS 1x and incubated overnight with 0.8 μg/ μl 
tetracycline at 37°C and 5% CO2. On the day of the transfection cells were counted using a 
hematocytometer and cell number was calculated as follows: Cell Concentration (cells/ml) = 
Dilution Factor (Total cell count/4) x10
4
. 4.0 x 10
6
 cells per sample were used to perform the 
transfection.  Cells were washed twice 1x PBS, suspended in RPM1+FBS without tetracycline 
and incubated for 4 hours to remove all traces of tetracycline in order to induce LMP1 
expression.  
 
When the electroporation procedure was used, it was performed as follows: after 4 hours of 
incubation, the cells were washed twice with PBS to remove RPMI+FBS and resuspended in 100 
μl per sample of RPM1 without FBS to have 1 million cells per 100 μl. One hundred microliters 
of the solution with cells was transferred into 1.5 ml Eppendorf tubes with their respective 
amount of plasmid (5μg) required for transfection. Once samples were homogenized with the 
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plasmid, the mixture was added to the 100 μl cuvettes and transfected using a cuvette of 0.2 cm 
with the program conditions of 975 uF, 200 ohms, 150 V to pulse. After transfection, 100 μl of 
RPMI+FBS was added into each cuvette containing cells, then the 200 μl was transferred into 
1.5 ml Eppendorfs where it was split: 100 μl was pipetted into 6 well plate with 5ml RPM1+FBS 
and the other 100 μl was pipetted into 5 ml RPM1+FBS+Tetracycline. The cells were incubated 
for 72 hrs. After 24 hrs, the media was changed by spinning the cells for 5 min at 600 rpm, 
removing the supernatant, and adding fresh media. Cell were harvested after 72 hrs, spun for 5 
min at 1000 rpm in 15 ml plastic tubes, washed once with 1x PBS and transferred into 1.5 ml 
Eppendorf tubes. The cells were washed another time with 1x PBS and the  pellet was left in 50 
μl of PBS (for easier resuspension of cells for Protein Lowry or RNA extraction) and were 
preserved at -20°C. 
 
If the nucleofection technique was used with Lonza nucleofection kit: after 4 hours, the cells 
were washed twice with PBS to remove RPMI+FBS and were resuspended in 100 ul per sample 
of reagent to have 4 million cells per 100 μl. One hundred microliters of the solution with cells 
was transferred into 1.5ml Eppendorfs with their respective amount of plasmid (3μg) required for 
transfection. Once samples were homogenized with plasmid, the mixture was added to the 100 μl 
cuvettes and transfected using the program provided by the company. After transfection, 100 μl 
RPMI+FBS was added to each respective cuvette containing cells, then the 200 μl was 
transferred into 1.5 ml Eppendorfs, where it was split: 100ul was pipetted into a 6 well plate with 
5 ml RPM1+FBS and the other 100ul was pipetted into 5 ml RPM1+FBS+tetracycline. The cells 
were incubated for 72 hrs. After 24 hrs, the media was changed by spinning the cells for 5 min at 
600 rpm, removing the supernatant, and adding fresh media. Cells were harvested after 72 hrs, 
spun for 5 min at 1000 rpm in 15 ml plastic tubes, washed once with 1x PBS and transferred into 
1.5 ml Eppendorfs. They were then washed another time with 1x PBS and the pellet was left in 
50 ul of PBS (for easier resuspension of cells for Protein Lowry or RNA extraction) and was 
preserved at -20°C. 
 
Flow Cytometry 
 
After the 72 hours transfection, the cells were aliquoted into a 15 ml tube, spun for 5 min at 600 
rpm then washed twice with 1x PBS and resuspended in 1 ml of fresh cold PBS and transferred 
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into the flow cytometry tubes. The FACS DIVA system was used according to manufacturer’s 
instructions with the following parameters: FSC 165 SSC 245 GFP 385 intensity). 
 
Fluorescent Microscopy 
 
To determine if the transfection was successful, after 72 hrs, the cells were left in the 6 well 
plates and centrifuged at 1000 rpm.  Once the cells were spun down, the 6 well plates were 
brought to the microscope. A pre-established program by Sheriff Lab was used for analysis. 
 
Western Blot 
 
The pellet previously harvested or stored at -20°C  was resuspended in 50 μl of 2X Laemmli 
loading buffer with DDT added (62.5 mM Tris pH 6.8, 25% v/v glycerol, 2% m/v SDS, 0.01% 
m/v bromophenol blue, 10% v/v 1M DDT and 50 μl of water. The samples were sonicated for 10 
min at 100 V in an ice bath (1 min sonication with 25 sec pause). The samples were boiled for 5 
minutes at 100°C in order to denature the proteins. The amount of protein per microliter was 
quantified using Protein Lowry colorimetry, which is a widely used method to estimate the 
amount of proteins within a biological sample, (Lowry, Rosenbrough, Farr & Randall, 1951) and 
20 μg of each sample was then analyzed on a 10% SDS-PAGE gel. For all Western blots, 
samples were migrated for 1 hour 40 min at 100 V. The proteins where then transferred to 
Hybond-C nitrocellulose membrane (GE Healthcare) using a BioRad mini Trans-blot Cell 
apparatus for 75 minutes at 100 V. Membranes were stained with Ponceau S in order to verify 
the quality of the proteins and transfer efficacy. The membranes were blocked with 5% m/v 
powdered milk dissolved in 1X PBS-T for 30 minutes. They were then washed 3 times for 5 
minutes each in PBS-T with agitation at room temperature. Membranes were incubated with 
rotation overnight at 4°C with antibody (Table 4). They were then washed 3 times for 5 minutes 
in 1X PBS-T at room temperature with agitation. Membranes were incubated for 1 hour at room 
temperature with the secondary antibody (Table 5). After this incubation, the membranes were 
washed again 3 times for 5 minutes with 1X PBS-T. Enhanced 32 chemiluminescence (ECL) 
was used to visualize the results with an ImageQuant LAS 4000 (GE Healthcare).  
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Primary Antibodies used for Western Blot 
Antibody Company Dilution Expected Size Secondary Antibody 
Anti-eGFP Roche 1:1000 26kDa HRP-conjugated anti-mouse 
Anti-Actin Sigma Aldrich 1:1000 45kDa HRP-conjugated anti-rabbit 
Anti-TRF2 IMGENEX 1:1000 60kDa HRP-conjugated anti-mouse 
Anti-Tubulin Cell Signaling 1:1000 65kDa HRP-conjugated anti-rabbit 
Anti-LMP1 Sigma Aldrich 1:200 70kDa HRP-conjugated anti-mouse 
Table 4: Primary antibodies with their properties for Western Blot usage. 
 
Secondary Antibodies used for Western Blot 
Secondary Antibody Company Dilution 
Mouse  Cell Signaling 1:5000 
Rabbit GE Healthcare Life Sciences 1:5000 
Table 5: Secondary antibodies and dilution. 
 
RNA Analysis 
 
Total cellular RNA was extracted by Trizol reagent and RNA extraction kit (Zymo Research, 
Direct-zol kit R2050, R2051) and purity of each sample was measured by optical density using a 
Nanodrop spectrophotometer. Total RNA (1 μg) was used to generate cDNA using the Qiagen 
QuantiTect Reverse Transcriptase kit following the manufacturer's instructions. Real-time PCR 
was performed with a hot start step 95°C for 10 min followed by 40 cycles of 95°C for 30 s, 
60°C for 30 s and 72°C for 30 s using iQ
TM
 SYBR Green Supermix (Bio-Rad Laboratories Inc.) 
on Real Time PCR System (Applied Biosystems). 
 
Nuclear Extraction Protocol 
 
Cells were incubated at 37°C and 5% CO2 until a density of 1x10
9
cells/culture was obtained. The 
cells were spun for 10 min at 2000 rpm in 50 ml plastic Falcon tubes at room temperature. 
Supernatant was removed and the cells were washed twice with cold 1x PBS for 5min at 2000 
rpm and 4°C. The cells were then resuspended in 5 volumes (compared to pellet volume) of 
autoclaved Buffer A (10 mM Hepes pH 7.9, 1.5mM MgCl2, 10 mM KCl and 0.5 mM DTT). The 
pellets with buffer were incubated for 10min on ice, centrifuged for 5 min at 2000 rpm at 4°C 
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and supernatant was removed. The pellet was then resuspended in 2 volumes of Buffer A and 
transferred into a 7 ml glass pestle Dounce homogenizer Type A with 15 strokes to lyse the cells. 
The mixture was then transferred to 15 ml Falcon tube and centrifuged for 10 min at 2000 RPM 
at 4°C to precipitate the nuclei. Supernatant containing the cytoplasmic mixture was removed 
and stored at -80°C for other experiments and the pellet was resuspended in 2 volumes 
(compared to nucleus pellet volume) of the Buffer A and centrifuged for 20 min at 17000 RPM 
(25000g) at 4°C (rotor SS34, Sorvall).  The supernatant was removed and the pellet resuspended 
in 2 volumes of Buffer C (20mM Hepes pH 7.9, 25% Glycerol, 420 mM KCl, 0.2 mM EDTA, 
0.5 mM DTT and 0.5 mM PMSF). The mixture was homogenized using the 7ml glass pestle 
dounce homogenizer Type B with 10 strokes on ice. The mixture was incubated on ice for 30 
min with occasional agitation. The pellet mixture was then centrifuged for 30 min at 17000 
RPM. The supernatant was transferred into a dialysis membrane (Spectra/Por 7 Dialysis 
Membrane MWCO 10Kd, #132119) in 1L Buffer D (20 mM Hepes pH 7.9, 20% glycerol, 100 
mM KCl, 0.2 mM EDTA, 0.5 mM DTT and 0.5 mM PMSF) for 1h-2h at 4°C lightly mixing 
with a stir bar. The dialysis buffer was changed an additional time and left overnight at 4°C. The 
next day, buffer D was changed and fresh buffer was added for 1h at 4°C. The samples were then 
centrifuged for 20 min at 17000 RPM and aliquoted on ice. Sample nuclear proteins were then 
measured using the Bradford technique (Bio-Rad Solutions), using a BSA standard curve and 
measured at 595 nm using a spectrometer.  
 
5’ γ-ATP32 labelling  
 
For the electrophoretic mobility shift assay (EMSA), the single stranded oligonucleotides were 
5’ labelled with γ-ATP32. A total reaction volume of 20μl was comprised of 5μl of the 1uM 
oligonucleotides, 2μl 10x PNK Buffer, 8μl sterile water, 4μl Gamma-ATP32 and 1μl of T4 PNK 
(10U/ml). The mixture was incubated at 37°C for 45 min and the reaction was stopped by 
heating at 65°C for 10 min. For the double stranded portion of the experiment, radiolabelled 
oligonucleotide were annealed together as described below.  
 
Annealing of Oligonucleotides 
 
In an Eppendorf, 22.5 μl of sense and 22.5 μl of antisense single-stranded oligonucleotides were 
mixed together with 5 μl of T4 DNA ligase buffer. The mixture was heated for 2 min at 95°C, 
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and immediately the Eppendorf (held by a float) was put into a beaker of 1L of boiling water. 
The mixture was gradually cooled by leaving it at room temperature. Once the mixture reached 
room temperature, the double-stranded oligonucleotide was stored at −20°C.  
 
EMSA 
 
A 4.5% native polyacrylamide gel was made fresh the day of the experiment. The gel was 
prepared using a medium plate with an 18 well spacer comb. The gel was comprised of  6 ml of 
acrylamide (30% 29:1), 4 ml 5x TBE Buffer (0.45 M Tris–borate, 10 mM EDTA), 2 ml glycerol 
(20%, vol/vol), 400μl 10% APS, 40ul 100% TEMED and 28ml sterile water (total volume 40 
ml). Once poured, the gel was left to solidify for 30 min-1 hour. The gel was pre-run at 150V in 
0.5x TBE with 2% glycerol buffer for 1 hour at 4°C. For EMSA sample preparation, all solutions 
were kept on ice. Each sample was brought to a final volume of 20μl, containing 4μl 5x binding 
buffer (100 mM HEPES, 25 mM MgCl2, 40% glycerol, 500 mM KCl in distilled water) 0.4 μl 10 
mg/ml BSA, 0.2 μl 10 mg/ml Poly(dI-dC)·Poly(dI-dC), 0.2 μl  dsDNA OligoB (90 μM stock), 
and 10 μg of nuclear extract (volume depending on the concentration of the nuclear extract). The 
mixture was incubated on ice for 5 min. Afterwards, 1 μl of labelled dsDNA oligonucleotide was 
added, mixed and incubated at room temperature for 30 min. Samples were loaded using 2 μl 
DNA dye. Once loaded, the gel was run for 4hours at 150 V in a 4°C fridge. Once running was 
completed, the gel was transferred to Whatman paper and vacuum pump dried at 80°C. The gel 
was exposed on radiography film (GE Healthcare, product 28906845) for 4h and stored at -80°C.  
 
 
DNA Affinity Chromatography (Pull-Down) Assay for DNA-Protein Affinity 
 
DNA Affinity Chromatography was performed using a 30 bp sequence from a region of 
100-130bp of the TRF2 promoter.  A 5’ biotin labelled sequence was added to the 30 bp 
sequence on the reverse strand of the DNA with an additional Teg tag (ordered from Integrated 
DNA Technologies). The assay was performed as follows: Step 1: Binding of oligos biotinylated 
on Dynabeads M-280 Streptavidin (catalog number: 11206D). For each sample, 100 μl of 
magnetic beads was aliquoted into a silicone Eppendorf tube and put on a magnetic particle 
concentrator (Invitrogen, product # 123.21D) for 2 min. The supernatant was removed and beads 
were washed 3 times with 100 μl of B&W 1x buffer (5mM Tris-HCl pH7.5, 0.5 mM EDTA and 
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1M NaCl). The beads were resuspended in 200 μl of B&W 2x buffer (10 mM Tris-HCl pH 7.5, 
1mM EDTA, and 2M NaCl). To each tube, 188 μl nano water with 12 μl of biotinylated oligo 
(50 μM:600pmol/μl/load) was added for a total volume of 400 μl. The tubes were agitated by 
flicking every couple of minutes to resuspend the beads for a total time of 15 min. The tube was 
put onto the magnet bar for 2 min to collect the beads and the supernatant was removed. The 
beads were washed three times with B&W 1x buffer and wash once with 200 μl of BB 1x buffer 
(20mM HEPES ph7.9, 100mM KCl, 5mM MgCl2, 8% Glycerol). After the washes, the buffer 
was removed and 100ul of BB 1x buffer was added. The tubes were then placed on ice. Step 2: 
Addition of nuclear extract. A total of 900 ul of Master Mix NE reaction was added to the beads 
and oligo that were resuspended in 100ul of BB1x buffer. For one sample, the final volume of 
the experiment was 1 ml.  With the 100 μl of BB 1x already added to the magnetic beads with 
biotin oligonucleotide, a master mix was prepared with 300 μl of BB5x buffer (100mM HEPES 
ph7.9, 500mM KCl, 25mM MgCl2, 40% Glycerol), 30 μl of acetylated BSA (10 mg/μl), 15 μl of 
ds Oligo B (90 µM), 15 μl of Poly dIdC 10 mg/μl), and 1.5 mg of nuclear extract (varies 
depending on the concentration). All products were added together and incubated for 3 min. 
0.05% CHAPS was added and left for 2 min of interaction with the mix. After 5 min, the nuclear 
extract mix was added to the beads and oligonucleotide. The nuclear extract and dsDNA were 
left to interact for 15 min. Samples were placed on the magnet bar for 2 min to collect the beads 
and then washed according to the time conditions in table 6. 
 
Samples #1 #2 #3 
 Time in Minutes 
Beads 0 1 2 
Wash 5 6 7 
500 μl BB 1x + 0.05% CHAPS 7 8 9 
Beads 12 13 14 
Remove then wash with 500 μl BB 1x (0.01% NP40) 14 15 16 
Beads 19 20 21 
Remove then wash with 500μl BB 1x (0.01% NP40) 21 22 23 
Beads 26 27 28 
Remove then wash with 500 μl BB 1x (0.01% NP40) 28 29 30 
Beads 33 34 35 
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Wash BB 1x 
Keep 100 μl for Silver Stain 35 36 37 
Beads 40 41 42 
Table 6: Example of a time course for the pull-down for 3 samples. Every sample was 
separated by 1 min for easier manipulation. 
 
Mass Spectrometry 
 
Mass spectrometry (MS) analysis of proteins measures the mass-to-charge ratio of ions to 
identify and quantify molecules in simple and complex mixtures. Samples were prepared using 
protocol “On-Beads Trypsin Digestion Boisvert Lab, May 2014”. This method allows better 
recovery of the immunoprecipitated proteins, at the cost of increased contamination with 
antibody and increased complexity of the sample. The steps are as follows: step 1 - digestion 
including reduction and alkylation. This step is required to prevent disulfide bonds between 
peptides, thus increasing peptide coverage. However, there are several reports indicating that 
antibodies which have not been reduced may be partially resistant to trypsin, which could help 
reduce the amount of antibodies in the sample. 1) Wash beads 5 times with 20 mM ammonium 
bicarbonate. 2) After the final wash step, add enough 10 mM DTT in 20 mM ammonium 
bicarbonate to the beads for complete immersion, mix and incubate at 60°C for 30 minutes. 3) 
After cooling, add an equal volume of 15 mM iodoacetamide in 20 mM ammonium bicarbonate 
to the DTT/bead suspension, mix and incubate in the dark for 1 hour. 4) Add 1M DTT to 
increase the concentration to 15 mM to quench the iodoacetamide and wait 10 minutes. 5) Add 
50 ng of trypsin to the beads. 6) Incubate at 37°C for 5 hours to overnight. 7) Stop trypsin 
digestion by acidifying to a final concentration of 1% formic acid. 8) Harvest the supernatant and 
transfer to a clean, protein lo-bind tube. 9) Resuspend beads in 60% ACN – 0.1 FA at room 
temperature for 5 min. 10) Transfer this second supernatant with the first supernatant. 11) Dry 
samples in the speed vac 3 hours at 65°C. 12) Resuspend in 20 µl sample buffer (0.1% TFA) to 
desalt on ZipTip. Samples were then measured by nanodrop. The samples were analyzed by 
Dominique Levesque from Francois-Michel Boisvert Lab. 
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Primers used in this study 
Primers Name Sequence (5’ -3’) 
 
Plasmid Construct Primers 
R13 (Starts at the ATG of 
TRF2 promoter) 
GACTAAGCTTGATAGAAACAGCGTTCCGAGCC 
F2GC GACACTCGAGATGGCATGAACCCAGAGGC 
F12 GACACTCGAGACTCATCCAGGACCTGCCTA 
F24 GACACTCGAGGTGATTACAAAGAGTATATGTCTAGCGGCTGG 
F25 GACACTCGAGCCTCTGTGTATGCTCTCTTCCACAATTTTCA 
F27 GACACTCGAGGTATCACACTGGTCTTTGCTTTATAATTACAG 
F28 GACACTCGAGGCGATCTCGGCTCACCGCAAC 
ALL-RW400 GACACTCGAGACAGGCATGCGCCACCAC 
ALL-RW300 GACACTCGAGTCCACCCGCCTCAGCC 
ALL-RW250 GACACTCGAGCGATCCCGGCCTGTTTTTCAGT 
ALL-RW200 GACACTCGAGTAGTAGCTGTTTTCTGTAAATTCGG 
ALL-RW150 GACACTCGAGGGGTTCACCGGCCTGGG 
ALL-RW140 GACACTCGAGCCTGGGCGGTGTGGACT 
ALL-RW125 GACACTCGAACTTCAAGCCCCAGGAGGC 
ALL-RW115 GACACTCGACCAGGAGGCATTGCGGC 
ALL-RW100 GACACTCGAGGCCGGCACATCGGGAACTAC 
ALL-RW50 GACACTCGAGTCCTTTCCCTCCCAGAAGCC 
ALL-RWR3 GACACTCGAG CAGGTGGCACTTTTCGGGGAAATG  
RT-qPCR Primers 
ACTB For ATGTCTCGCTCCGTGGCCTTA 
ACTB Rev ATCTTGGGCTGTGACAAAGTC 
GAPDH For GCGGGAAATCGTGCGTGACATT 
GAPDH Rev GATGGAGTTGAAGGTAGTTTCGTG 
B2M For  CAACCAATAGAGTCCACCAGT 
B2M Rev TCTTCAGAAGAGACCTTCTCT 
LMP1 For CAACCAATAGAGTCCACCAGT 
LMP1 Rev TCTTCAGAAGAGACCTTCTCT 
TRF2 For GTACCCAAAGGCAAGTGGAA 
TRF2 Rev TGACCCACTCGCTTTCTTCT 
GFP1 For AGATCCGCCACAACATCGAG 
GFP1 Rev GTCCATGCCGAGAGTGATCC 
GFP2 For CTACCCCGACCACATGAAGC 
GFP2 Rev AAGTCGATGCCCTTCAGCTC 
GFP16 For CAACCACTACCTGAGCACCC 
GFP16 Rev GTCCATGCCGAGAGTGATCC 
GFP18 For CGACCACTACCAGCAGAACAC 
GFP18 Rev GTCTTTGCTCAGGGCGGACT 
DNA Affinity Chromatography Primers (Pull-Down) 
100-130 F TGTGGACTTCAAGCCCCAGGAGGCATTGCG 
100-130 R Anti-Sense Biotin-TEG-CGCAATGCCTCCTGGGGCTTGAAGTCCACA 
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Oligo B+ (competitor) GATCCGGAGTACTTCAAGAACG 
Oligo B- (competitor) GATCCGTTCTTGAAGTACTCCG 
EMSA Primers 
100-130 F TGTGGACTTCAAGCCCCAGGAGGCATTGCG 
100-130 R CGCAATGCCTCCTGGGGCTTGAAGTCCACA 
Table 7: Primers used in this study 
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Results-Chapter 1 
 
TRF2 promoter plasmid constructions and analyses 
 
Preamble 
 
LMP1 has been shown to affect gene activation/inhibition pathways, leading to shorter 
telomeres with a decrease of TRF2 levels. The mechanism by which it does this has been linked 
to those involved in the pathogenesis of EBV-negative Hodgkin Lymphoma (Knecht et al., 
2009). Understanding the role of LMP1 in the production of Hodgkin's and Reed-Sternberg cells 
will provide insight into the mechanisms through which B lymphocyte cells become Reed-
Sternberg cells with/without the presence of EBV. To investigate our hypothesis, a BJAB tTA 
LMP1 cell line was used to control the expression of LMP1 by the addition or removal of 
tetracycline. To determine if the LMP1 pathway interacts with TRF2 at its promoter region, 
plasmids containing different TRF2 promoter lengths were transfected into the BJAB tTA LMP1 
cell line and analyzed by Western blot, flow cytometry, RT-qPCR and/or microscopy to see 
whether differences in GFP protein or GFP RNA levels could be observed. 
 
pTRF2-GFP Construct and Transfection Optimization 
 
 The first objective of this project was to construct a plasmid containing an ampicillin 
resistance (AMP) gene and the multi-cloning site (MCS) in front of a GFP reporter gene. A brief 
description of the process will be given here, with full details explained in the materials and 
methods section. Plasmid pGL3 was used for the backbone as it already contained the AMP gene 
and MCS but had a luciferase gene that was ultimately replaced by a GFP gene from plasmid 
pEGFP-N1. Using restriction enzymes XbaI and HindIII, the luciferase gene was removed in 
order to use the plasmid as a vector and the GFP gene was inserted in its place. The vector and 
insert were placed on a 0.8% TAE gel, purified using a gel purification kit (Biobasic), ligated 
and transformed into E. coli. The plasmid was then extracted from E. coli and sent for 
sequencing (https://www.sequences.ulaval.ca). This new plasmid construct was named PL-GFP. 
The next step was to clone different sizes of the TRF2 promoter that were obtained by extracting 
the genomic DNA from the cell line BJAB tTA LMP1 and using it for PCR amplification of the 
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desired primer region. PCR was performed with forward primers F12, F2GC and reverse primers 
R13. The forward primers have an XhoI site and the reverse primers have a HindIII site. The 
plasmid called PL-GFP and the PCR products were digested with XhoI and HindIII enzymes. 
They were then ligated and transformed into E. coli. The plasmid was then extracted from E. coli 
and sent for sequencing (https://www.sequences.ulaval.ca). The plasmid using F12-R13 was 
named p2566-GFP and the plasmid that used F2GC-R13 was called p1307-GFP. These plasmid 
constructs were then analyzed using microscopy, flow cytometry, and Western blot.  
To determine the efficiency of the transfection, fluorescence microscopy was used for 
analysis. Electroporation was used with different conditions as well as nucleofection to 
determine which technique produced the better percentage of cells transfected with the GFP-
containing plasmid. For optimization purposes, the pCMV-GFP plasmid was used since this 
plasmid contains a strong viral promoter and therefore should express maximum GFP proteins. 
The pCMV-GFP plasmid was transfected using different conditions, as seen in Figure 15 and 16: 
(a) condition is the normal condition mentioned previously in the materials and methods, (b) 
after the transfection, the cells were placed on ice for 10min (Potter & Heller, 2003), (c) the 
ohms were changed for 1000ohms, (d) 5mM of glutathione was added before the transfection to 
help prevent leakage of the cytoplasmic components and protection of membrane against 
oxidation (van den Hoff, Moorman & Lamers, 1992) (e) nucleofection using program called DN-
100, (f) nucleofection using program called DS-137 and (g) nucleofection using program called 
EN-150 (Lonza Nucleofector Technology). By taking random picture frames, the number of 
transfected cells was counted to determine which experiment yielded a higher percentage of 
transfected cells. 
  
 
37 
(a) pCMV-GFP  (b) pCMV-GFP Ice 10min (c)  pCMV-GFP 1000ohms (d)pCMV-GFP Glutathione 
5mM 
(e) pCMV-GFP DN-100 (f) pCMV-GFP DS-137 (g) pCMV-GFP EN-150 
Figure 15: Fluorescence microscopy.  
pCMV-GFP (positive control) was transfected using different programs and cells were imaged 
using fluorescence microscopy to find the optimal transfection conditions for further 
experimentation.  
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Figure 16: Graph depicting the transfection analysis of pCMV-GFP using BJAB tTA cell 
line. 
Electroporation vs Nucleofection after 72h of transfection. Electroporation yielded 10-20% of 
positive cells with GFP while Nucleofection yielded a positive transfection of 40-80%. 
Nucleofection using program En-150 provided 80% GFP positive cells. 
 
Western Blot Analysis of promoter regulation via GFP protein levels 
 
 Once the program and technique producing the greatest transfection GFP yield were 
determined, the next step was to verify the protein levels by Western blot. As mentioned 
previously, LMP1 indirectly interferes with the RNA levels of TRF2 (Lajoie et al., 2015). By 
integrating a portion of the TRF2 promoter linked to a GFP reporter gene, we wanted to 
determine if LMP1 causes a downregulation due to its influence on the promoter region of TRF2. 
A transfection was performed using nucleofection with the program EN-150, that was previously 
0
10
20
30
40
50
60
70
80
90
G
FP
 P
O
SI
TI
V
E 
C
EL
LS
 (
%
) 
GFP-Transfected Cells (%)  
pCMV-GFP N=1 pCMV-GFP N=2 pCMV-GFP N=3
Electroporation Nucleofection 
  
 
39 
determined to be best for future experiments. The experiment consisted of integrating the 
plasmid within the BJAB tTA LMP1 cell line by using the negative control called PL-GFP 
(promoterless plasmid), p1307-GFP, p2566-GFP and positive control pCMV-GFP. Figure 17 
represents the results of the experiment and the protein analysis via Western blot. The proteins 
were quantified using the protein Lowry protocol. The membrane was probed with anti-LMP1, 
anti-GFP, and anti-actin as a housekeeping gene loading control. 
 
 
 
 
 
Figure 17: Western blot of TRF2 promoter analysis.  
Lanes 1-8 represent the different promoters used in front of the GFP reporter gene as indicated 
on top of lanes. 
 
The loading control anti-actin demonstrates that the proteins were evenly loaded. Lane 1 and 
lane 2 are the negative control, in PL-GFP Lanes 3-4 are the p1307-GFP construct. LMP1 is 
absent in lane 3 and present in lane 4. A downregulation of the GFP levels can be observed when 
comparing lane 3 to lane 4. Lanes 5-6 are the p2566-GFP construct, with LMP1 absent in lane 5 
and present in lane 6. A downregulation of GFP is again observed when comparing lane 5 to lane 
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6. Lanes 7 (LMP1 absent) and 8 (LMP1 present) are the positive control pCMV-GFP. There is 
no apparent change of GFP protein levels in the positive control.  
 
 
Analysis of GFP through Flow Cytometry 
 
 This technique is based on biophysical technology in fluorescent cell counting. It 
measures the cells one by one, in a rapid flowing fluid where the cells are passed through an 
optical system that excites the stained cells with a light source thus producing a fluorescence 
emission. This information is processed through the electronics component of the flow cytometer 
(ThermoFisher Scientific). Using samples from the previous transfection as seen in the Western 
blot above, 1 ml was taken for flow cytometry analysis. The goal of this experiment was to see a 
distinguishable horizontal shift between samples with LMP1 versus samples with no LMP1. The 
objective was to determine if LMP1 indirectly downregulates TRF2 via its promoter. It was 
expected that in samples where LMP1 is present, the GFP would be shifted to the left and in 
samples without LMP1, GFP expression would shift to the right. Figure 18 represents the 
samples transfected with negative control PL-GFP. Figure 19 contains both PL-GFP (negative 
control) and CMV-GFP (positive control). CMV is a strong viral promoter and therefore a shift 
to the far right would be expected due to high expression of GFP protein. In the constructs used 
in this study, TRF2 does not have a strong promoter and therefore it was expected that the results 
would be found between the PL-GFP and the CMV-GFP. Figure 20 is the experiment with 
p2566-GFP, the purple line is without LMP1 and the blue line is with LMP1. A very minimal 
shift with and without LMP1 was observed. Figure 21 is the experiment with p1307-GFP, the 
purple line is without LMP1 and the blue line is with LMP1. Again, a very minimal shift with 
and without LMP1 was observed. These shifts within the data presented in Figure 19-22 are not 
significant enough to conclusively determine that LMP1 downregulates TRF2 at the promoter 
level. Therefore, no further experiments were analyzed using flow cytometry as it is not sensitive 
enough to detect minimal changes.   
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Figure 18: FACS analysis of PL-GFP.  
This graph represents the negative control in the FACS experiments. The yellow line represents 
cells with no LMP1 induction (+Tet) and the grey line represents cells with LMP1 induction (-
Tet). 
 
 
Figure 19: FACS Analysis of PL-GFP and CMV-GFP.  
This graph represents the negative control (PL-GFP) and positive control (CMV-GFP). The 
yellow line represents cell with no LMP1 induction (+Tet), the grey line represents cells with 
LMP1-induction (-Tet), the purple line represents CMV-GFP with no LMP1 induction (+Tet), 
and blue indicates LMP1 induction (-Tet). 
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Figure 20: FACS analysis of negative and positive controls versus p2566-GFP. 
This graph represents the negative control (PL-GFP) in grey, the positive control (CMV-GFP) in 
red, p2566-GFP transfected cells with no LMP1 induction (+Tet) in blue, and p2566-GFP 
transfected cells with LMP1-induction (-Tet) in purple. 
 
 
 
 
Figure 21: FACS analysis of negative and positive controls versus p1307-GFP.  
This graph represents the negative control (PL-GFP) in grey, the positive control (CMV-GFP) in 
red, p1307-GFP transfected cells with no LMP1 induction (+Tet) in blue, and p1307-GFP 
transfected cells with LMP1 induction (-Tet) in purple. 
 
 
RT-qPCR analysis of GFP mRNA 
 
 As seen in the above Western blots, changes in protein expression demonstrate a clear 
TRF2 promoter-GFP downregulation when LMP1 is expressed. Consequently, analysis of GFP 
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RNA levels was also performed, as it was shown in Lajoie et al. (2015) that LMP1 
downregulates both protein and RNA levels of TRF2 and other shelterin proteins. In order to 
perform this analysis, total RNA was extracted from the cell culture transfected with p1307-GFP, 
p2566-GFP, negative control pPL-GFP and positive control pCMV-GFP. Using primers GFP 
F2-R2 for qPCR analysis, the expression levels of GFP RNA were measured (Figure 22).  
Problems arose during RT-qPCR, in which the primers weren’t specific enough to detect the 
change in RNA expression levels and therefore, we could not accurately distinguish the readings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: RT-qPCR results of quantification of mRNA GFP in the BJAB tTA LMP1 cells 
transfected with the different promoter constructs. 
One example of RT-qPCR analysis between the PL-GFP, p1307-GFP, p2566-GFP and pCMV-
GFP using qPCR GFP F2-R2 primers. Error bars indicate the reproducibility of three 
independent experiments.  
 
 
RNA levels for TRF2 and LMP1 were also measured via RT-qPCR to determine if the 
experiment could be reproducible from previous work that clearly showed downregulation of the 
endogenous TRF2 and the upregulation of LMP1 when induced. In Figure 23, we see that the 
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endogenous TRF2 is downregulated upon LMP1 induction by the removal of tetracycline, as 
shown in Figure 24. In each experiment where a plasmid was transfected for GFP analysis, a 
downregulation of endogenous TRF2 is observed in the presence of LMP1-induction. The levels 
of TRF2 differ depending on the expression of LMP1. Since no apparent change was observed 
using quantitative PCR for mRNA GFP levels, another method known as ddPCR was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: RT-qPCR quantification of mRNA TRF2. 
An example of TRF2 levels in BJAB tTA cells transfected with the different promoter 
constructs. After transfection with promoter PL-GFP, p1307-GFP, p2566-GFP and pCMV-GFP, 
and RNA extraction was performed and by RT-qPCR, TRF2 levels were measured using primers 
called TRF2 For and TRF2 Rev. 
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Figure 24: RT-qPCR quantification of mRNA LMP1. 
An example of LMP1 levels in BJAB tTA LMP1 transfected with the different promoter 
constructs. After transfection with promoter PL-GFP, p1307-GFP, p2566-GFP and pCMV-GFP, 
and RNA extraction was performed and by RT-qPCR, LMP1 levels were measured using 
primers called LMP1 For and LMP1 Rev.The relative mRNA expression levels are represented.  
 
 
GFP mRNA analysis through ddPCR 
 
 Droplet digital PCR (ddPCR) is a method in which the cDNA sample is fractionated into 
water-oil droplets and in each individual droplet, there is PCR amplification of the targeted 
template molecule that can be measured (Taylor, Laperriere & Germain, 2017). Figure 25-28 are 
the results from the transfection of PL-GFP, p50-GFP, p100-GFP, p115-GFP, p125-GFP, p140-
GFP and p150-GFP in which GFP, TRF2 and LMP1 levels were measured using ddPCR. 
Primers GFP F16-R16 were used as a first trial. As seen in Figure 25, no downregulation 
between no LMP1 and with LMP1 samples was observed. The assay was performed with 
another set of primers, GFP F18-R18, as seen in Figure 26. Again, there was no observable 
downregulation between non-induced and induced LMP1 samples. However, LMP1 detection 
with ddPCR in Figure 27 showed clear upregulation in samples containing LMP1 induction. 
Endogenous TRF2 levels were also measured as an internal control for the experiment. TRF2 
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showed clear downregulation between non-induced versus induced LMP1 (Figure 28). These 
data therefore strongly suggest that the primers used in ddPCR weren’t specific enough for our 
GFP analysis. This was determined as RNA levels in the plasmid containing no promoter 
upstream the GFP gene, had expression level comparable to cell containing a promoter in front 
of the GFP gene. No further experiments were performed with ddPCR or qPCR.   
 
 
Figure 25: ddPCR analysis of expression levels of GFP RNA using primers GFP F16-R16 
The number on the side represents the plasmid transfected into the BJAB tTA LMP1 cell line. 
The sign beside each name represents the sample induced with and without LMP1 during the 
experiment. 
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Figure 26: ddPCR analysis of expression levels of GFP RNA using primers GFP F18-R18 
The number on the side represents the plasmid transfected into the BJAB tTA LMP1 cell line. 
The sign beside each name represents the sample induced with and without LMP1 during the 
experiment. 
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Figure 27: ddPCR analysis of expression levels of LMP1 RNA 
The number on the side represents the plasmid transfected into the BJAB tTA LMP1 cell line. 
The sign beside each name represents the sample induced induced with and without LMP1 
during the experiment. 
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Figure 28: ddPCR analysis of expression levels of TRF2 RNA 
The number on the side represents the plasmid transfected into the BJAB tTA LMP1 cell line. 
The sign beside each name represents the sample induced with and without LMP1 during the 
experiment. 
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Results-Chapter 2 
 
Localization and analysis of a smaller region of the TRF2 promoter regulated by LMP1-
induction 
 
Preamble 
 
 The first objective of this project was answered by the Western blot shown in Figure 17. 
That result demonstrated that LMP1 induction in the BJAB tTA LMP1 cell line caused LMP1 to 
repress the TRF2 promoter. Once this was determined, the next objective was to localize a 
smaller region of the TRF2 promoter where LMP1 indirectly affects TRF2 at the promoter. To 
answer this question, Western blots for GFP protein analysis were used to determine if a region 
in which LMP1 did not affect the regulation any longer could be delineated. Once the region was 
localized, EMSA, DNA affinity chromatography and mass spectrometry were used for protein 
analysis in the identified significant region in an attempt to find regulatory factors.  
 
Identification of a promoter region affected by LMP1-induction 
 
 To proceed with the analysis, constructs with various extents of the TRF2 gene promoter 
ranging from 821 bp down to 50 bp were made to identify where LMP1 induction stops 
regulating the TRF2 promoter. It was hypothesized that LMP1-induction might be interfering 
with an enhancer or a region of regulation. The first construct was made by using plasmid 
p1307-GFP, in which the plasmid was digested with restriction enzyme XhoI and EcoRV, to 
remove a 486 bp fragment from the region between 1307bp and 822bp. Using a Klenow 
treatment, 3’overhangs were removed or 3’ resected (5’ overhang) ends were filled in to create 
blunt ends. The vector was then ligated to form a circularized plasmid and sent for sequencing. 
This created the plasmid called p821-GFP. Plasmid p737-GFP was made by PCR amplification 
by using primers F24 and R13 and as the DNA template, the plasmid p821-GFP was used. The 
same plasmid, p821-GFP, was then used as a vector by linearizing with restriction enzymes XhoI 
and HindIII, to then insert the 737 bp promoter fragment. The same procedure was done for 
plasmid p614-GFP except primers F25 and R13 were used, plasmid p680-GFP primers F27 and 
R13 was used and for plasmid p484-GFP, primers F28 and R13 were used. All plasmids were 
sent for sequencing before use in downstream applications. The BJAB tTa cells were transfected 
(nucleofection) using the program EN-150. After transfection, the sample was split in two. Half 
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went into a media with tetracycline and the other half into tetracycline-free media. A 10% SDS-
PAGE gel was prepared for Western blot analysis. The membrane was probed with anti-LMP1, 
anti-GFP, anti-actin and anti-tubulin as housekeeping gene loading controls (Figure 29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Western Blot of BJAB tTA LMP1 transfected with TRF2 promoter plasmids 
containing different promoter lengths. 
Transfection with the different plasmid constructs of the TRF2 promoter. Membrane was probed 
with anti-LMP1, anti-GFP, anti-actin and anti-tubulin. Lanes 1-2 were cells transfected with a 
TRF2 promoter of 821bp, lanes 3-4 were cells transfected with a TRF2 promoter of 737bp, lanes 
5-6 were cells transfected with a TRF2 promoter of 680bp, lanes 7-8 were cells transfected with 
a TRF2 promoter of 614bp, lanes 9-10 were cells transfected with TRF2 promoter of 484bp. 
 
 
Downregulation of GFP was still observed with promoter constructs of 821bp, 727bp, 680bp, 
614bp and 484bp. There is weak downregulation from promoter of length 680bp and 614 bp 
since the experiments depend on the strength in which LMP1 is induced. The more LMP1- 
induction, the more it will exert its effect of the TRF2 promoter. A double band can also be 
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observed in the anti-LMP1. This band is from anti-Tubulin. LMP1 and tubulin migrate at a 
height of 65kDa and 70kDa which are pretty close together. If the antibodies are used on the 
same western blot, and depending on the migration and separation, a double band can be seen. 
We can also see a stronger signal for LMP1 in lanes 4 and 10 because Tubulin and LMP1 are at 
the same height. Nevertheless, the construct p484-GFP, shows downregulation in three different 
experiments. Therefore, it was decided to further dissect the promoter in order to localize a 
region in which LMP1-induction no longer affected the expression of GFP protein via the TRF2 
promoter. Using the p821-GFP as DNA template with forward and reverse primers, whole 
plasmid PCR was performed in order to obtain a long fragment that can be ligated to form a 
circularized plasmid. Plasmids p400-GFP, p300-GFP, p250-GFP and p200-GFP were produced 
using their respective forward primers as mentioned in table 7 and with the reverse primer ALL-
RW R3. Figure 30 represents the Western blot results after transfection of the plasmids into 
BJAB tTA cell line induced (-Tet) and non-induced (+Tet) with LMP1. The membrane was 
probed with anti-LMP1 and anti-GFP, as well as anti-actin and anti-tubulin for housekeeping 
gene loading controls. 
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Figure 30: Western Blot of BJAB tTA LMP1 transfected with TRF2 promoter plasmid 
containing different promoter lengths. 
Transfection with the different plasmid constructs of the TRF2 promoter. The membrane was 
probed with anti-LMP1, anti-GFP, anti-actin and anti-tubulin. Lanes 1-2 were cells transfected 
with TRF2 promoter 400bp, lanes 3-4 were cells transfected with TRF2 promoter 300bp, lanes 5-
6 were cells transfected with TRF2 promoter 250bp and lanes 7-8 were cells transfected with 
TRF2 promoter 200bp. 
 
 
At 150bp of the promoter region, a downregulation is observed when LMP1 is induced (Figure 
31). When the promoter regions of 100bp and 50 bp were examined, basal GFP transcription 
similar to background levels was observed (Figure 31). Depending if our GFP primary antibody 
was fresh or older, the levels of GFP expression for 50bp would vary. The GFP expression 
would be visible on the blot with a fresh GFP, but if extra time for washing were added after 
incubation of the secondary antibody, the GFP level were not detectable on the blot. 
Nevertheless, the GFP expression was weak or undetectable on both p100-GFP and p50-GFP 
when the experiment was repeated multiple times. It was decided to dissect in between 100 and 
150bp to see if a more precise region could be localized for further analysis. 
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Figure 31: Western Blot of BJAB tTA LMP1 transfected with TRF2 promoter plasmid 
containing different promoter lengths. 
Transfection with the different plasmid constructs of the TRF2 promoter. Membrane was probed 
with anti-LMP1, anti-GFP, anti-actin and anti-tubulin. Lanes 1-2 were cells transfected with 
TRF2 promoter 150bp, lanes 3-4 were cells transfected with TRF2 promoter 100bp, lanes 5-6 
were cells transfected with TRF2 promoter 50bp and lanes 7-8 were cells transfected with no 
promoter in front of the GFP gene. 
 
 
Using whole plasmid PCR as mentioned in the materials and methods, constructs of 115bp, 
125bp and 140bp promoters were made. The results shown in Figure 32 are representative of 
three independent experiments for which one representative Western blot is shown. In Figure 32 
lanes 13-14 (150 bp promoter) a downregulation was observed upon LMP1 induction. In lanes 
11-12, the 140bp promoter also shows downregulation in the presence of LMP1, which is again 
seen for the 125bp promoter in lanes 9-10. Significantly, low basal transcription of GFP is seen 
for the 100 bp promoter (lanes 5-6) and 115 bp promoter (lanes 7-8). The experiment was 
repeated three times, each time showing similar results. From this, it was determined that a 125 
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bp promoter length is needed for sufficient GFP transcription. When the promoter section is 
below 125 bp, minimal basal transcription leads to GFP levels undetectable under the Western 
blot conditions used.  
 
 
 
Figure 32: Western Blot of BJAB tTA LMP1 transfected with TRF2 promoter plasmid 
containing different promoter lengths. 
Transfection with the different plasmid constructs of the TRF2 promoter. Membrane was probed 
with anti-LMP1, anti-GFP, anti-actin and anti-tubulin. Lanes 1-2 are cells transfected with no 
promoter in front of the GFP gene, lanes 3-4 are cells transfected with 50 bp of TRF2 promoter, 
lanes 5-6 are cells transfected with 100 bp of TRF2 promoter, lanes 7-8 were transfected with 
115 bp of TRF2 promoter, lanes 9-10 were transfected with 125 bp of TRF2 promoter, lanes 11-
12 were transfected with 140 bp of TRF2 promoter, lanes 13-14 were transfected with a TRF2 
promoter of 150 bp.  
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Figure 33: Quantification of three independent western blots for GFP analysis.  
The green line represents the GFP expression of three independent experiments quantified (using 
image.j) and normalized against actin. The blue lines represent the expression levels of TRF2 of 
one experiment from western blot in Figure 29. The yellow lines represent the expression levels 
of LMP1-induced in the cell line.  
 
The TRF2 promoter was dissected from a region of 2566 bp down to 50 bp where 
downregulation could be observed down to 125 bp. If the promoter is shorter than 125 bp, low 
basal GFP transcription is seen. A quantification of three independent experiments for GPF 
analysis was performed (Figure 33). The goal of our experiments was to delineate a region in 
which LMP1-induction did not affect the regulation of TRF2 at its promoter. In this case, no 
matter how low we dissected the promoter, downregulation could be observed. The promoter at 
length 115bp, was also at limit for GFP detection and showed downregulation. Thus, showing 
that for transcription of GFP gene, at least 125bp is needed for the basal transcription machinery 
to be able to attach and transcribe. At 100bp and 50bp of promoter length, basal background GFP 
expression was undetectable. What we were looking for was a region not affected by LMP1-
induction but instead, no matter how short the promoter length was, LMP1 was having an effect. 
Therefore, we hypothesize that LMP1-induction could interfere at the beginning of the promoter 
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either at the level of the basal transcription machinery or with a transcription regulator. To 
further study the promoter, it was decided to take a region between -130 bp and -100 bp of the 
TRF2 promoter. This region provides 30 bp of DNA for analysis by EMSA to first confirm if 
protein complexes bind to the region. Secondly, upon confirmation of protein binding, DNA 
Affinity Chromatography analysis of nuclear extract could be performed to provide further 
information on the protein complexes bound when LMP1 is present and absent.  
 
 
Electrophoretic-mobility shift assay (EMSA) 
 
 EMSA is a technique used to study protein-DNA interactions. By using a 5’ γ-ATP32 
radiolabelled dsDNA probe, band patterns can be observed and compared to nuclear extract from 
cells with LMP1 induced and non-induced. A region of 30 bp was chosen between -130 and -100 
bp of the TRF2 promoter to study the effects of LMP1 induction in the cell. An EMSA was 
performed to first determine if protein complexes bind to the region previously determined to be 
significant by Western blot analysis of GFP levels. As per description of the procedure found in 
the materials and methods, an EMSA was performed (Figure 34).  Lane 2 contains nuclear 
extract without LMP1 induction, meaning the BJAB tTA LMP1 cells were incubated in media 
with tetracycline. Lanes 3-5 contain samples where 10x, 50x or 200x fold excess of the specific 
competitor was added. The yellow stars in Figure 34 indicate the bands that are disappearing 
when excess of a specific competitor was added, in this case, it was unlabelled 30 bp dsDNA. A 
non-specific competitor was also added in excess fold of 50x or 200x to determine if the same 
bands that are disappearing are disappearing with the specific competitor will still be present 
when a non-specific competitor is added. As can be observed in lanes 7-8, the bands that 
disappear in lanes 4-5 are still present in lanes 7-8. This confirms that the protein complexes 
found in lanes 3-5 are most likely complexes specific to the 30 bp dsDNA probe. Lane 9 contains 
nuclear extract with LMP1 induced, meaning the BJAB tTA LMP1 cells were incubated in 
media without tetracycline. Lanes 10-12 contain samples where 10x, 50x or 200x fold excess of 
the specific competitor was added. The white stars in Figure 34, indicate the bands that disappear 
when an excess of a specific competitor is added. A non-specific competitor was also added in 
excesses of 50x or 200x fold excess. As can be observed, the bands that disappear in lanes 10-12 
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are still present in lanes 14-15. This confirms that the protein complexes found in lanes 3-5 are 
specific complexes binding to the 30 bp region of the dsDNA probe. 
 
 
 
 
 
Figure 34: Electrophoretic-mobility shift assay (EMSA) with the 30bp dsDNA 
An EMSA was performed using an oligonucleotide probe containing the region between -130 bp 
and -100 bp of the TRF2 promoter starting from the ATG start site as 1. Lanes 2-8 are with 
nuclear extract with No LMP1 (+Tet) and lanes 9-15 are with nuclear extract with LMP1 
induction (-Tet). Lanes 3-5 and lanes 10-12 used a specific competitor (unlabelled 30 bp 
dsDNA). Lanes 7-8 and lanes 14-15 used a non-specific competitor (Oligo B). Disregard lanes 6 
and 13 from the data analysis as the wrong competitor was added during the experiment.  
 
 
The EMSA data analysis confirmed that there is a change of proteins in the nuclear extract in the 
presence or absence of LMP1 induction. Consequently, an RNA sequencing assay (RNA-Seq) 
was performed to determine what other genes could be downregulated in the presence of LMP1 
induction in the BJAB tTA LMP1 cell line.  
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RNA Sequencing 
 
 LMP1 affects multiple pathways in the cell for the purpose of growth, proliferation and 
survival of the Epstein-Barr virus. The LMP1 oncogenic protein was found to effect multiple 
pathways such as activating the NF-kB, JNK, and p38 (Soni, Cahir-McFarland & Kieff, 2007). 
For the purposes of this study, only downregulated genes were focused on. TRF1 and TRF2, 
important telomeric proteins, were found to be downregulated when LMP1 was induced in the 
cells. To find a potential pathway affecting these genes, all RNAs extracted were studied to find 
what other genes were downregulated by LMP1-induction. Table 8 represents a list of the top 26 
genes affected by LMP1 induction. RNA seq data confirm the expected TRF1 and TRF2 
downregulation upon induction of LMP1. Congruent with previously published results (Lajoie et 
al., 2015), no significant change was observed in POT1 levels in LMP1-induced and non-
induced cells. 
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Gene Q-Value Log2-ratio 
(No LMP1 
versus 
LMP1 
sample) 
Reads 
Sample 1 
(No 
LMP1) 
Reads 
Sample 1 
(LMP1) 
Reads 
Sample 2 
(No 
LMP1) 
Reads 
Sample 2 
(LMP1) 
JCHAIN 2.36E-01 3.9 20.4 1.3 23.2 1.7 
SPINK2 2.55E-01 3.3 163.8 14.5 219.1 23.9 
LTB.d 2.25E-01 3.2 55.3 5.8 52.3 5.5 
AIF1.b 2.40E-01 3.0 11.7 1.7 13.8 1.5 
KCNN3 2.50E-01 3.0 9.3 1.2 11.5 1.3 
LDLRAP1 2.74E-01 2.9 23.2 1.7 14.8 3.4 
AIF1.d 2.40E-01 2.8 11.8 1.9 13.8 1.9 
AIF1.c 2.40E-01 2.8 11.8 1.9 13.8 1.9 
AIF1 2.40E-01 2.8 11.8 1.9 13.8 1.9 
CA11 2.47E-01 2.7 9.8 1.5 12.0 1.8 
ITK 2.25E-01 2.6 11.7 1.9 10.9 1.9 
LRMP 2.53E-01 2.6 157.3 28.9 198.2 30.7 
DBN1 2.40E-01 2.5 39.2 7.5 45.8 7.5 
TRAF3IP3 2.07E-01 2.4 12.1 2.1 12.3 2.5 
MED20 3.73E-01 2.4 5.3 2.7 26.3 3.5 
PRKCE 3.73E-01 2.3 44.7 8.4 11.4 3.0 
RGS13 2.11E-01 2.2 391.3 76.0 369.6 85.4 
TNS3 2.25E-01 2.1 17.1 5.6 18.9 2.6 
NCAM2 2.77E-01 2.1 9.4 4.8 15.9 1.0 
RETREG1 2.25E-01 2.1 108.0 24.5 116.9 28.3 
MEIKIN 3.09E-01 2.1 15.7 4.2 29.1 6.4 
TRIB1 2.36E-01 2.1 13.5 3.2 15.4 3.8 
CD69 2.36E-01 2.1 79.5 14.5 66.3 20.7 
BCL6 2.58E-01 2.0 12.4 2.9 16.7 4.2 
TERF2 3.73E-01 1.1 13.7 9.7 30.3 10.8 
TERF1 2.25E-01 0.6 11.3 7.8 12.0 7.5 
POT1 4.64E-01 0.0 37.7 37.4 28.2 22.6 
Table 8: RNA-Seq data of the most downregulated genes in LMP1-induced BJAB tTA 
LMP1 cells. 
 
Data analysis of the RNA-Seq results confirmed that 119 genes had equal to or greater 
downregulation than TRF2. With this data, bioinformatics analysis was performed to determine 
if transcription factor common motifs could be found within their promoters. With the help of the 
Université de Sherbrooke RNomics platform, bioinformatic analysis was carried out between -
130 bp and -100 bp of the TRF2 promoter to determine what motifs occur within this region. The 
JASPAR program was used to perform the analysis. Once found, the motifs were then compared 
within a region limited to 500bp of each gene promoter to see if some common motifs could be 
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observed in the downregulated genes. 14 motifs were found within the region between -130 bp 
and -100 bp of the TRF2 promoter. Table 9 contains the motifs with the total number of 
occurrences. Overall, 121 genes were analysed as TPP1 and POT1 were added to the list. A 
value of 1 was given to each gene in which a motif could be found and a 0 value was given if the 
motif is not found within their promoter.  
TRF2  Motifs Name JASPAR id Occurrence 
within 121 
genes 
Percentage 
Occurrence/121 
Found 
TRF1 
Promoter 
Found 
TPP1 
Promoter 
1 SPIB MA0081.1 100 82.64 1 1 
1 NFATC2 MA0152.1 100 82.64 1 1 
1 SP1 MA0079.3 101 83.47 1 1 
1 ZNF354C MA0130.1 94 77.69 0 1 
1 KLF5 MA0599.1 95 78.51 1 1 
1 ELF5 MA0136.2 82 67.77 1 0 
1 VDR MA0693.2 77 63.64 1 0 
1 TFAP2A MA0810.1 77 63.64 1 1 
1 E2F6 MA0471.1 75 61.98 0 0 
1 TFDP1 MA1122.1 73 60.33 1 0 
1 TFAP2C MA0524.2 71 58.68 1 1 
1 TFAP2B MA0811.1 67 55.37 1 1 
1 Ddit3:Cebpa MA0019.1 44 36.36 1 1 
Table 9: Common motifs found in promoters of TRF2 and 119 downregulated genes.  
 
The common motifs were then compared with the RNA-Seq data to see if the genes are being 
influenced in the presence or absence of LMP1 induction. Table 10 represents the results of the 
bioinformatic analysis combined with the RNA-seq results. The motifs found by using 
bioinformatics, are sites in which potential transcription factor proteins, listed in table 9, could 
potentially bind to our promoter region of interest. The genes were then verified in the RNA seq 
data to analyze and observe their behaviour when the cells are induced with LMP1. It was 
observed that SPIB, NFATC2, SP1 and Ddit3: CEBPA genes are upregulated, TFDP1 gene is 
downregulated in the presence of LMP1. KLF5 and E2F6 genes were found to be unaffected by 
the induction of LMP1 in the RNA-Seq data. ZNF354C, ELF5, VDR, TFAP2C, TFAP2B were 
not observed in the RNA-Seq data. These transcription factors have a probability of binding to 
our region of interest. 
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Motifs Gene Name No LMP1 vs LMP1 
Log2-ratio 
RNA-Seq: RNA regulation in 
the presence of LMP1-
Induction 
SPIB -0.9 Upregulated 
NFATC2 -0.3 Upregulated 
SP1 -0.3 Upregulated 
ZNF354C No Sample No Data 
KLF5        0.0     No Change 
ELF5 No Sample No Data 
VDR No Sample No Data 
TFAP2A No Sample No Data 
E2F6 0.0 No Change 
TFDP1 0.5 Downregulated 
TFAP2C No Sample No Data 
TFAP2B No Sample No Data 
Ddit3:Cebpa -0.7 Upregulated 
Table 10: Motifs found using bioinformatics combined with the RNA-Seq data.  
The RNA levels were analyzed in the presence and absence of LMP1 and annotated as 
upregulated, no change, no data or downregulated depending of its change in the cell when 
tetracycline was removed and LMP1 induced. 
 
With this new data, DNA affinity chromatography was performed to determine what protein are 
bound to the region found between -130 bp and -100 bp of the TRF2 promoter and if any 
proteins mentioned above could be pull-down.  
 
 
DNA Affinity Chromatography 
 
 The EMSA results determined protein complexes are binding to the 30 bp 
oligonucleotide probe of the TRF2 promoter region between -130 bp and -100 bp. The EMSA 
results showed different protein complexes binding to the 30 bp oligonucleotide probe in the 
nuclear extract with LMP1 induced and nuclear extract with no LMP1 induction. To determine 
what proteins were binding to the 30bp region, an oligonucleotide with a 5’-teg-biotin tag was 
ordered (Integrated DNA Technologies), in which the negative strand had the tag. (See protocol 
for DNA affinity chromatography mentioned in the materials and methods). By using 
streptavidin beads, the oligonucleotide was bound and with addition of 1.5 mg of nuclear extract 
the proteins were eluted through a series of washes. One-fifth of the sample was used for a gel 
analysis. A 10% acrylamide gel was used to separate the proteins and a silver stain was 
performed. As seen in Figure 35, lanes 1-3 are the inputs of the experiment and lanes 4-5 are the 
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proteins eluted.  Lane 4 is the control with nuclear extract but no oligonucleotide. Lane 5 is the 
oligonucleotide with nuclear extract with no LMP1 induction; multiple bands are observed at 
different molecular weights. When nuclear extract from cells where LMP1 has been induced for 
72hrs is used in the same conditions, the banding pattern changed and a new one appears, as 
observed in lane 6. Once the silver stain was obtained and a clearly different banding pattern was 
observed between the two experimental conditions, the remaining sample was sent to mass 
spectrometry. 
 
 
 
Figure 35: Silver stain from sample obtained after DNA affinity chromatography 
experiment. 
A biotin labelled 5’ end of the dsDNA oligonucleotide probe containing the region between -
130bp and -100bp of the TRF2 promoter was used for this experiment. Lane 1 is input of 
negative control with no oligonucleotide, Lane 2 is input of nuclear extract non-induced with 
LMP1, Lane 3 is input of nuclear extract of LMP1-induction, Lane 4 is the eluted negative 
Nuclear Extract
dsDNA-Teg-Biotin
LMP1
Inputs Elution
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control, lane 5 is the elution when a nuclear extract with no LMP1 and Lane 6 is with LMP1. 
Different band patterns appear in Lane 6 when an LMP1-induced nuclear extract was used.  
 
 Mass spectrometry was performed by the laboratory of Francois-Michel Boisvert to 
determine what was bound to the 30 bp region of interest. 1169 proteins were identified. See 
annex Table 15-16 for the complete list of proteins identified. A negative control (with no 
oligonucleotide dsDNA) was used to eliminate any non-specific proteins binding to the 
streptavidin beads. All samples that had proteins lesser or equal to the negative control found 
during mass spectrometry analysis were dismissed. Afterwards, the samples with LMP1-
induction versus the sample with No LMP1 were compared to each other to find which had more 
proteins in one compared to the other. What we want is to find specific proteins in each sample. 
If the total protein MS/MS count was lower than 2 peptides, the proteins were not considered 
further.  If the proteins between the LMP1 non-induced and induced samples were equal to each 
other they were grouped together for potential further analysis. The proteins were then separated 
by the protein MS/MS counts and assigned to two separate groups. The groups were determined 
as follows: proteins where LMP1>No LMP1 were assigned to Group “LMP1”; and proteins 
where No LMP1>LMP1 were assigned to Group “No LMP1”. Once the proteins were separated 
into the “No LMP1” and “LMP1” groups, a ratio between the Total MS count over the sample 
was made between the two samples. Then a cut-off of 2-fold increase was made. This is to 
determine what proteins within the samples were found to be 2-times greater than the sample 
being compared to. The experiment and analysis was repeated a second time using the same 
parameters. Once obtained, the samples N=1 and N=2 for both “No LMP1” and “LMP1” were 
verified for a common set of proteins. For the No LMP1 experiment, it was found that N=1 had 
434 proteins, N=2 had 371 proteins, and there were 293 proteins in common between the two 
assays (reproducible by 73%). For the LMP1 experiment, it was found that N=1 had 227 
proteins, N=2 had 198 proteins, and there were 144 proteins in common between the two assays 
(reproducible by 66%).  The set of proteins found in each experiment were taken as the group of 
specific proteins for further analysis (Figure 36).  
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Figure 36: Schematic chart analysis of the Mass Spectrometry results of No LMP1 versus 
LMP1 samples from DNA Affinity Chromatography experiments. 
Pie charts were designed to show to percentage of proteins that went into each category. A) 
Sample from the no LMP1(+Tet) in which 31% proteins fall in the category of transcription 
factors, core promoter binding, chromatin binding, sequence-specific DNA binding, protein in 
the basal transcription machinery, 35% are RNA binding or RNA splicing and 34% are other 
proteins such as ribosomes, DNA-Damage response proteins, histones and etc. B) are samples 
from the LMP1-induced (-Tet) in which 45% proteins fall in the category of transcription factors, 
core promoter binding, chromatin binding, sequence-specific DNA binding, protein in the basal 
transcription machinery, 8% are RNA binding or RNA splicing and 47% are other proteins such 
as ribosomes, DNA-Damage response proteins, histones and etc. 
 
 For the full list of proteins found in the MS analysis, please see Annex 14-15. Proteins 
were classified according to their molecular function as per Go Annotation: Gene ontology 
Consortium (http://www.geneontology.org/). The proteins were then chosen for analysis based 
on their unique peptides count, peak intensities, and function. In parallel, they were verified 
against the RNA-Seq experiment to compare if they are upregulated or downregulated in the 
presence of LMP1. The proteins shown below, table 12-13, are the top ten proteins that were 
found within the categories of core promoter binding or sequence-specific DNA binding for the 
No LMP1 and LMP1 group. The region being studied is a small region of the TRF2 promoter; 
therefore, we wanted to focus on proteins possibly binding to DNA or part of the basal 
transcription machinery. 
31%
35%
34%
No LMP1 (+Tet)
Transcription Factors/DNA
binding/Chromatin
RNA binding/RNA Splicing
Other:Ribosomes,DDR,Histones,etc
1169 Proteins identified
N=2 Experiments
Classified  them according:
Molecular Function
Found in absence LMP1 Found in presence LMP1After Analysis
Reproducible at 73%
144 specific proteins293 specific proteins
Reproducible at 66%
45%
8%
47%
LMP1 (-Tet) 
BA
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Table MS No Change Between No LMP1 and LMP1  
Protein 
Name 
Unique 
Peptides 
Sequence 
Coverage 
Peak 
Intensities 
RNA Seq GO 
Annotation 
Molecular 
Function 
SPIB 4 11 1.15E+08 Upregulated Sequence-
specific DNA 
binding 
NFATC2 5 3.6 3.30E+06 No Change Sequence-
specific DNA 
binding 
Pax5 9 44.2 7.09E+09 No Change Sequence-
specific DNA 
binding 
SPI1 2 28.1 3.66E+08 Downregulated Sequence-
specific DNA 
binding 
Table 11: Proteins found in both No LMP1 and LMP1 sample with no apparent change in 
the mass spectrometry analysis and are sequence-specific DNA binding proteins. 
 
 
The bioinformatics found possible proteins that could be binding to the region of interest that is 
between -150bp and -100bp. With the mass spectrometry analysis, we were able to pull-down 
proteins previously mentioned by the bioinformatics identified to bind to conserved regions. 
SPIB and NFATC2 were proteins pull-down with the 30bp region and identified by mass 
spectrometry (Table 11). These proteins were found in both samples in the presence or absence 
of LMP1. I also performed promoter sequence analysis to find possible transcription factors 
binding to our region. Pax5 and SPI1 were two different proteins identified from the 14 others 
identified in table 8. Pax5 and SPI1 were found by mass spectrometry analysis (Table 11). These 
proteins are candidates for binding to our region and possibly being regulated by unknown 
mechanism during LMP1-induction. 
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Table MS No LMP1  
Protein 
Name 
Unique 
Peptides 
Sequence 
Coverage 
Peak 
Intensities 
RNA Seq GO 
Annotation 
Molecular 
Function 
DNMT1 51 36.5 
 
2.05E+09 
 
No Change Sequence-
specific DNA 
binding 
HNRNPU 
 
45 45.9 
 
3.02E+09 
 
No Change Core promoter 
binding 
IFI16 
 
22 50.2 
 
8.24E+09 
 
Upregulated Core promoter 
binding 
MED1 
 
19 15.1 3.40E+08 
 
No Change Core promoter 
binding 
BRD4 
 
17 14 
 
7.88E+08 
 
Upregulated Core promoter 
binding 
RUVBL2 
 
17 29.4 
 
3.28E+08 
 
Downregulated Core promoter 
binding 
SLTM 
 
16 17 
 
8.42E+08 
 
Upregulated Sequence-
specific DNA 
binding 
BRD2 
 
14 29.7 
 
4.79E+08 
 
Upregulated Core promoter 
binding 
THRAP3 12 16.4 8.03E+08 
 
No Change Core promoter 
binding 
BRD3 8 27 
 
3.95E+08 No Change Core promoter 
binding 
Table 12: Top 10 proteins found in mass spectrometry for sample with No LMP1 induction 
that are either core promoter binding proteins or sequence-specific DNA binding proteins. 
 
From the DNA affinity chromatography and mass spectrometry, multiple proteins with different 
roles were identified. The list in table 12, are the top proteins that were assigned, by Go 
Annotation, a category such as core promoter binding or sequence-specific proteins. Many 
proteins play a role in chromatin remodelling such as DNMT1, BRD2, BRD3, BRD4 and 
RUVBL2. BRD4 plays a key role in regulating the transcription of signal-inducible genes by 
associating with the P-TEFb complex and recruiting it to promoters (Ai et al. 2011) IF116 is a 
transcription activator binding to double-stranded DNA (Li et al. 2012) and a potential candidate 
for further analysis. The MED1 was also found through mass spectrometry, a co-activator 
protein important in transcription regulation. A lot of proteins found in the No LMP1 data are 
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interesting proteins as they a coincides with transcription DNA-binding or chromatin 
remodelling. 
When it came to protein data found in the LMP1 samples analyzed by mass spectrometry in the 
region between -130 bp and -100bp of the TRF2 promoter, the protein composition changed 
(Table 13). Interestingly, two repressors were found: CTCF and YY1;YY2 (Austen, Luscher & 
Luscher-Firzlaff, 1997) MYBBP1A also plays a role in repression when interacting with 
sequence specific DNA-binding proteins (Hara et al., 2009). 
 
Table MS LMP1 (-Tet) 
Protein 
Name 
Unique 
Peptides 
Sequence 
Coverage 
Peak 
Intensities 
RNA Seq GO 
Annotation 
Molecular 
Function 
UBTF 45 43.3 
 
1.09E+10 
 
No Change Core promoter 
binding 
WDR76 
 
19 27.5 
 
7.40E+08 
 
No Change Core promoter 
binding 
NOC2L 19 21.9 
 
1.42E+09 
 
No Change Sequence-
specific DNA 
binding 
CTCF 17 18.8 
 
1.77E+09 
 
Downregulated Sequence-
specific DNA 
binding 
MYBBP1A 
 
13 7.8 
 
1.86E+08 
 
No Change Core promoter 
binding 
ZNF106 12 17.9 
 
2.65E+08 
 
No Change Sequence-
specific DNA 
binding 
ZNF629 10 10.4 
 
3.54E+08 
 
No Change Sequence-
specific DNA 
binding 
YY1; YY2 10 13.5 
 
1.48E+09 
 
No Change Core promoter 
binding 
ABT1 6 20.2 
 
1.97E+08 
 
No Change Sequence-
specific DNA 
binding 
HOXB4 6 17.9 
 
2.37E+08 
 
No Change Sequence-
specific DNA 
binding 
Table 13: Top 10 proteins found in mass spectrometry in sample induced with LMP1 that 
are either core promoter binding proteins or sequence-specific DNA binding proteins. 
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Discussion and Conclusions 
 
 EBV-positive Hodgkin lymphoma has been shown to have telomeric dysfunction as cells 
transition from mononucleated cells into multinucleated cells. It was also published by Lajoie et 
al., 2015, that the oncogenic protein LMP1 produces multinucleation and downregulates TRF1, 
TRF2 and POT1 through pathways that remain to be determined. Further, LMP1 had no effect 
on TRF2 regulation when a Myc-driven TRF2 was reintegrated into a BJAB tTA LMP1 cell line 
expressing LMP1. These experimental analyses therefore shed light into how a virally induced 
cancer originates via the regulation of telomere-related proteins, in particular TRF2. It was then 
hypothesized that LMP1 might play a role in the downregulation of TRF2 by affecting its 
promoter function. Understanding how TRF2 is expression is regulated might allow us to 
determine a new pathway of regulation by LMP1 in Hodgkin Lymphoma. 
 
LMP1-induction affects TRF2 at its promoter 
 
 LMP1 is a trans-membrane protein that mimics a cellular necrosis receptor (TNFR) 
family member. Its two spanning domains, referred to as CTAR-1 and CTAR-2, have been 
shown to be critical for signalling through TNFR-associated factors (TRAFS) (Devergne et al., 
1996), activation of transcription factors such as NF-κB (Brodeur, Cheng, Baltimore & Thorley-
Lawson, 1997), AP-2 (by p38 mitogen-activated protein kinase) (Eliopoulos et al., 1999) and 
AP-1 via the JNK pathway (Eliopoulos, Blake et al., 1999). As a key factor in B-cell 
transformation, the pathways by which it activates and inhibits transcription factors are not fully 
understood. It was shown by Lajoie et al., 2015, that if a myc-driven TRF2 is integrated in an 
LMP1-expressing cell, this expression did not affect the promoter function. We therefore 
hypothesize that LMP1-induction might be interfering with TRF2 expression via gene promoter 
inhibition. In previous studies, it was shown by Everly, Mainou  
and Raab-Traub, 2009, that LMP1 decreases p27 RNA levels and the activity of the p27 
promoter. LMP1 was found to regulate the promoter element through the E2F family 
transcription factors (E2F4 and p130). Therefore, to determine if LMP1 affects TRF2 via the 
promoter region, constructs were made in which a GFP reporter gene was placed under the 
control of various portions of the TRF2 promoter. The precise constitution of the TRF2 promoter 
is unknown. Furthermore, there is a lack of knowledge regarding its regulation in terms of 
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silencers or other regulatory sites. For the dissection of the TRF2 promoter, we started with 
2566bp and 1307 bp of upstream sequences from the translation start site (TSS) of the ATG (+1), 
including the known 5’UTR of 17bp. This length was chosen in order to try to include any 
regulatory sites, as they can be found thousands of base pairs away from the gene. It was 
important to include the 5’ UTR, as it can also be regulated by different mechanisms. By 
Western blot, we showed that the GFP protein is downregulated with both the 2566bp and 1307 
bp TRF2 promoter fragments (Figure 17). To our knowledge, these findings provide the first 
demonstration that LMP1-induction can influence the regulation of a telomeric protein, TRF2, 
via its promoter sequences.  
 
 Flow cytometry is another technique that we attempted to use to determine the GFP 
downregulation as observed by Western blot. This approach was thought to be simple and rapid, 
as no antibody was needed, and the protein can be detected directly inside cells. To start the 
analysis, a negative control was created with no promoter (PL) upstream the GFP gene and 
analyzed via flow cytometry to determine where our peaks fall. Figure 18 represents the data 
obtained for the cells expressing or not LMP1. This represents the background noise for when 
cells were transfected with the PL-GFP. We also included a positive control with a CMV 
promoter as shown in Figure 19. As predicted, we found the plasmid construct with the TRF2 
promoter in between the two controls, as seen in Figure 20 and 21. However, the analysis could 
not be continued with flow cytometry as the plasmids, p2566-GFP and p1307-GFP did not show 
any detectable and reliable shift when LMP1 expressing cells were compare to non-expressing 
cells. One explanation for this may be that TRF2 has a weak promoter, and therefore weak GFP 
protein expression. When LMP1 is expressed, the TRF2 promoter is downregulated by 
approximately 40% (Lajoie et al 2015), therefore, if we have a weak promoter and a small 
amount of GFP protein produced, the flow cytometry might not be sensitive enough to detect the 
change.  
 
 Another way to assess eGFP gene expression, could be real-time PCR (RT-qPCR). For 
these analyses, different primers were used for quantification as shown in the materials and 
methods section. Some difficulties arose when analyzing the data in Figure 22. The negative 
control, positive control and the experimental samples all had similar high CT values of over 30. 
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A ct value above 30 indicates minimal amounts of the target nucleic acids being amplified. 
However, the housekeeping genes were located in the range of 23-24 for CT values, which is 
within the expected range for successful RT-qPCR target amplification, indicating that the 
problem was specifically with amplification of the GFP mRNA target. The melting curves 
showed one peak for each primer, thus confirming that it was targeting one amplicon and not 
many. The amplicons were also verified on agarose gel. There was amplification of the no cDNA 
template control in the mixture, indicating possible contamination by GFP.  To eliminate the 
possible contamination and to improve reproducibility, RT mix (Quantitect RT Kit 205311) 
Biorad qPCR buffer (iScript
TM
RT supermix, Product 1708840) was used. In order to optimize 
the RT-qPCR, different concentrations of the cDNA for qPCR were quantified. By performing a 
serial dilution of a sample containing cDNA for qPCR, it was found that for the primers used in 
this study, a good starting amount was 2ug of cDNA to obtain sufficient amplification during 
qPCR. A standard primer dilution curve was made to test the efficiency of the primers at 
different concentrations. These modifications and optimizations led to better results for the 
housekeeping genes, TRF2 (Figure 28) and LMP1 (Figure 27), however the eGFP expression 
levels were still not comparable, as only low expression of the target gene was detected (Figure 
25-26). Also, when qPCR samples were loaded on a gel, the no template sample was still 
amplifying the GFP gene. To resolve this problem, it was decided to utilize the relatively new 
technique ddPCR for eGFP analysis, as it has shown to be beneficial when trying to quantify low 
abundance targets. In addition, to reduce the possibility that contamination could be coming from 
our lab, after cells were harvested, they were mixed with Trizol and given to the Université de 
Sherbrooke RNomics platform for RNA extraction, RT and ddPCR analysis. Furthermore, new 
primers targeting the end of the gene were designed for the eGFP quantification. Since the eGFP 
gene does not have an exon, the end of the gene was targeted for better amplification and also to 
minimize any non-specific annealing with other genes. The primers GFP F16R16 and GFP 
F18R18 were used in the ddPCR analysis. As can be seen in both Figures 25-26 of the eGFP 
analysis by ddPCR, the plasmid with no promoter upstream the eGFP gene is being amplified 
within the samples. Samples that could not be detected in the Western blot analysis seemed to be 
present in the ddPCR, such as the promoterless plasmid, and the plasmids containing 50 bp and 
100 bp promoter regions. Even more concerning, the plasmids that expressed detectable eGFP in 
our Western blot, seemed to be comparable in terms of RNA expression to the promoterless 
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plasmid. Thus far, we have found it difficult to explain why eGFP is detectable in ddPCR, other 
than the possibility there is GFP contamination in the buffers or RT mix being used in RT-qPCR 
experiment. Upon discussion with other laboratories using GFP as a reporter gene, unexplained 
GFP signal was found to be a common and recurring problem. For future experiments, the 
construct could be switched to a luciferase gene in which both RT-qPCR and fluorescent analysis 
could be performed. This could confirm RNA expression levels in the experiment in which a 
downregulation can be seen during LMP1 induction. However, for the purposes of this project, 
we decided to continue analyzing GFP-expression from the various promoter constructs  via 
Western blot analysis as the plasmid constructs were already done and a downregulation could 
be documented with this approach. 
 
Identifying a smaller region of TRF2 affected by LMP1-induction 
 
 By Western blot analysis (Figure 17) it was determined that LMP1 induction 
downregulated expression of GFP via the TRF2 promoter. To determine a region of regulation, 
the TRF2 promoter was progressively shortened until a region would no longer be affected by 
LMP1-induction. We started with regions containing 2566bp and 1307 bp upstream of the ATG 
and then dissected with shorter promoters. The first constructs used for analysis were 821bp, 
737bp, 680bp, 614bp and 484 bp all of which showed a downregulation in the presence of 
LMP1-induction. The downregulation for promoters 680bp, 614bp was not as pronounced as the 
other promoters. Two things will influence the experiment: level of transfection of the plasmid 
into the cell and the induction level of LMP1 upon removal of tetracycline. Therefore, depending 
on the experiment and the cells’ ability to express LMP1, it will influence and vary the degree of 
downregulation on the promoters.  The experiment was repeated three times, confirming that 
LMP1-induction downregulated the TRF2 promoter of 821bp, 737bp, 680bp, 614bp and 484 bp 
(Figure 29). We then constructed plasmids with smaller promoter regions comprising 400bp, 
300bp, 250bp and 200bp. Again, the downregulation in the presence of LMP1- induction 
persisted in all these constructs (Figure 30). Therefore, the site of regulation on the TRF2 
promoter should be further downstream. For further analysis, constructs of 150bp, 100bp and 50 
bp were made. As seen in Figure 31, in the construct of 150bp, a good GFP expression can be 
observed by Western blot but when a length of 100 bp promoter was used, a low level of GFP 
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expression was seen. If a 50bp promoter length construct was used, minimal to no expression 
could be detected. This analysis indicated that a promoter of minimally 100 bp is needed for 
proper expression. We hypothesize that the regulation at the TRF2 promoter is occurring 
between 150bp and 100bp. To find a smaller region for analysis, the TRF2 promoter was 
dissected between the 150bp and 100bp and constructs of promoter length of 140bp, 125bp and 
115bp were made for further analysis. In fact, 140bp as well as 125bp were still enough for the 
downregulation by LMP1-induction (Figure 32). When a promoter length of 115bp was used, 
only a low amount of eGFP can be detected by Western blot analysis and a downregulation could 
still be observed. It was reasoned that a minimum of 125 bp of the TRF2 promoter was needed 
for gene transcription. At 125 bp, downregulation affected by LMP1-induction could be easily 
observed. In parallel, the endogenous TRF2 was also probed with anti-TRF2 to show that it was 
also downregulated by the presence of LMP1-induction in the cell. Quantification was also done 
on three independent experiments to visualize the GFP expression of promoters 150bp, 140bp, 
125bp, 115bp, 100bp and the promoterless via a bar graph (Figure 33). Only one quantification 
was done for LMP1 and TRF2 and this was taken from the Western blot in Figure 32. Figure 33 
visually represents the downregulation occurring between promoter 150bp-100bp when LMP1 is 
induced. Even if the expression of GFP is minimal on a Western blot, a downregulation by 
LMP1 is still observed down to 100bp. To move forward with the TRF2 promoter analysis, it 
was decided to take the region between -130bp and -100bp for protein analysis. 
 
RNA Sequencing Analysis 
 
RNA Seq was performed on the cells cultivated for 72hrs after addition or removal of 
tetracycline for the induction of LMP1. This technology was used to provide information on all 
of the transcripts that were upregulated or downregulated. For our specific case, we wanted to 
assess what other genes besides TRF2 were downregulated upon LMP1 induction. Data analysis 
of the RNA-Seq results confirmed that 119 genes had equal to or greater downregulation than 
TRF2. With these new genes found to be regulated in the presence of LMP1, a bioinformatic 
analysis was performed to detect possible common motifs in the region of -130 bp and -100 bp 
of the TRF2 promoter vs the region of 500bp of each of the promoters of the co-regulated genes. 
With this approach, 14 motifs were found, as described in table 9. The analysis was also 
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compared with TPP1, since this gene was not affected by LMP1-induction. It was found that 
ELF5, VDR E2F6 and TFDP1 motifs were found in both the TRF1 and TRF2 promoters but not 
the TPP1 promoter. Therefore, the RNA Seq provided a starting point as to we might expect as 
factors to be found via DNA Affinity Chromatography and Mass Spectrometry analysis.  
 
RNA seq did confirm some upregulated genes that play role in the LMP1 signalling pathway, 
such as TRAF1, STAT3, STAT2, STAT5A, STAT1, ATF2 and JUNB. When these genes are 
activated, they induce numerous downstream effectors and impact a variety of cellular processes 
such as proliferation, cytokine induction, apoptosis and cell survival (Morris, Dawson & Young, 
2009). These data hence confirm that our RNA Seq is comparable to other published articles 
showing genes affected by LMP1-induction. 
 
Protein Analysis on promoter region between -130bp and -100bp 
 
 To determine protein-DNA interactions, an EMSA was performed. A 5’ γ-ATP32 
radiolabelled 30bp dsDNA probe corresponding to the region between -130bp and -100bp of the 
TRF2 promoter and nuclear extract from LMP1-expressing or non-expressing cells were used for 
the assay.  After including specific and non-specific competitor DNA in the assay, it could be 
determined that we had a number of specific complexes binding to our 30bp probe. When the 
experiment was repeated using a nuclear extract in which LMP1 was induced for 72hrs, there 
was a significant change in observed banding patterns. This confirmed that LMP1-induction 
creates a cascade of events leading to a change in protein composition within the nucleus. 
Altogether, this EMSA assay confirmed two things: firstly, we have protein-DNA interaction 
with our probe and secondly, we have a different protein composition binding to our probe 
depending on the presence or absence of LMP1 in the cell.  
 
 To determine what the different proteins were on the small region of the TRF2 promoter, 
a pull-down was performed (also known as DNA affinity chromatography). The BJABJ tTa 
LMP1 cell line was used to obtain nuclear extracts with and without LMP1. By using a biotin-teg 
tag on a dsDNA 30bp region (-130bp and -100 bp), and nuclear extract, proteins were pull-down 
and analyzed by PAGE. The silver stained gel revealed multiple bands with both nuclear 
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extracts. However, the patterns of them were very different with many bands in the absence of 
LMP and two major bands that appear around 26kDa with LMP1 (Figure 35). These results are 
congruent with the EMSA results, confirming there are different protein interactions within the 
30bp region in the presence or absence of LMP1.  
 
 Finally, the proteins binding to the region between -130 bp and -100bp were identified by 
mass spectrometry. After systematic analyses, the data were placed in two groups: No LMP1 
(cells with tetracycline) and LMP1 (cell induced by removal of tetracycline). By doing so, 293 
specific proteins were found in the No LMP1 group and 144 specific proteins were found for the 
LMP1 group. The reproducibility for No LMP1 was 73% and 66% for LMP1. Table 10 and 
Table 11 represent the top 10 proteins found in both groups. For the No LMP1 group, 
interestingly, the top protein found was DNMT1 and that this protein was not found within the 
samples with LMP1. DNA methyltransferase (DNMT) is a common epigenetic factor that 
methylates CpG islands and contributes to regulation of gene expression (Robertson, 2001). 
Upon LMP1-induction, DNMT1 and DNMT3b were found to be downregulated in GC B cells 
(Leonard et al. 2011) This is significant as our RNA seq data also confirmed that both DNMT1 
and DNMT3b are downregulated within the data set. Dnmt1 also interacts with a large number of 
repressor proteins, such as histone deacetylases to inhibit transcription in a methylation-
independent manner. Based on this information, DNMT1 might not be the protein of interest in 
our case as it is a transcriptional repressor while our results require a transcriptional activator. 
 
One of the top 3 proteins found in mass spectrometry in the group No LMP1 was a protein called 
IFI16. The IFI16 was found to be upregulated in the RNA seq data. It is a member of the 
interferon-inducible HIN-200 family of nuclear proteins that is implicated in activation in 
transcriptional regulation by modulating protein-protein interactions. IFI16 is involved in p53-
mediated transcriptional activation and apoptosis by upregulating p53 and downregulating 
MDM2 (Fujiuchi et al., 2004). These data coincide with other data that shows LMP1 suppressing 
MDM2 and thus promoting p53 accumulation (Li et al., 2012) in which in this case, could be 
because of IF116 upregulation. This is interesting because our region of interest is a double-
stranded DNA promoter region and we are trying to identify regulatory proteins binding to this 
region. Since it is upregulated in the presence of LMP1-induction as shown in the RNA-seq data, 
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it could be hypothesized that it could be binding to our promoter region but its protein partners or 
mediators are downregulated, therefore, decreasing interaction and possible recruitment of the 
transcription machinery. This would in fact decrease the expression levels of TRF2 during 
transcription.  
 
Combined with the bioinformatics analysis, 14 different motifs were found within the 30bp 
region of the TRF2 promoter and these motifs were also found in 82% of the 119 genes co-
downregulated. Mass spectrometry of the No Change group, found SPIB, and NFATC2 that 
were pulled-down and the binding motifs of these proteins are included in the 14 motifs above. 
However, these proteins were grouped separately as they were found equally in both No LMP1 
and LMP1 samples. SP1I and Pax5 were also added as they were found using ALGGEN.com 
program (identification of putative transcription binding sites in DNA sequences) (Table 9). To 
fit with our hypotheses, MED1 and THRAP3 (Table 10) could be potential candidates as both 
are core promoter binding proteins and part of basal transcription machinery. Not shown in the 
top proteins but can be found in the annex, are other MED proteins, ERCC2/ERCC3 and also 
transcription factors such as GTF2 (H4, F1, H2C, H2, E2), and MNAT1. These proteins are all 
part of basal transcription machinery. For the LMP1 group, the entire protein composition 
changes, as confirmed by EMSA and silver stain, instead of having the basal transcription 
factors, DNMT1 or IFI16. The shift is towards activator or repressor proteins such as YY1; YY2 
and CTCF, which are known gene regulators (Austen et al., 1997) (Table 11). 
 
RNA Seq analyses combined with mass spectrometry will need to undergo further refinement. 
However, a preliminary hypothesis emerges from this information. It is possible that the proteins 
found by bioinformatics and mass spectrometry (Table 9) are proteins that are bound to the 
promoter in the presence or absence of LMP1. These could be the key proteins that interact with 
the DNA and then recruit the transcription machinery to the promoter. We further speculate that 
the proteins found in the No LMP1 group could be found in a complex(es) and interact with the 
DNA bound proteins on the promoter to initiate transcription. Therefore, it is also possible that 
these proteins such as SPIB and NFATC2 are stabilized by its interacting partners to the DNA 
and recruit the transcription machinery. Then upon LMP1-induction, their interacting partners 
are downregulated, thus decreasing transcription of TRF2. If SPIB, Pax5 or NFATC2 need an 
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interacting partner to stay bound at the promoter, but during LMP1-induction this partner is 
downregulated, this would cause the proteins to dissociate from the DNA. Then during LMP1-
induction, it would give the chance of competing proteins to associate with the promoter. In this 
case, there will be site competition and giving the opportunity of other regulatory repressor 
proteins such as CTCF or YY1; YY2 proteins to bind to the promoter (Table 11). These proteins 
were found in the mass spectrometry in our LMP1 group, giving new insight that a repressor 
might be considered in the TRF2 promoter regulation during LMP1-induction. These hypotheses 
need to be tested in future experiments. 
 
The results of this project clearly demonstrate that the LMP1 mediated signalling 
pathway interferes with TRF2 transcription at its promoter. To date, only one EMSA was 
performed using nuclear extracts using the same extracts and then used for mass spectrometry. 
To confirm the results, these experiments will be repeated with new nuclear extracts for both the 
EMSA and mass spectrometry. Additional EMSAs will be performed using BJAB tTA cells with 
the addition and removal of tetracycline to verify that the tetracycline is not the cause of the 
protein shifts. Even though the proteins previously mentioned are proteins with the function of 
DNA binding, chromatin DNA binding and RNA splicing proteins cannot be excluded as they all 
could play a dynamic role in transcription. As many genes were found to be upregulated or 
downregulated as well as the different proteins found during the mass spectrometry analysis, 
further work will be needed to elucidate the role of LMP1-induction at the TRF2 promoter. By 
understanding how LMP1-induction affects the regulation of TRF2 at its promoter, we could 
determine a pathway back the trans-membrane LMP1 to fully understand its role in the cascade 
of events leading to the downregulation of TRF2.  
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Annex 
 
RNA-Seq Data 
 
Table RNA Seq Downregulated Genes 
Gene T-test Q-value 
Log2-
ratio 
Sample1 
No 
LMP1 
Sample2 
 LMP1 
Sample2 
No 
LMP1 
Sample2 
LMP1 
JCHAIN 4.09E-02 2.36E-01 3.9 23.2 1.7 20.4 1.3 
SPINK2 9.37E-02 2.55E-01 3.3 219.1 23.9 163.8 14.5 
LTB.d 1.90E-02 2.25E-01 3.2 52.3 5.5 55.3 5.8 
AIF1.b 5.83E-02 2.40E-01 3.0 13.8 1.5 11.7 1.7 
KCNN3 7.64E-02 2.50E-01 3.0 11.5 1.3 9.3 1.2 
LDLRAP1 1.46E-01 2.74E-01 2.9 14.8 3.4 23.2 1.7 
AIF1.d 5.81E-02 2.40E-01 2.8 13.8 1.9 11.8 1.9 
AIF1.c 5.81E-02 2.40E-01 2.8 13.8 1.9 11.8 1.9 
AIF1 5.81E-02 2.40E-01 2.8 13.8 1.9 11.8 1.9 
CA11 6.70E-02 2.47E-01 2.7 12.0 1.8 9.8 1.5 
ITK 2.50E-02 2.25E-01 2.6 10.9 1.9 11.7 1.9 
LRMP 8.69E-02 2.53E-01 2.6 198.2 30.7 157.3 28.9 
DBN1 5.95E-02 2.40E-01 2.5 45.8 7.5 39.2 7.5 
TRAF3IP3 3.01E-03 2.07E-01 2.4 12.3 2.5 12.1 2.1 
MED20 4.38E-01 3.73E-01 2.4 26.3 3.5 5.3 2.7 
PRKCE 4.03E-01 3.73E-01 2.3 11.4 3.0 44.7 8.4 
RGS13 8.66E-03 2.11E-01 2.2 369.6 85.4 391.3 76.0 
TNS3 2.56E-02 2.25E-01 2.1 18.9 2.6 17.1 5.6 
NCAM2 1.54E-01 2.77E-01 2.1 15.9 1.0 9.4 4.8 
RETREG1 1.47E-02 2.25E-01 2.1 116.9 28.3 108.0 24.5 
MEIKIN 2.31E-01 3.09E-01 2.1 29.1 6.4 15.7 4.2 
TRIB1 4.21E-02 2.36E-01 2.1 15.4 3.8 13.5 3.2 
CD69 4.09E-02 2.36E-01 2.1 66.3 20.7 79.5 14.5 
BCL6 1.04E-01 2.58E-01 2.0 16.7 4.2 12.4 2.9 
NMU 8.49E-02 2.52E-01 1.9 40.8 9.2 33.2 10.1 
NTNG1 5.97E-02 2.40E-01 1.8 11.4 3.1 10.0 3.0 
LDLRAD4 7.08E-02 2.47E-01 1.8 12.6 3.0 10.4 3.5 
SOX5 6.68E-03 2.08E-01 1.8 19.4 5.7 19.3 5.4 
MAP3K7CL 1.54E-02 2.25E-01 1.8 17.9 5.7 18.1 4.7 
UBL4A 5.39E-02 2.37E-01 1.8 14.0 6.3 18.1 3.0 
DLG3 1.54E-02 2.25E-01 1.8 12.2 4.1 10.8 2.6 
PTPN6 7.50E-02 2.49E-01 1.7 203.0 56.4 171.6 55.2 
CAMK1 2.16E-03 1.95E-01 1.7 18.3 6.1 19.2 5.3 
SMIM14 6.55E-02 2.45E-01 1.7 53.9 14.4 45.9 15.8 
NUGGC 2.84E-01 3.37E-01 1.7 14.6 3.1 7.3 3.6 
INPPL1 1.48E-01 2.74E-01 1.7 9.9 3.4 13.9 3.8 
NT5DC2 1.30E-01 2.66E-01 1.7 21.1 5.7 15.8 5.6 
  
 
88 
SNX29 7.83E-03 2.08E-01 1.7 25.5 7.4 25.7 8.2 
NME4 1.10E-01 2.59E-01 1.7 18.3 5.2 14.3 4.8 
PXK 6.93E-02 2.47E-01 1.7 15.8 6.0 15.8 3.6 
SYNJ2BP-
COX16 4.90E-01 3.73E-01 1.7 3.7 2.8 18.9 4.1 
ASMT 6.00E-02 2.40E-01 1.7 25.4 8.0 20.8 6.2 
NLRP7 1.83E-01 2.92E-01 1.7 13.5 3.2 8.8 3.7 
C1orf53 3.50E-01 3.59E-01 1.7 8.3 3.0 21.4 6.2 
CCDC69 5.21E-03 2.08E-01 1.7 177.7 59.5 165.6 47.5 
NUDT7 3.25E-01 3.51E-01 1.7 6.2 3.3 14.0 3.1 
TSC22D1 2.13E-02 2.25E-01 1.7 13.7 4.1 15.4 5.0 
GRAMD4 4.11E-01 3.73E-01 1.7 21.1 5.2 6.7 3.6 
RALB 3.29E-01 3.53E-01 1.7 7.8 4.3 17.7 3.8 
PITPNC1 1.10E-01 2.59E-01 1.7 22.8 6.6 18.0 6.4 
HVCN1 1.10E-01 2.59E-01 1.6 57.7 16.7 45.4 16.3 
NADK2 2.31E-02 2.25E-01 1.6 37.5 12.9 39.8 12.4 
PLEKHA2 1.72E-02 2.25E-01 1.6 21.1 7.9 18.8 5.3 
TMEM206 5.29E-01 3.85E-01 1.6 18.8 2.2 2.8 5.1 
ECI2 7.13E-03 2.08E-01 1.6 20.1 6.9 20.1 6.6 
MARCH6 1.37E-01 2.69E-01 1.6 20.7 8.2 27.8 8.3 
LGALS9 2.71E-02 2.26E-01 1.6 38.5 13.8 41.2 13.3 
CYFIP2 2.21E-02 2.25E-01 1.5 68.8 26.4 66.1 20.0 
FCRLA 8.32E-03 2.09E-01 1.5 16.6 5.6 17.7 6.2 
CORO1A 1.74E-01 2.87E-01 1.5 39.0 18.3 57.5 15.3 
ZNF778 3.61E-01 3.65E-01 1.5 5.9 4.0 14.4 3.0 
LMO2 1.72E-02 2.25E-01 1.5 51.9 18.1 48.8 17.1 
PPP2R3B.b 5.88E-02 2.40E-01 1.5 16.7 5.6 14.8 5.6 
TMEM116 6.06E-03 2.08E-01 1.5 17.1 6.6 18.1 6.0 
RIOK1 1.15E-01 2.62E-01 1.5 21.0 8.1 27.0 9.1 
DAAM1 1.01E-02 2.19E-01 1.5 14.4 5.2 14.1 5.2 
MCTP2 5.93E-03 2.08E-01 1.4 14.5 5.6 13.5 4.8 
CD72 3.59E-03 2.08E-01 1.4 16.7 6.4 16.0 5.8 
PRKCB 3.76E-03 2.08E-01 1.4 58.9 21.0 61.6 24.3 
POU2AF1 3.55E-02 2.33E-01 1.4 13.9 5.0 13.0 5.1 
STX10 5.42E-02 2.37E-01 1.4 20.1 7.1 18.0 7.2 
ERI3 3.44E-02 2.32E-01 1.4 13.2 3.9 11.2 5.3 
PHF19 4.55E-02 2.37E-01 1.4 19.0 7.1 17.3 6.8 
DOCK7 7.29E-02 2.48E-01 1.4 19.0 5.5 18.2 8.7 
PTPN7 4.41E-03 2.08E-01 1.4 49.6 19.9 48.1 17.5 
ALDH3A2 1.41E-02 2.24E-01 1.4 32.9 12.4 35.9 14.1 
PTEN 3.89E-02 2.36E-01 1.4 703.2 264.6 644.5 253.8 
MACC1 1.93E-02 2.25E-01 1.4 11.5 4.7 12.1 4.5 
EVL 5.70E-02 2.39E-01 1.4 19.7 7.5 17.3 7.0 
SDHAF4 2.72E-01 3.32E-01 1.3 19.7 7.1 37.8 15.4 
SIGLEC10 6.59E-03 2.08E-01 1.3 22.4 9.1 21.0 8.0 
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TSTD1 2.31E-02 2.25E-01 1.3 30.5 13.1 29.8 11.0 
PYCARD 1.97E-02 2.25E-01 1.3 21.8 8.3 22.1 9.4 
TUBA4A 1.49E-02 2.25E-01 1.3 32.9 14.7 30.6 11.4 
APPL2 3.10E-02 2.30E-01 1.3 10.9 4.4 10.0 4.2 
RALGPS2 2.10E-02 2.25E-01 1.3 20.6 9.6 21.5 7.7 
HDAC9 6.77E-02 2.47E-01 1.3 60.4 26.3 68.7 27.1 
ADARB1 1.12E-01 2.60E-01 1.3 12.8 3.4 9.3 5.8 
SMIM11B 2.08E-01 2.96E-01 1.3 20.7 13.3 22.0 4.6 
LCP2 3.05E-02 2.29E-01 1.2 24.5 10.6 26.2 10.9 
ITPR2 8.78E-05 1.24E-01 1.2 31.2 13.4 30.9 13.2 
DVL3 1.06E-01 2.58E-01 1.2 52.4 34.0 71.3 19.0 
GPX7 5.49E-03 2.08E-01 1.2 14.9 6.2 15.1 6.7 
ZNF236 4.09E-02 2.36E-01 1.2 13.7 6.0 15.2 6.4 
CHM 6.34E-01 4.20E-01 1.2 4.4 24.8 65.9 5.8 
ADAM15 1.67E-01 2.85E-01 1.2 23.2 6.6 24.0 14.0 
CD3G 6.96E-02 2.47E-01 1.2 15.0 6.2 13.3 6.2 
EEPD1 4.22E-02 2.36E-01 1.2 14.3 7.1 12.5 4.7 
VNN2 5.75E-02 2.39E-01 1.2 17.5 9.1 20.6 7.8 
PLEKHF2 1.71E-03 1.88E-01 1.2 35.8 16.7 37.0 15.5 
RFXANK 1.01E-01 2.58E-01 1.2 15.5 5.5 16.0 8.5 
LIMD2 2.66E-02 2.26E-01 1.2 16.6 6.9 16.8 7.9 
EIF2B3 3.06E-01 3.42E-01 1.2 162.4 17.6 121.9 109.0 
PKN2 4.87E-01 3.73E-01 1.2 9.9 8.3 32.5 10.6 
SNX22 5.60E-03 2.08E-01 1.2 12.7 5.6 12.5 5.6 
ATP8A1 8.84E-02 2.53E-01 1.2 129.8 50.9 108.7 55.5 
ARV1 2.37E-02 2.25E-01 1.1 14.2 5.9 13.1 6.4 
AC022016.2 5.61E-02 2.38E-01 1.1 34.4 19.3 37.4 13.2 
DTX1 8.16E-02 2.50E-01 1.1 11.7 4.3 11.3 6.2 
ETV5 1.38E-02 2.24E-01 1.1 11.3 4.6 10.7 5.5 
STAMBPL1 2.00E-02 2.25E-01 1.1 25.9 11.7 25.0 11.7 
MZB1 3.27E-02 2.32E-01 1.1 51.9 24.0 57.3 26.2 
AC134669.2 1.10E-01 2.59E-01 1.1 13.3 4.7 10.2 6.1 
GSN 1.65E-02 2.25E-01 1.1 11.0 5.0 10.5 4.9 
DCXR 4.75E-02 2.37E-01 1.1 240.3 113.9 203.9 92.7 
RASGRP3 3.75E-03 2.08E-01 1.1 92.2 41.6 95.9 46.0 
RNASET2 8.01E-02 2.50E-01 1.1 13.2 6.3 10.6 4.8 
TERF2 3.92E-01 3.73E-01 1.1 30.3 10.8 13.7 9.7 
TMEM256 3.47E-02 2.32E-01 1.1 19.2 9.9 17.1 7.1 
TMEM256.b 3.47E-02 2.32E-01 1.1 19.2 9.9 17.1 7.1 
PAGR1 1.68E-03 1.88E-01 1.1 17.9 8.2 18.2 8.7 
DOK3 1.41E-01 2.71E-01 1.1 10.6 5.4 13.8 6.2 
CD22 1.82E-02 2.25E-01 1.1 46.0 23.4 49.4 21.7 
PNKD 1.39E-02 2.24E-01 1.1 13.7 6.1 14.8 7.4 
CD180 4.97E-02 2.37E-01 1.1 12.4 6.0 13.8 6.5 
ZC3H12D 1.07E-01 2.58E-01 1.1 10.5 5.4 12.5 5.5 
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TK2 1.75E-01 2.88E-01 1.1 12.8 3.3 8.9 7.2 
HSBP1L1 4.71E-02 2.37E-01 1.1 13.6 6.4 12.5 6.2 
STIM2 6.71E-02 2.47E-01 1.1 39.4 18.2 35.2 17.8 
STRBP 1.30E-01 2.66E-01 1.0 96.6 42.0 77.9 42.5 
CD79A 8.36E-03 2.09E-01 1.0 36.6 18.4 35.3 16.4 
TKFC 3.48E-01 3.59E-01 1.0 15.5 5.3 8.0 6.2 
PRDX2 1.96E-02 2.25E-01 1.0 55.6 27.2 51.8 25.4 
ZDHHC23 3.51E-01 3.59E-01 1.0 7.0 7.7 14.0 2.6 
TEC 3.38E-02 2.32E-01 1.0 10.7 5.2 10.0 5.0 
ODF2L 1.55E-01 2.77E-01 1.0 27.1 18.6 30.3 9.8 
SNX25 3.93E-02 2.36E-01 1.0 91.8 48.3 91.8 42.5 
BPNT1 1.06E-01 2.58E-01 1.0 46.5 21.8 39.1 21.1 
MSI2 3.69E-02 2.33E-01 1.0 24.5 13.0 24.2 11.4 
DPP3 1.32E-01 2.66E-01 1.0 26.3 10.2 19.9 13.0 
SGSM3 7.06E-02 2.47E-01 1.0 34.1 15.0 33.7 19.0 
ZCCHC2 4.01E-01 3.73E-01 1.0 11.4 8.9 24.1 9.1 
CPNE5 1.53E-02 2.25E-01 1.0 11.5 5.8 11.2 5.8 
S100A4 1.47E-01 2.74E-01 1.0 55.6 33.7 71.4 30.7 
SMYD3 1.82E-02 2.25E-01 1.0 16.7 8.7 15.2 7.6 
PLA2G12A 8.44E-02 2.52E-01 1.0 21.5 10.5 18.6 10.0 
CDCA7L 4.21E-02 2.36E-01 1.0 53.0 28.7 45.6 21.7 
CDK14 2.70E-02 2.26E-01 1.0 38.8 19.5 37.1 19.3 
BLOC1S2 5.24E-01 3.82E-01 1.0 234.7 61.7 72.0 95.6 
LMCD1 1.17E-01 2.63E-01 1.0 9.9 5.7 11.9 5.6 
NT5C3B 1.80E-01 2.91E-01 1.0 35.6 16.3 26.8 16.0 
USP22 3.73E-01 3.71E-01 1.0 35.6 27.1 69.2 27.1 
PIK3AP1 5.42E-02 2.37E-01 0.9 151.3 72.6 136.3 76.6 
HMGA1 7.62E-02 2.49E-01 0.9 91.4 45.7 79.9 43.1 
DIS3L 4.55E-01 3.73E-01 0.9 10.5 11.6 26.0 7.4 
AC270107.10 8.10E-02 2.50E-01 0.9 22.1 10.1 18.8 11.2 
AC270107.5 8.10E-02 2.50E-01 0.9 22.1 10.1 18.8 11.2 
AC270107.4 8.10E-02 2.50E-01 0.9 22.1 10.1 18.8 11.2 
AC270107.7 8.10E-02 2.50E-01 0.9 22.1 10.1 18.8 11.2 
AC270107.9 8.10E-02 2.50E-01 0.9 22.1 10.1 18.8 11.2 
AC270107.3 8.10E-02 2.50E-01 0.9 22.1 10.1 18.8 11.2 
EEF1A2 9.36E-02 2.55E-01 0.9 47.4 23.6 40.8 22.6 
CARHSP1 1.02E-01 2.58E-01 0.9 11.5 5.4 9.8 5.8 
HADH 1.36E-01 2.68E-01 0.9 12.8 8.2 13.1 5.4 
AKT1 1.28E-01 2.65E-01 0.9 24.3 12.0 20.0 11.5 
ARHGAP25 7.70E-03 2.08E-01 0.9 24.0 12.0 22.8 12.8 
SUGCT 2.91E-01 3.37E-01 0.9 16.2 8.7 9.5 4.9 
LMO4 1.36E-01 2.68E-01 0.9 17.2 7.8 13.7 8.6 
SUPT4H1 2.94E-02 2.28E-01 0.9 59.5 33.0 59.4 30.4 
RBM41 3.95E-01 3.73E-01 0.9 16.8 6.4 33.4 20.3 
BMP2K 4.95E-02 2.37E-01 0.9 23.6 12.9 25.5 13.2 
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ACADM 3.99E-02 2.36E-01 0.9 55.8 31.0 59.3 30.6 
LRP11 1.53E-01 2.76E-01 0.9 14.0 8.5 10.6 4.7 
MXD4 1.53E-01 2.76E-01 0.9 12.7 6.1 10.1 6.1 
IKZF1 1.00E-03 1.87E-01 0.9 26.6 13.9 26.1 14.4 
ODC1 1.52E-02 2.25E-01 0.9 345.0 171.0 332.6 193.3 
CBFB 1.50E-01 2.75E-01 0.9 74.5 35.5 59.4 36.6 
ATE1 5.41E-01 3.88E-01 0.9 20.3 20.9 65.4 25.2 
CLECL1 1.53E-01 2.76E-01 0.9 73.6 45.5 92.5 44.1 
PDE7A 4.40E-04 1.85E-01 0.9 20.4 10.9 20.6 11.2 
CCNY 1.96E-01 2.95E-01 0.9 63.5 29.1 47.1 30.5 
CHN2 1.99E-02 2.25E-01 0.9 21.1 10.3 19.3 11.5 
TMC6 1.32E-01 2.66E-01 0.9 19.1 9.8 15.2 8.7 
CD79B 3.96E-02 2.36E-01 0.9 191.0 96.1 174.3 102.4 
NUDT1 5.12E-02 2.37E-01 0.9 14.1 8.0 15.2 7.9 
KANK1 1.33E-01 2.66E-01 0.9 14.3 8.2 18.1 9.5 
DCK 2.98E-02 2.28E-01 0.9 36.4 20.7 36.1 19.0 
NPM3 4.33E-02 2.37E-01 0.9 74.9 36.0 65.7 41.5 
PEBP1 7.06E-02 2.47E-01 0.9 53.5 27.0 47.4 28.6 
CEP250 2.93E-01 3.37E-01 0.9 15.5 12.0 24.8 10.3 
SDHAF3 1.48E-01 2.74E-01 0.8 40.0 22.1 30.0 16.7 
FCHO1 7.78E-02 2.50E-01 0.8 16.2 8.8 13.9 7.9 
APEH 6.85E-02 2.47E-01 0.8 61.1 32.3 55.4 32.6 
GAK 4.97E-02 2.37E-01 0.8 28.3 16.3 30.3 16.4 
ASPH 4.62E-02 2.37E-01 0.8 43.1 26.5 44.5 22.3 
CAMSAP1 9.89E-02 2.58E-01 0.8 44.8 24.7 36.6 20.8 
METTL26 3.27E-02 2.32E-01 0.8 14.9 8.3 16.6 9.3 
LYSMD2 4.75E-02 2.37E-01 0.8 15.1 9.0 15.0 7.9 
LYRM1 2.45E-02 2.25E-01 0.8 50.0 29.1 50.0 27.4 
RMI2 3.08E-02 2.30E-01 0.8 12.5 7.3 11.2 6.1 
NFS1 2.11E-02 2.25E-01 0.8 14.1 8.3 14.9 8.0 
PRPS2 7.64E-02 2.50E-01 0.8 29.9 16.3 26.5 15.6 
CDV3 4.97E-03 2.08E-01 0.8 205.7 118.6 198.1 109.6 
DPM3 8.32E-03 2.09E-01 0.8 32.0 19.5 33.5 17.6 
AC068547.1 2.46E-02 2.25E-01 0.8 15.9 9.3 15.9 8.8 
CUX1 8.29E-02 2.51E-01 0.8 44.2 26.3 50.0 27.3 
SLC27A5 6.49E-02 2.45E-01 0.8 12.0 5.5 10.1 7.1 
MYO1E 1.48E-02 2.25E-01 0.8 120.4 69.6 111.6 62.7 
HGS 1.59E-01 2.78E-01 0.8 58.4 28.8 46.2 30.9 
PSD4 1.23E-01 2.65E-01 0.8 9.0 6.9 11.5 4.8 
SERPINB6 3.39E-02 2.32E-01 0.8 15.0 9.0 13.6 7.3 
GCDH 1.88E-03 1.92E-01 0.8 40.0 22.8 39.8 22.8 
NPIPB13 9.57E-03 2.19E-01 0.8 11.1 6.3 10.8 6.2 
AK3 1.23E-03 1.87E-01 0.8 11.2 6.6 11.5 6.4 
SEL1L3 2.40E-02 2.25E-01 0.8 12.3 7.3 11.3 6.2 
CHEK2 3.19E-02 2.31E-01 0.8 15.5 8.7 17.4 10.1 
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GON7.b 1.54E-02 2.25E-01 0.8 12.8 7.5 13.2 7.4 
GON7 1.54E-02 2.25E-01 0.8 12.8 7.5 13.2 7.4 
MAP4K1 1.81E-02 2.25E-01 0.8 25.6 15.1 25.1 13.9 
UBE2J1 1.36E-02 2.23E-01 0.8 10.3 6.5 11.1 5.8 
DHRS4L2 3.63E-01 3.66E-01 0.8 15.3 10.6 9.6 3.6 
MAIP1 4.60E-01 3.73E-01 0.8 10.1 8.9 22.3 9.7 
PLEKHO1 3.36E-02 2.32E-01 0.8 16.7 9.4 15.9 9.3 
STAU2 1.12E-01 2.59E-01 0.8 41.8 27.6 50.2 25.1 
SMARCAL1 5.24E-01 3.82E-01 0.8 18.9 18.6 51.1 21.6 
CDK5 9.23E-02 2.54E-01 0.8 11.1 6.2 13.7 8.1 
TIMM8B 1.46E-02 2.25E-01 0.8 42.1 23.7 45.4 26.6 
ANXA4 1.36E-01 2.68E-01 0.8 13.9 9.3 14.0 6.7 
CCDC138 1.01E-01 2.58E-01 0.8 40.4 24.8 46.4 25.2 
SKAP1 2.63E-02 2.26E-01 0.8 14.4 8.3 13.1 7.5 
BIK 7.75E-02 2.50E-01 0.8 13.4 6.8 11.5 7.6 
CNN3 3.63E-02 2.33E-01 0.8 52.0 31.6 46.8 25.6 
NIPSNAP1 7.39E-03 2.08E-01 0.8 19.0 11.2 18.0 10.3 
CHD7 7.58E-02 2.49E-01 0.8 11.0 6.6 12.7 7.2 
LRRTM4 3.47E-02 2.32E-01 0.8 11.4 6.0 10.3 6.6 
TMC8 3.69E-02 2.33E-01 0.8 11.6 7.1 12.4 6.9 
SNRPN 6.83E-03 2.08E-01 0.8 33.3 18.4 32.3 19.9 
IFT81 1.13E-01 2.60E-01 0.8 19.6 13.0 19.7 10.0 
GUK1 1.91E-01 2.95E-01 0.8 322.0 156.7 243.7 174.0 
WDR54 8.54E-02 2.52E-01 0.8 15.6 8.9 13.3 8.0 
HMOX2.b 2.46E-01 3.18E-01 0.8 21.2 10.8 15.1 10.4 
NPIPB4 6.97E-02 2.47E-01 0.8 75.2 42.4 89.5 54.1 
AIG1 5.32E-03 2.08E-01 0.8 12.7 7.6 12.3 7.1 
MZT2B 1.82E-02 2.25E-01 0.8 45.1 25.1 44.2 27.3 
ITGB2 6.31E-02 2.44E-01 0.8 36.6 24.4 41.9 21.8 
CBR4 7.95E-02 2.50E-01 0.8 25.9 14.9 22.4 13.6 
PRKRA 1.22E-02 2.23E-01 0.8 23.3 14.4 24.4 13.8 
CDK2AP1 2.44E-02 2.25E-01 0.8 45.3 26.4 42.5 25.3 
ARPC4-
TTLL3 1.82E-01 2.92E-01 0.8 18.9 14.8 21.3 8.9 
PRPSAP2 2.41E-02 2.25E-01 0.8 81.6 49.6 74.5 42.5 
OCIAD2 4.33E-02 2.37E-01 0.8 62.4 42.7 68.2 34.4 
AC073610.3 7.10E-02 2.48E-01 0.8 18.4 9.8 16.2 10.7 
ANAPC15 1.17E-01 2.63E-01 0.8 42.3 26.5 50.1 28.2 
EVI2A 1.02E-01 2.58E-01 0.8 16.5 10.2 19.3 11.0 
PTPRC.b 8.06E-03 2.08E-01 0.8 108.9 68.1 114.4 64.2 
COMT 3.05E-01 3.42E-01 0.8 19.1 18.6 25.6 7.9 
E2F5 1.16E-01 2.63E-01 0.8 19.3 10.9 16.3 10.2 
KLF13 1.95E-01 2.95E-01 0.8 29.7 17.9 21.3 12.4 
ATP5G1 3.22E-01 3.50E-01 0.7 36.3 17.2 23.0 18.1 
C1D 3.51E-02 2.33E-01 0.7 35.3 21.5 36.9 21.6 
  
 
93 
TTC7B 3.22E-01 3.50E-01 0.7 10.6 6.5 17.5 10.3 
SLAIN1 2.96E-02 2.28E-01 0.7 10.3 6.2 11.2 6.7 
COTL1 1.23E-01 2.65E-01 0.7 44.8 24.7 38.2 25.1 
TRIM27.g 3.27E-01 3.52E-01 0.7 11.2 4.3 12.8 10.0 
PAQR3 8.12E-02 2.50E-01 0.7 12.4 7.6 14.3 8.4 
MMADHC 5.38E-01 3.87E-01 0.7 74.5 73.9 196.4 89.2 
GPI.b 1.64E-01 2.82E-01 0.7 26.4 15.9 19.9 12.0 
H3F3A 2.86E-02 2.28E-01 0.7 249.0 142.7 233.9 148.4 
PPP6R1 3.33E-02 2.32E-01 0.7 40.3 22.8 39.5 25.3 
AES 1.09E-02 2.21E-01 0.7 59.1 35.5 62.6 38.0 
RAB4A 2.10E-02 2.25E-01 0.7 20.9 11.6 19.3 12.7 
CCDC91 1.28E-01 2.65E-01 0.7 195.2 129.6 229.8 127.1 
MAPK10 1.15E-02 2.23E-01 0.7 30.5 18.4 28.9 17.4 
TTC39C 6.47E-02 2.45E-01 0.7 11.1 8.0 13.0 6.6 
AKT2 3.42E-01 3.59E-01 0.7 17.3 12.6 28.3 15.1 
PTPRC 2.36E-02 2.25E-01 0.7 35.0 23.7 38.3 20.8 
AL132780.3 2.58E-01 3.24E-01 0.7 10.1 7.9 10.2 4.5 
MYCBP 4.75E-02 2.37E-01 0.7 29.3 16.1 28.1 18.9 
CYB5R4 3.24E-02 2.32E-01 0.7 29.3 18.4 29.1 17.2 
BCL7B 1.76E-02 2.25E-01 0.7 14.4 9.1 14.0 8.3 
TRIM27.c 3.31E-01 3.54E-01 0.7 11.2 4.5 12.9 10.2 
AFMID 2.71E-02 2.26E-01 0.7 25.6 15.4 28.2 17.4 
NDUFB10 4.91E-02 2.37E-01 0.7 111.6 63.5 102.0 66.9 
GALNT14 5.64E-02 2.38E-01 0.7 14.7 9.5 14.7 8.5 
MGST3 4.45E-01 3.73E-01 0.7 18.7 9.9 9.3 7.3 
GATAD2A 6.81E-03 2.08E-01 0.7 25.6 16.6 26.6 15.4 
KLHL8 1.53E-01 2.76E-01 0.7 16.6 11.5 20.2 11.1 
CDC40 4.20E-01 3.73E-01 0.7 25.4 12.5 13.7 11.5 
HIST2H2AB 4.86E-02 2.37E-01 0.7 780.0 426.0 692.1 477.0 
BIN2 6.27E-03 2.08E-01 0.7 18.5 11.8 19.3 11.3 
POLE3 7.69E-02 2.50E-01 0.7 94.7 59.4 109.0 65.6 
RNF180 5.00E-02 2.37E-01 0.7 23.5 13.7 23.6 15.2 
MRPL42 5.41E-02 2.37E-01 0.7 95.1 57.5 86.0 54.0 
SRA1 3.57E-01 3.63E-01 0.7 19.8 10.1 12.1 9.6 
FAM216A 2.66E-02 2.26E-01 0.7 47.3 28.9 44.2 27.5 
PRKD3 8.95E-02 2.53E-01 0.7 37.0 22.4 31.5 19.8 
TXNIP 2.67E-03 2.04E-01 0.7 10.2 6.3 10.0 6.1 
ACTR6 4.80E-01 3.73E-01 0.7 36.0 41.5 77.8 28.9 
NDUFAF8 8.01E-03 2.08E-01 0.7 213.6 124.4 205.2 134.7 
SON 6.74E-01 4.33E-01 0.7 32.2 77.7 167.1 45.6 
TRPT1 3.26E-01 3.52E-01 0.7 32.7 18.5 20.5 14.5 
DTD2 1.14E-02 2.23E-01 0.7 13.4 8.6 13.9 8.3 
BAG1 1.17E-01 2.63E-01 0.7 66.3 38.8 57.4 38.0 
UCHL1 3.23E-02 2.32E-01 0.7 47.5 28.0 46.9 30.6 
ULK4 4.95E-02 2.37E-01 0.7 24.9 16.4 23.9 14.0 
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CEP192 6.01E-02 2.40E-01 0.7 10.6 6.8 11.5 7.0 
HIST1H4H 2.29E-01 3.09E-01 0.7 56.2 43.0 75.9 39.2 
TFB1M 3.29E-02 2.32E-01 0.7 21.2 12.7 23.4 15.0 
NEK6 4.33E-02 2.37E-01 0.7 17.1 9.5 15.3 10.7 
COCH 4.94E-03 2.08E-01 0.7 36.9 23.2 35.5 21.9 
CSK 1.56E-02 2.25E-01 0.7 44.2 27.9 44.1 27.1 
MAPK9 1.21E-01 2.65E-01 0.7 13.2 8.7 15.8 9.4 
MYC 2.78E-02 2.28E-01 0.7 38.2 26.4 40.7 22.8 
PET100 1.38E-01 2.69E-01 0.7 434.3 273.0 341.4 210.7 
ELL3 1.81E-01 2.91E-01 0.7 25.5 14.2 20.5 14.5 
VPS13A 3.64E-01 3.67E-01 0.7 19.3 6.0 13.3 14.3 
MEF2C 3.97E-02 2.36E-01 0.7 170.3 116.2 187.4 107.2 
MAZ 4.86E-03 2.08E-01 0.7 41.9 25.1 40.4 26.3 
KIFC1 1.47E-01 2.74E-01 0.7 9.8 7.5 10.7 5.3 
RAP1A 8.64E-03 2.11E-01 0.7 30.6 19.9 31.8 19.2 
NCF1 2.26E-01 3.07E-01 0.7 22.6 12.3 17.1 12.5 
GRAMD2A 4.88E-01 3.73E-01 0.7 9.9 7.3 21.4 12.3 
SSBP4 1.75E-02 2.25E-01 0.7 11.5 7.4 10.9 6.6 
PEX1 2.07E-01 2.96E-01 0.7 12.6 10.4 17.1 8.2 
DCUN1D4 5.33E-02 2.37E-01 0.7 17.0 9.1 14.9 10.9 
AP000275.2 7.96E-02 2.50E-01 0.7 93.6 56.3 85.2 56.0 
COX5A 1.09E-01 2.59E-01 0.7 54.1 32.6 46.6 30.7 
MRPL20 2.90E-01 3.37E-01 0.7 205.1 104.9 141.1 112.7 
SERPINA9 1.72E-02 2.25E-01 0.7 27.2 16.6 28.1 18.2 
ITGB1BP1 1.61E-01 2.80E-01 0.7 40.8 23.8 33.4 22.8 
AK9 9.46E-02 2.55E-01 0.7 9.7 6.9 11.3 6.3 
EPHA7 1.65E-02 2.25E-01 0.7 19.9 13.5 20.8 12.2 
POLD4 1.63E-01 2.81E-01 0.7 20.3 14.6 19.2 10.3 
SFXN4 1.61E-02 2.25E-01 0.7 15.9 9.9 15.4 9.8 
CYTIP 6.51E-02 2.45E-01 0.7 14.0 9.1 15.3 9.4 
TMCO3 6.92E-02 2.47E-01 0.7 11.2 8.5 12.8 6.7 
ROCK2 3.38E-02 2.32E-01 0.7 33.3 20.7 31.7 20.4 
CD9 9.64E-02 2.56E-01 0.7 12.3 7.8 10.2 6.4 
GOT2 9.84E-02 2.58E-01 0.7 29.3 17.4 26.1 17.5 
SGK1 5.21E-02 2.37E-01 0.7 75.4 54.7 85.8 47.2 
NECAP2 8.21E-02 2.51E-01 0.7 49.4 29.5 44.7 30.0 
GSR 8.37E-04 1.85E-01 0.7 22.7 14.1 22.5 14.5 
PARP1 1.19E-02 2.23E-01 0.7 74.6 48.5 75.4 46.3 
TRIAP1 2.85E-02 2.28E-01 0.7 26.5 16.2 25.3 16.6 
CDCA7 2.94E-02 2.28E-01 0.7 21.1 13.6 21.8 13.6 
RAPGEF5 1.91E-01 2.95E-01 0.7 20.0 10.6 22.4 16.4 
PTK2 2.04E-01 2.95E-01 0.7 25.2 16.2 34.3 21.7 
IMPDH1 5.95E-02 2.40E-01 0.7 37.3 22.5 38.0 25.5 
BOLA2B 1.38E-01 2.69E-01 0.6 107.2 76.4 104.6 58.7 
PEX16 3.01E-01 3.40E-01 0.6 21.2 9.8 22.0 17.9 
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SYNGR2 3.82E-02 2.33E-01 0.6 82.7 49.6 76.6 52.1 
C12orf45 1.66E-01 2.84E-01 0.6 37.1 20.0 29.5 22.6 
RPGR 3.70E-01 3.70E-01 0.6 10.5 7.5 17.7 10.5 
MSL3 8.31E-02 2.51E-01 0.6 44.8 29.9 49.3 30.2 
OSBPL8 7.82E-02 2.50E-01 0.6 41.3 25.4 37.8 25.2 
MDM2 1.10E-01 2.59E-01 0.6 104.0 73.3 104.5 60.2 
ACSF3 1.93E-01 2.95E-01 0.6 11.5 6.8 9.0 6.3 
TMEM154 1.89E-01 2.95E-01 0.6 17.1 12.7 15.8 8.5 
ANAPC5 8.02E-03 2.08E-01 0.6 50.5 32.0 51.1 33.3 
TRIM28 1.31E-01 2.66E-01 0.6 87.6 44.9 78.9 62.2 
CERCAM 4.78E-01 3.73E-01 0.6 834.9 616.8 1703.2 1017.4 
WDR20 3.38E-02 2.32E-01 0.6 11.2 7.3 12.0 7.7 
PRDX6 2.10E-03 1.92E-01 0.6 36.5 23.0 35.9 23.8 
GNAS 5.33E-03 2.08E-01 0.6 103.0 67.5 100.4 64.0 
CARS2 2.62E-01 3.27E-01 0.6 9.0 6.0 13.0 8.3 
UBAC1 3.93E-02 2.36E-01 0.6 74.2 43.6 70.6 50.2 
ERP29 5.67E-03 2.08E-01 0.6 92.4 59.9 89.4 57.9 
AC138969.1 3.85E-01 3.73E-01 0.6 46.1 21.6 27.6 26.2 
GGA2 1.18E-02 2.23E-01 0.6 27.3 17.7 26.0 16.8 
RERE 1.83E-01 2.92E-01 0.6 11.1 7.9 13.7 8.1 
DONSON 1.02E-01 2.58E-01 0.6 33.2 22.6 37.3 23.2 
HDAC8 7.01E-01 4.41E-01 0.6 6.2 18.6 31.8 6.1 
CFAP36 1.91E-02 2.25E-01 0.6 25.9 16.7 24.5 16.0 
CIT 4.40E-01 3.73E-01 0.6 7.3 4.5 13.2 8.8 
NSMAF 3.42E-01 3.59E-01 0.6 26.9 19.2 42.6 26.0 
ZC3H14 1.68E-01 2.85E-01 0.6 38.4 21.5 31.0 23.6 
MPP6 2.86E-02 2.28E-01 0.6 31.8 19.3 29.5 20.6 
HERC3 2.48E-01 3.19E-01 0.6 15.3 9.7 21.5 14.3 
VAV3 1.20E-01 2.65E-01 0.6 11.8 9.1 12.8 6.9 
CMC4 5.13E-02 2.37E-01 0.6 10.9 7.0 10.1 6.7 
HDAC1 3.62E-03 2.08E-01 0.6 76.5 49.8 75.4 49.3 
TPGS2 1.77E-02 2.25E-01 0.6 39.2 25.8 36.6 23.7 
CAMK2D 7.49E-02 2.49E-01 0.6 10.8 6.2 9.4 7.0 
STUB1 7.72E-02 2.50E-01 0.6 164.4 111.7 179.2 112.9 
RHOBTB3 1.92E-01 2.95E-01 0.6 127.1 83.7 96.2 62.5 
ATPIF1 5.25E-02 2.37E-01 0.6 376.8 246.1 335.8 220.9 
SMIM4 1.26E-01 2.65E-01 0.6 28.9 23.1 35.4 19.1 
PSMD5 1.46E-01 2.74E-01 0.6 10.0 6.7 12.6 8.2 
MZT2A 1.45E-01 2.73E-01 0.6 80.4 50.5 66.4 45.9 
PDLIM7 4.95E-02 2.37E-01 0.6 13.3 10.0 14.6 8.4 
TERF1 2.53E-02 2.25E-01 0.6 12.0 7.5 11.3 7.8 
GLUD1 1.61E-02 2.25E-01 0.6 92.8 65.9 98.9 60.2 
CLUAP1 2.10E-01 2.97E-01 0.6 12.0 6.9 9.5 7.2 
POP5 5.26E-02 2.37E-01 0.6 24.1 15.2 24.3 16.7 
NLK 2.22E-02 2.25E-01 0.6 10.8 7.2 10.0 6.6 
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NUCB2 1.97E-01 2.95E-01 0.6 343.2 255.2 299.1 168.0 
ABRACL 4.80E-02 2.37E-01 0.6 231.3 158.5 231.4 146.5 
TMEM156 2.95E-02 2.28E-01 0.6 24.9 18.2 27.2 16.2 
UBE2H 3.09E-02 2.30E-01 0.6 16.2 9.8 14.8 10.7 
MAP4K1.b 2.83E-02 2.28E-01 0.6 27.5 18.1 25.4 16.8 
TCTN1 7.74E-02 2.50E-01 0.6 12.5 7.7 13.0 9.2 
TPD52 1.48E-02 2.25E-01 0.6 65.9 46.8 70.1 43.1 
OXLD1 1.82E-01 2.92E-01 0.6 14.5 8.9 11.7 8.4 
COX8A 1.05E-01 2.58E-01 0.6 23.6 14.3 23.5 16.9 
OIP5 2.88E-01 3.37E-01 0.6 10.2 7.3 14.8 9.3 
CD53 2.21E-02 2.25E-01 0.6 89.6 55.2 83.5 59.4 
OXNAD1 8.09E-02 2.50E-01 0.6 10.6 6.8 9.7 6.7 
CERS2 3.14E-02 2.31E-01 0.6 20.4 13.5 18.7 12.4 
PPP1R10 7.90E-01 4.69E-01 0.6 1.4 4.2 47.8 28.5 
IRAK1 7.85E-02 2.50E-01 0.6 12.5 9.0 14.0 8.5 
PPIP5K2 1.08E-01 2.58E-01 0.6 29.8 21.2 33.6 20.8 
SPICE1 6.06E-02 2.41E-01 0.6 18.5 12.9 16.8 10.6 
KCTD19 1.94E-01 2.95E-01 0.6 16.0 11.2 20.7 13.2 
CRLS1 2.22E-01 3.04E-01 0.6 10.4 7.5 13.5 8.4 
ZSWIM7 9.91E-02 2.58E-01 0.6 133.4 84.5 119.9 83.6 
PTDSS1 1.28E-02 2.23E-01 0.6 50.2 31.2 47.5 33.7 
KMT5A 3.70E-02 2.33E-01 0.6 55.9 37.7 58.3 38.1 
STK24 7.57E-02 2.49E-01 0.6 40.7 26.0 37.6 26.1 
NECAB3 3.28E-01 3.53E-01 0.6 12.0 5.4 11.0 9.9 
ARPC1B 7.47E-02 2.49E-01 0.6 101.6 66.1 90.6 61.8 
RNASEH2B 2.64E-01 3.27E-01 0.6 645.7 348.5 470.1 394.3 
INVS 8.44E-02 2.52E-01 0.6 11.0 7.0 10.1 7.0 
MSANTD3 7.80E-03 2.08E-01 0.6 18.4 12.5 17.8 11.7 
SYK 3.58E-02 2.33E-01 0.6 36.6 23.7 36.6 25.1 
GAPT 1.44E-01 2.73E-01 0.6 46.1 33.8 54.1 32.9 
EEF1B2 9.73E-02 2.56E-01 0.6 862.6 507.4 742.5 562.5 
EEF1B2.b 9.73E-02 2.56E-01 0.6 862.6 507.4 742.5 562.5 
FGD6 7.48E-02 2.49E-01 0.6 12.0 7.7 11.0 7.6 
STIM1 5.77E-02 2.39E-01 0.6 18.5 12.2 16.7 11.3 
PHF10 3.77E-02 2.33E-01 0.6 15.6 10.1 14.8 10.2 
POLR2G 1.79E-02 2.25E-01 0.6 26.3 16.3 24.6 17.7 
SYCP1 7.07E-02 2.47E-01 0.6 12.4 9.1 12.8 7.8 
SEPT6 1.20E-02 2.23E-01 0.6 60.7 40.7 57.5 38.1 
GCSH 8.22E-02 2.51E-01 0.6 77.9 48.4 70.1 50.5 
CENPM 5.61E-02 2.38E-01 0.6 13.0 7.5 11.8 9.1 
ABHD10 5.13E-03 2.08E-01 0.6 43.1 28.8 44.3 29.6 
TOP2B 3.16E-02 2.31E-01 0.6 46.1 31.5 47.7 31.3 
MRPL36 4.14E-02 2.36E-01 0.6 148.1 95.0 139.5 97.5 
USP11 1.41E-01 2.71E-01 0.6 11.6 7.0 9.9 7.4 
CLK3 2.02E-01 2.95E-01 0.6 14.7 9.2 11.6 8.5 
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POLR3GL 5.22E-02 2.37E-01 0.6 18.9 13.1 17.0 11.0 
ENOPH1 1.75E-02 2.25E-01 0.6 30.3 21.5 32.1 20.3 
MPC2 1.17E-01 2.63E-01 0.6 33.8 20.2 33.1 24.6 
SPC24 1.12E-01 2.59E-01 0.6 24.3 14.6 21.0 15.7 
TMEM230 1.67E-01 2.85E-01 0.6 32.1 25.0 39.3 22.9 
ALAS1 9.33E-02 2.55E-01 0.6 14.3 9.5 12.2 8.3 
ARPC2 2.46E-02 2.25E-01 0.6 471.3 323.5 467.1 307.1 
LBR 5.81E-02 2.40E-01 0.6 26.6 18.6 26.2 16.9 
MTCP1 1.27E-01 2.65E-01 0.6 31.9 20.3 27.9 19.9 
MTAP 2.64E-01 3.27E-01 0.6 172.7 101.4 129.2 101.8 
STN1 9.76E-02 2.57E-01 0.6 16.1 10.9 13.7 9.1 
TMEM141 4.14E-02 2.36E-01 0.6 19.5 13.5 20.4 13.4 
SLC4A7 6.32E-02 2.44E-01 0.6 44.8 29.3 42.0 29.2 
ENAH 2.09E-02 2.25E-01 0.6 21.0 14.3 19.6 13.1 
SLFN11 6.26E-02 2.43E-01 0.6 25.7 17.5 22.6 15.0 
CENPV 2.42E-02 2.25E-01 0.6 107.0 73.8 100.1 66.0 
FYN 1.06E-01 2.58E-01 0.6 59.8 38.7 53.2 37.7 
PPAT 2.52E-02 2.25E-01 0.6 31.7 21.3 34.3 23.3 
PHC1 1.31E-01 2.66E-01 0.6 12.0 8.3 14.6 9.7 
SMN2.c 9.87E-02 2.58E-01 0.6 26.3 17.0 23.8 16.9 
POC1B 2.96E-01 3.37E-01 0.6 19.3 10.3 21.6 17.4 
LPCAT3 1.35E-01 2.68E-01 0.6 13.2 11.2 15.6 8.3 
PLPBP 8.70E-02 2.53E-01 0.6 21.7 12.5 18.6 14.8 
AARSD1 2.89E-02 2.28E-01 0.6 24.4 15.0 22.4 16.7 
TMEM14B 7.89E-02 2.50E-01 0.6 43.4 31.2 43.5 27.7 
AMZ2 7.23E-03 2.08E-01 0.6 42.6 28.9 41.0 27.7 
BMPR1A 2.19E-01 3.03E-01 0.6 20.2 11.4 15.6 12.9 
ATP6V1G1 3.61E-02 2.33E-01 0.6 139.0 97.6 131.2 85.7 
CENPW 1.45E-01 2.73E-01 0.6 62.8 40.8 52.5 37.4 
PET117 2.21E-02 2.25E-01 0.6 11.6 7.8 11.1 7.6 
POLR3K 2.13E-02 2.25E-01 0.6 19.0 12.2 18.5 13.2 
NFE2L3 3.90E-02 2.36E-01 0.6 15.1 10.2 13.8 9.4 
PUS7 1.33E-02 2.23E-01 0.6 21.9 15.2 21.4 14.3 
TIMMDC1 8.58E-02 2.52E-01 0.6 35.2 23.0 32.2 22.8 
SYPL1 2.15E-02 2.25E-01 0.6 10.8 7.3 10.2 7.0 
ARL6IP4 1.32E-01 2.66E-01 0.6 205.0 130.0 179.0 131.2 
MTFR1 1.53E-01 2.76E-01 0.6 33.8 25.4 39.8 24.6 
CTBP1 1.36E-02 2.23E-01 0.6 14.8 10.7 15.7 10.0 
TIAM2 8.01E-02 2.50E-01 0.6 11.5 8.4 11.7 7.4 
MRPS27 4.28E-02 2.37E-01 0.6 122.2 85.8 121.6 80.4 
GRPEL1 1.52E-02 2.25E-01 0.6 37.2 26.3 38.8 25.5 
NDUFB11 1.42E-01 2.72E-01 0.6 16.0 9.6 13.4 10.5 
LTA4H 3.10E-02 2.30E-01 0.6 51.2 31.7 47.6 35.8 
FAM3C 4.12E-02 2.36E-01 0.6 20.9 15.4 21.8 13.7 
TCF4 1.31E-01 2.66E-01 0.6 66.0 49.8 76.5 47.5 
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ACO2 3.92E-02 2.36E-01 0.6 14.3 9.4 14.8 10.5 
MAGEF1 3.10E-02 2.30E-01 0.6 20.1 13.8 18.5 12.6 
Table 14: Downregulated genes in the presence of LMP1-induction found via RNA Seq 
 
Table RNA Seq Upregulated Genes 
Gene T-test Q-value 
Log2-
ratio 
Sample1 
No 
LMP1 
Sample2 
 LMP1 
Sample2 
No 
LMP1 
Sample2 
LMP1 
DAPP1 2.79E-03 2.06E-01 -0.6 21.1 30.9 21.6 31.6 
IFT46 1.77E-01 2.89E-01 -0.6 9.3 15.5 12.5 16.4 
LYN 7.92E-03 2.08E-01 -0.6 20.6 31.3 21.3 30.2 
MYH9 1.45E-01 2.74E-01 -0.6 27.7 40.4 33.7 49.7 
NFKBIE 1.12E-01 2.59E-01 -0.6 17.9 27.3 17.1 24.0 
SLC38A2 7.05E-02 2.47E-01 -0.6 25.1 43.2 30.5 38.4 
DNAJA1 1.84E-02 2.25E-01 -0.6 226.5 341.0 247.0 354.6 
CALM3 3.00E-02 2.28E-01 -0.6 275.7 395.5 263.1 396.7 
B2M 3.55E-02 2.33E-01 -0.6 660.6 999.5 667.5 959.2 
NRP2 2.02E-02 2.25E-01 -0.6 9.2 13.9 9.9 14.3 
BAZ2B 2.57E-02 2.25E-01 -0.6 12.2 18.3 12.2 17.8 
ZNF682 1.07E-01 2.58E-01 -0.6 8.1 11.1 6.6 10.7 
CD86 6.24E-02 2.43E-01 -0.6 77.9 120.9 85.8 121.5 
SLC5A6 7.01E-02 2.47E-01 -0.6 10.3 16.1 11.7 16.5 
TM9SF4 1.30E-01 2.66E-01 -0.6 6.5 10.6 7.9 10.7 
TYW3 3.98E-02 2.36E-01 -0.6 28.0 43.3 32.3 46.3 
PRKAG1 6.17E-02 2.41E-01 -0.6 14.9 23.3 18.0 25.5 
SCYL2 1.63E-01 2.81E-01 -0.6 6.9 13.0 9.7 11.7 
UBE2B 3.72E-02 2.33E-01 -0.6 17.7 27.4 19.7 28.3 
TLR1 1.95E-01 2.95E-01 -0.6 5.7 10.4 8.0 9.9 
CTSH 4.16E-02 2.36E-01 -0.6 51.0 69.2 46.6 76.2 
USP9X 4.65E-02 2.37E-01 -0.6 11.2 18.1 12.6 17.5 
SQLE 1.66E-01 2.83E-01 -0.6 175.7 284.7 175.1 238.7 
MPZ 2.54E-01 3.23E-01 -0.6 9.8 12.8 5.9 10.5 
APOBEC3G 1.05E-02 2.21E-01 -0.6 11.2 17.3 11.5 16.7 
QPRT 1.58E-01 2.77E-01 -0.6 12.2 19.9 12.4 16.8 
PLOD1 8.26E-02 2.51E-01 -0.6 9.4 15.6 11.1 15.1 
DBI 5.08E-03 2.08E-01 -0.6 453.9 682.8 446.7 668.7 
RAB12 1.47E-01 2.74E-01 -0.6 6.4 11.1 7.1 9.2 
ACSL1 1.68E-02 2.25E-01 -0.6 64.9 102.8 68.2 97.4 
NUP62 1.01E-01 2.58E-01 -0.6 16.7 28.9 20.7 27.4 
TFG 1.51E-02 2.25E-01 -0.6 16.8 24.1 15.7 24.7 
POC5 2.33E-01 3.10E-01 -0.6 10.4 19.6 15.5 19.3 
SFT2D1 2.61E-02 2.26E-01 -0.6 53.2 86.1 57.0 80.0 
NPC1 1.15E-01 2.62E-01 -0.6 14.8 25.3 16.2 21.6 
ISG15 2.18E-01 3.03E-01 -0.6 19.9 26.8 20.5 34.2 
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HLA-
DQB1.e 1.07E-01 2.58E-01 -0.6 10.2 18.4 12.1 15.3 
RIDA 5.19E-02 2.37E-01 -0.6 43.9 67.6 42.2 62.5 
RAB3IP 3.53E-03 2.08E-01 -0.6 21.1 31.8 20.2 30.8 
TAGAP 8.52E-02 2.52E-01 -0.6 8.5 14.1 9.0 12.5 
GOLGB1 1.96E-02 2.25E-01 -0.6 9.5 14.4 10.2 15.4 
FKTN 4.95E-01 3.73E-01 -0.6 59.0 80.1 101.4 163.2 
CD55 9.30E-02 2.54E-01 -0.6 6.9 11.0 6.8 9.9 
ABHD3 9.24E-02 2.54E-01 -0.6 31.4 58.8 40.5 50.7 
IRF2BP2 1.55E-01 2.77E-01 -0.6 8.0 14.0 10.4 14.0 
KIAA1191 6.35E-02 2.44E-01 -0.6 16.7 27.2 17.3 24.9 
ZNF33A 2.76E-02 2.27E-01 -0.6 17.5 26.8 16.1 24.7 
SEC61B 8.22E-02 2.51E-01 -0.6 55.8 82.3 56.8 90.5 
ANXA5 9.67E-02 2.56E-01 -0.6 51.0 82.0 50.6 73.7 
STAT3 2.73E-02 2.26E-01 -0.6 8.8 14.6 9.5 13.4 
ABHD2 2.85E-02 2.28E-01 -0.6 7.9 12.5 8.5 12.7 
ARID2 5.85E-01 4.05E-01 -0.6 8.0 6.0 6.4 16.2 
IFI30 4.58E-02 2.37E-01 -0.6 87.7 120.8 78.6 134.9 
PLSCR1 6.69E-02 2.47E-01 -0.6 15.7 25.3 15.9 23.4 
RAB8B 5.26E-02 2.37E-01 -0.6 41.6 70.9 45.4 63.6 
ARAP1 5.70E-01 3.98E-01 -0.6 12.2 9.5 9.9 24.6 
EPB41 3.32E-02 2.32E-01 -0.6 44.7 68.3 46.4 72.8 
SMARCA2 2.48E-02 2.25E-01 -0.6 29.5 46.7 30.8 46.8 
ZNF140 1.43E-01 2.72E-01 -0.6 8.9 15.1 9.1 12.8 
DNAJB4 8.73E-02 2.53E-01 -0.6 12.4 21.0 14.5 20.8 
MLLT6.b 2.66E-01 3.28E-01 -0.6 5.5 9.7 9.4 13.5 
SASH3 2.45E-01 3.17E-01 -0.6 14.2 20.2 16.6 27.9 
ST20 1.35E-01 2.68E-01 -0.7 13.2 23.6 18.5 26.2 
KRAS 5.05E-02 2.37E-01 -0.7 6.6 11.6 7.8 11.1 
HLA-B.f 2.42E-02 2.25E-01 -0.7 91.3 139.8 85.3 138.0 
ACSL5 4.37E-02 2.37E-01 -0.7 42.2 65.2 43.2 69.4 
CNTNAP4 1.99E-02 2.25E-01 -0.7 6.5 10.6 7.1 10.9 
IKBKE 5.48E-02 2.37E-01 -0.7 12.6 21.3 15.7 23.7 
MBD5 1.43E-01 2.73E-01 -0.7 8.4 12.6 9.3 15.5 
HELLS 1.75E-01 2.88E-01 -0.7 189.0 394.3 247.4 298.6 
LAP3 1.61E-02 2.25E-01 -0.7 82.2 142.5 91.2 133.1 
CCDC124 6.73E-02 2.47E-01 -0.7 25.7 42.2 25.3 38.8 
UBE2L6 2.10E-02 2.25E-01 -0.7 18.4 29.2 19.7 31.3 
B4GALT4 1.49E-01 2.74E-01 -0.7 8.3 15.0 8.8 12.3 
RAB21 3.53E-02 2.33E-01 -0.7 42.7 78.0 50.5 70.8 
BAZ2A 2.01E-01 2.95E-01 -0.7 6.9 9.6 6.8 12.3 
ARHGAP45 1.13E-02 2.23E-01 -0.7 6.2 10.4 6.5 9.9 
EIF2AK2 1.81E-01 2.91E-01 -0.7 17.9 25.9 18.5 32.3 
TNIP2 3.54E-02 2.33E-01 -0.7 28.4 49.0 31.9 47.6 
MT-ND6 2.26E-01 3.07E-01 -0.7 63.8 134.4 101.4 131.1 
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FYTTD1 5.65E-02 2.38E-01 -0.7 77.6 131.6 86.8 132.6 
CLPTM1 7.65E-03 2.08E-01 -0.7 9.1 14.3 8.4 13.7 
HLA-B.c 6.48E-03 2.08E-01 -0.7 10.2 15.6 9.7 16.3 
PPP3CC 4.39E-02 2.37E-01 -0.7 7.0 12.1 7.9 11.8 
FAHD2A 9.85E-04 1.87E-01 -0.7 8.4 13.4 8.3 13.4 
LRTOMT 6.03E-01 4.11E-01 -0.7 12.4 18.1 2.8 6.5 
SVIP 7.47E-02 2.49E-01 -0.7 6.6 10.9 6.3 9.9 
RHOQ 1.40E-03 1.87E-01 -0.7 38.5 61.1 37.6 61.6 
STK40 5.60E-02 2.38E-01 -0.7 12.0 20.9 13.7 20.5 
SPPL2A 9.16E-02 2.53E-01 -0.7 20.5 29.6 16.7 30.4 
RGS5 4.39E-02 2.37E-01 -0.7 8.8 16.6 10.6 14.8 
HIST1H2BM 1.98E-01 2.95E-01 -0.7 12.8 19.1 14.5 25.1 
HSPA1B.b 7.83E-02 2.50E-01 -0.7 28.0 52.7 35.2 49.6 
HLA-A 1.45E-01 2.74E-01 -0.7 38.8 68.0 38.2 56.8 
AP1S3 2.19E-02 2.25E-01 -0.7 14.0 22.9 15.5 24.9 
CCDC93 1.59E-01 2.78E-01 -0.7 11.7 17.7 12.8 22.0 
SLC25A12 5.80E-01 4.02E-01 -0.7 16.2 13.2 16.1 39.2 
PMAIP1 9.36E-02 2.55E-01 -0.7 19.4 34.6 20.5 30.2 
N4BP1 8.15E-02 2.50E-01 -0.7 7.4 13.0 9.9 15.1 
LACTB 5.75E-02 2.39E-01 -0.7 12.1 17.8 10.2 18.4 
ARL8B 1.64E-01 2.82E-01 -0.7 37.4 54.4 37.0 66.8 
CBX4 7.23E-03 2.08E-01 -0.7 8.1 13.6 8.7 14.0 
C2orf76 7.05E-02 2.47E-01 -0.7 22.4 36.3 18.7 30.9 
METTL1 1.01E-01 2.58E-01 -0.7 6.0 11.6 7.0 9.6 
ZNF12 5.04E-01 3.74E-01 -0.7 3.9 19.1 18.1 16.9 
PPP1R9B 1.49E-02 2.25E-01 -0.7 18.6 30.2 18.9 31.3 
MTRNR2L12 3.41E-01 3.59E-01 -0.7 18.9 26.7 24.2 44.0 
HLA-B 7.87E-02 2.50E-01 -0.7 79.6 120.8 76.4 135.2 
OPTN 3.34E-02 2.32E-01 -0.7 43.5 72.3 41.4 67.2 
DTX3L 2.35E-02 2.25E-01 -0.7 12.1 20.1 13.6 22.0 
YIPF3 3.93E-02 2.36E-01 -0.7 17.7 30.8 21.6 34.1 
IKBKB 1.89E-01 2.95E-01 -0.7 4.7 10.7 7.6 9.6 
SLC3A2 2.40E-02 2.25E-01 -0.7 37.3 67.6 42.5 64.6 
ANKRD12 3.31E-02 2.32E-01 -0.7 149.3 280.5 177.4 261.9 
HTRA2 5.32E-02 2.37E-01 -0.7 9.1 14.9 9.8 16.6 
PHACTR1 2.34E-02 2.25E-01 -0.7 5.6 9.7 6.5 10.3 
RBM19 5.34E-02 2.37E-01 -0.7 8.3 13.9 9.5 15.8 
STX3 1.93E-02 2.25E-01 -0.7 11.9 19.2 10.3 17.9 
ARNTL2 4.29E-02 2.37E-01 -0.7 11.9 20.8 13.0 20.8 
TANK 4.08E-02 2.36E-01 -0.8 102.4 183.2 113.8 180.8 
LPCAT1 7.96E-02 2.50E-01 -0.8 23.9 43.7 25.1 38.8 
DNAJB9 7.86E-02 2.50E-01 -0.8 45.2 66.9 35.9 70.1 
PSD3 6.10E-02 2.41E-01 -0.8 25.2 46.6 32.2 50.4 
HLA-B.d 1.93E-02 2.25E-01 -0.8 57.4 103.5 60.7 97.0 
CD58 3.53E-03 2.08E-01 -0.8 58.2 96.9 56.9 99.1 
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FGFR1 5.99E-02 2.40E-01 -0.8 6.6 10.8 6.6 11.7 
PIAS1 2.33E-02 2.25E-01 -0.8 10.6 18.2 11.5 19.7 
PREX1 7.91E-02 2.50E-01 -0.8 25.8 40.5 19.3 37.3 
CHCHD6 1.31E-01 2.66E-01 -0.8 11.0 16.7 8.0 16.3 
LRR1 2.65E-02 2.26E-01 -0.8 294.6 537.5 350.4 577.6 
MT-ATP6 6.77E-02 2.47E-01 -0.8 145.2 270.3 194.3 317.3 
FBXW11 4.31E-01 3.73E-01 -0.8 14.9 34.0 14.4 16.8 
PSMB9.h 4.88E-02 2.37E-01 -0.8 12.8 23.5 14.6 23.9 
NPC2 2.83E-02 2.28E-01 -0.8 5.6 9.6 6.0 10.5 
XBP1 2.58E-02 2.25E-01 -0.8 26.5 50.3 30.2 48.6 
DHRS7B 1.94E-02 2.25E-01 -0.8 6.1 10.2 5.7 10.3 
PTTG1IP 8.45E-02 2.52E-01 -0.8 15.1 23.5 13.9 27.2 
SQSTM1 9.44E-02 2.55E-01 -0.8 17.3 28.9 18.2 33.3 
DPH6 1.37E-01 2.69E-01 -0.8 16.4 24.6 11.7 24.6 
SPOCK2 2.56E-02 2.25E-01 -0.8 9.9 19.8 11.4 17.9 
CD70 4.83E-02 2.37E-01 -0.8 45.5 74.2 39.2 75.8 
EIF1 1.85E-02 2.25E-01 -0.8 21.5 39.1 24.1 42.6 
RBM7 2.23E-01 3.05E-01 -0.8 5.2 14.0 9.9 13.1 
CTSS 2.87E-02 2.28E-01 -0.9 63.0 112.2 65.2 119.2 
TRIM27.e 3.73E-01 3.71E-01 -0.9 13.3 29.7 12.0 16.1 
PSME2 4.39E-03 2.08E-01 -0.9 212.0 384.9 206.1 374.2 
SERPINB9 2.04E-02 2.25E-01 -0.9 5.1 10.6 6.1 9.9 
UNC119 3.31E-02 2.32E-01 -0.9 15.5 25.3 13.0 26.6 
HLA-C.g 1.32E-02 2.23E-01 -0.9 49.7 94.9 51.9 90.3 
NR6A1 1.52E-02 2.25E-01 -0.9 8.0 14.8 8.9 16.0 
FTH1 1.29E-01 2.65E-01 -0.9 90.6 153.4 95.1 186.5 
HSPB1 6.51E-02 2.45E-01 -0.9 6.9 13.8 8.3 14.0 
STARD4 1.87E-01 2.94E-01 -0.9 18.4 38.0 17.7 28.6 
LITAF 2.50E-02 2.25E-01 -0.9 10.9 20.0 9.8 18.1 
HLA-B.b 3.54E-02 2.33E-01 -0.9 63.1 139.4 78.7 122.4 
PARP9 1.60E-02 2.25E-01 -0.9 19.9 40.2 22.7 38.6 
RHOG 8.20E-03 2.08E-01 -0.9 10.3 19.0 10.6 19.6 
POTEI 3.66E-02 2.33E-01 -0.9 5.9 10.4 5.3 10.4 
CD274 1.53E-01 2.76E-01 -0.9 8.5 19.8 13.0 20.0 
ACTB 1.18E-03 1.87E-01 -0.9 776.1 1438.1 761.1 1414.6 
HLA-E.b 2.15E-01 3.00E-01 -0.9 17.6 31.7 10.8 21.1 
OAS1 1.84E-01 2.92E-01 -0.9 11.9 18.9 11.7 25.0 
STAT2 6.24E-02 2.43E-01 -0.9 7.7 14.0 8.4 16.0 
SPIB 2.17E-02 2.25E-01 -0.9 14.9 27.8 16.1 30.1 
UGCG 2.72E-05 4.50E-02 -0.9 9.4 17.5 9.4 17.6 
MKNK2 3.58E-02 2.33E-01 -0.9 13.8 27.2 15.4 27.4 
MX1 5.68E-02 2.39E-01 -0.9 35.9 54.8 28.2 65.2 
VRK2 1.45E-02 2.25E-01 -0.9 14.3 30.1 16.7 28.1 
DOCK10 1.17E-01 2.63E-01 -0.9 8.0 18.0 11.6 18.9 
PCMTD2 6.97E-02 2.47E-01 -0.9 6.4 13.7 7.1 11.8 
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CERS4 5.42E-03 2.08E-01 -0.9 6.8 12.2 6.5 12.7 
IFT52 5.91E-01 4.06E-01 -0.9 7.5 5.3 7.7 23.4 
CDC42SE1 4.06E-02 2.36E-01 -0.9 12.4 22.3 12.0 24.0 
IFI16 1.38E-02 2.24E-01 -0.9 17.1 35.4 19.5 33.8 
IFIH1 1.68E-02 2.25E-01 -0.9 10.4 20.3 11.1 20.4 
HLA-C.f 4.44E-03 2.08E-01 -0.9 24.5 49.6 26.7 47.5 
ISG20 1.04E-02 2.21E-01 -0.9 11.1 22.5 12.2 21.9 
ZNF260 1.34E-01 2.67E-01 -0.9 87.6 210.6 131.1 205.4 
RAPGEF1 1.32E-03 1.87E-01 -0.9 11.0 21.2 11.5 21.8 
IL10 6.80E-02 2.47E-01 -0.9 19.2 42.9 24.7 41.3 
CRYZ 8.26E-02 2.51E-01 -0.9 14.1 26.1 15.4 30.6 
LEPROT 1.26E-01 2.65E-01 -0.9 4.9 14.3 8.5 11.3 
OAS2 7.90E-02 2.50E-01 -0.9 5.7 10.5 6.1 12.1 
SNORD3B-1 6.97E-02 2.47E-01 -0.9 52.2 99.0 59.6 116.3 
PELI1 7.42E-02 2.49E-01 -0.9 8.1 16.4 7.9 14.6 
JUNB 2.02E-02 2.25E-01 -1.0 8.5 17.0 9.1 17.1 
SLF1 3.63E-01 3.67E-01 -1.0 25.0 64.3 25.7 33.9 
STX12 6.13E-02 2.41E-01 -1.0 8.8 16.8 9.9 19.4 
LSAMP 1.15E-01 2.62E-01 -1.0 18.1 29.5 12.7 30.2 
TNNT1 7.97E-02 2.50E-01 -1.0 28.9 54.9 33.0 65.4 
ZCCHC18 5.97E-01 4.08E-01 -1.0 0.3 16.2 10.0 3.9 
CCL5.b 3.06E-02 2.29E-01 -1.0 9.8 19.0 10.6 20.8 
FLOT2 1.75E-01 2.88E-01 -1.0 15.8 24.0 9.0 24.6 
SLC6A6 9.90E-02 2.58E-01 -1.0 8.4 17.3 7.8 14.5 
MT-CYB 8.50E-02 2.52E-01 -1.0 55.6 125.1 73.5 127.8 
LTBR 8.22E-02 2.51E-01 -1.0 19.4 39.2 25.3 48.9 
TRIM27 3.51E-01 3.59E-01 -1.0 11.3 29.4 11.6 15.8 
JDP2 3.72E-02 2.33E-01 -1.0 9.8 17.9 7.8 17.0 
C1orf54 4.94E-02 2.37E-01 -1.0 8.5 16.4 8.9 18.1 
DUSP2 1.81E-02 2.25E-01 -1.0 16.9 30.2 14.3 31.7 
CYBB 1.63E-02 2.25E-01 -1.0 7.7 15.3 7.8 15.7 
TSPAN33 7.34E-03 2.08E-01 -1.0 11.8 25.8 13.2 24.2 
IFI35 1.09E-01 2.59E-01 -1.0 5.8 10.9 6.2 13.2 
IFITM1 2.27E-02 2.25E-01 -1.0 18.1 36.8 17.8 35.2 
CASP1 4.64E-03 2.08E-01 -1.0 196.2 401.9 214.3 422.4 
CCL5 7.45E-02 2.49E-01 -1.0 8.9 21.5 13.6 24.2 
SUOX 1.13E-01 2.60E-01 -1.0 6.1 10.3 4.2 10.4 
PDXK 1.45E-03 1.87E-01 -1.0 23.0 46.8 23.3 47.4 
ARID3A 1.18E-02 2.23E-01 -1.0 10.3 22.2 12.2 24.0 
RNF213 2.89E-01 3.37E-01 -1.0 6.0 10.0 7.2 17.0 
FAM98B 6.21E-01 4.16E-01 -1.0 2.1 35.9 17.9 5.2 
NCK2 1.26E-01 2.65E-01 -1.0 9.9 24.2 11.1 19.2 
IRF8 4.69E-02 2.37E-01 -1.1 99.0 186.7 76.9 178.2 
NDUFB4 4.72E-01 3.73E-01 -1.1 25.8 25.5 21.1 72.2 
SEC14L1 1.70E-01 2.85E-01 -1.1 12.0 23.3 14.6 32.3 
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TRPS1 1.06E-02 2.21E-01 -1.1 5.4 11.0 5.1 11.0 
LAT2 3.65E-02 2.33E-01 -1.1 24.1 53.8 25.0 49.9 
MAP3K4 4.23E-01 3.73E-01 -1.1 17.6 28.0 28.4 69.5 
BST2 1.52E-01 2.75E-01 -1.1 138.9 502.9 297.1 424.9 
IFNGR2 4.47E-02 2.37E-01 -1.1 15.6 34.2 15.2 31.5 
CD82 2.86E-02 2.28E-01 -1.1 4.8 11.3 6.4 12.9 
EXTL2 8.32E-02 2.51E-01 -1.1 9.1 16.1 7.6 19.8 
PRKCZ 6.99E-02 2.47E-01 -1.1 12.9 33.4 17.6 32.3 
MT2A 1.54E-01 2.76E-01 -1.1 6.7 13.8 8.2 18.8 
RAB11FIP1 1.72E-02 2.25E-01 -1.1 9.3 19.3 8.3 18.9 
ABCC4 6.59E-03 2.08E-01 -1.1 24.8 58.6 27.4 55.2 
CASP4 4.72E-03 2.08E-01 -1.1 31.6 70.1 32.3 70.2 
TFRC 5.97E-02 2.40E-01 -1.1 73.4 170.9 74.5 154.0 
IVNS1ABP 1.72E-02 2.25E-01 -1.1 42.1 97.2 43.6 92.4 
MXI1 1.03E-01 2.58E-01 -1.1 16.1 38.0 15.4 31.6 
ALCAM 7.95E-03 2.08E-01 -1.2 11.8 26.6 12.8 28.2 
NCKAP1 3.45E-01 3.59E-01 -1.2 7.7 113.8 74.6 70.9 
SLC39A1 1.75E-03 1.88E-01 -1.2 9.3 20.2 8.7 20.7 
AGPAT3 2.45E-02 2.25E-01 -1.2 8.3 16.7 7.2 18.6 
VPS26A 2.28E-02 2.25E-01 -1.2 14.0 37.2 17.6 35.3 
FSD1L 3.18E-02 2.31E-01 -1.2 4.3 10.8 5.9 12.6 
LONRF1 4.48E-02 2.37E-01 -1.2 10.2 27.2 11.8 23.7 
FCHSD2 3.64E-03 2.08E-01 -1.2 70.2 162.5 68.6 158.9 
SKIL 3.09E-02 2.30E-01 -1.2 5.6 12.6 5.6 13.4 
MT-CO1 1.92E-02 2.25E-01 -1.2 281.9 697.9 357.3 785.0 
CTSB 8.08E-03 2.08E-01 -1.2 8.7 19.9 7.9 18.6 
SZT2 5.68E-01 3.98E-01 -1.2 3.8 4.8 10.7 29.1 
HLA-C.c 6.72E-02 2.47E-01 -1.2 5.4 13.4 5.4 11.9 
VCAM1 1.88E-02 2.25E-01 -1.2 10.4 26.7 13.3 28.6 
MT-ND2 2.64E-02 2.26E-01 -1.2 107.4 278.5 147.3 318.9 
NABP1 4.80E-02 2.37E-01 -1.2 26.0 68.6 32.7 69.7 
CD84 7.56E-02 2.49E-01 -1.2 6.2 14.3 7.0 17.0 
ATP1B1 2.12E-02 2.25E-01 -1.2 9.0 23.7 10.7 23.1 
TRIM69.b 5.73E-02 2.39E-01 -1.3 7.0 14.7 5.0 14.1 
RNF145 3.82E-03 2.08E-01 -1.3 12.3 32.4 13.8 30.7 
LRRC32 2.33E-02 2.25E-01 -1.3 4.6 10.5 4.1 10.5 
CSRP2 5.39E-02 2.37E-01 -1.3 8.7 21.2 7.5 18.2 
HLA-E.g 1.74E-01 2.87E-01 -1.3 13.1 25.4 11.8 35.8 
STAT5A 4.40E-03 2.08E-01 -1.3 8.7 21.0 7.8 19.8 
SLC2A5 5.03E-02 2.37E-01 -1.3 5.3 13.7 5.1 12.4 
DENND5A 4.72E-02 2.37E-01 -1.3 4.1 10.9 4.2 9.9 
CCDC28B 3.55E-02 2.33E-01 -1.3 71.9 184.0 84.9 210.6 
C1orf61 9.66E-02 2.56E-01 -1.3 4.0 11.8 7.0 16.0 
NFKB2 8.83E-04 1.85E-01 -1.3 31.1 82.8 33.2 80.9 
CLIP2 3.90E-02 2.36E-01 -1.4 7.8 21.1 8.0 19.4 
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CSTB 1.18E-03 1.87E-01 -1.4 4.8 12.6 5.2 13.0 
DUSP22 1.38E-01 2.70E-01 -1.4 64.8 196.6 70.0 148.8 
IFI6 1.94E-01 2.95E-01 -1.4 6.6 13.1 6.1 19.4 
MT-ND4 1.64E-02 2.25E-01 -1.4 107.5 308.1 145.2 342.4 
FN3KRP 1.65E-01 2.83E-01 -1.4 13.8 28.2 4.4 18.7 
CD80 1.30E-02 2.23E-01 -1.4 8.9 25.4 11.3 27.0 
WDFY1 2.16E-01 3.01E-01 -1.4 16.1 26.1 10.5 43.2 
MT-ND5 4.60E-02 2.37E-01 -1.4 70.7 221.1 102.1 232.6 
SSTR2 4.26E-02 2.37E-01 -1.4 14.3 37.4 16.1 42.4 
FMNL3 3.60E-02 2.33E-01 -1.4 5.2 15.1 6.2 15.0 
IFI44 3.74E-02 2.33E-01 -1.4 10.3 29.4 13.7 34.9 
PPP1R15A 6.93E-02 2.47E-01 -1.4 4.8 13.7 4.7 11.9 
NAMPT 1.48E-01 2.74E-01 -1.4 73.4 251.3 87.3 181.5 
RAB9A 5.67E-02 2.39E-01 -1.4 30.3 87.9 31.3 78.2 
PPP4R4 6.50E-04 1.85E-01 -1.4 5.2 14.6 5.5 14.3 
HERPUD1 2.23E-02 2.25E-01 -1.4 8.9 27.6 10.4 24.7 
NEDD4L 4.06E-02 2.36E-01 -1.5 5.0 14.9 6.9 17.9 
RGS1 4.23E-02 2.36E-01 -1.5 88.3 312.5 120.2 259.9 
CFLAR 9.89E-03 2.19E-01 -1.5 25.7 72.8 29.5 78.9 
XAF1 4.10E-02 2.36E-01 -1.5 3.0 9.5 4.6 11.6 
DENND4A 8.01E-02 2.50E-01 -1.5 20.3 51.0 19.8 60.0 
TCFL5 1.74E-02 2.25E-01 -1.5 4.1 11.5 4.5 12.3 
HYOU1 6.91E-02 2.47E-01 -1.5 18.1 53.0 16.8 45.4 
HYOU1.b 6.65E-02 2.47E-01 -1.5 18.1 53.0 16.8 45.6 
PPP4R4.b 5.76E-04 1.85E-01 -1.5 6.1 17.6 6.5 18.0 
MTMR4 1.83E-02 2.25E-01 -1.5 5.6 15.0 5.3 16.0 
NDE1 3.90E-03 2.08E-01 -1.5 8.6 23.4 8.1 24.2 
MT-ND1 3.40E-02 2.32E-01 -1.6 65.3 205.5 86.7 242.0 
ZBTB32 1.74E-01 2.87E-01 -1.6 1.4 11.0 6.6 12.8 
IL6ST 2.48E-02 2.25E-01 -1.6 3.2 11.6 5.1 13.3 
NDE1.b 6.56E-02 2.45E-01 -1.6 8.6 23.3 8.1 27.0 
MAP3K5 1.10E-01 2.59E-01 -1.6 5.0 22.3 7.8 16.1 
CAPG 7.08E-04 1.85E-01 -1.6 22.6 71.8 24.3 70.0 
SNX11 1.47E-02 2.25E-01 -1.6 7.1 23.7 9.6 26.7 
CCND1 1.83E-02 2.25E-01 -1.6 4.6 14.2 4.6 13.7 
CD40 1.79E-03 1.88E-01 -1.6 52.5 176.3 59.6 169.5 
TRIM22 3.58E-02 2.33E-01 -1.6 24.3 88.0 32.0 86.6 
IRF9 4.80E-02 2.37E-01 -1.7 9.1 31.0 9.6 27.8 
IFIT3 8.16E-02 2.50E-01 -1.7 5.8 17.9 6.8 22.0 
SPIC 1.77E-02 2.25E-01 -1.7 2.7 10.2 3.8 10.8 
HLA-A.g 3.16E-02 2.31E-01 -1.7 13.3 47.0 18.3 55.3 
ARID5A 4.71E-02 2.37E-01 -1.7 2.9 12.6 4.2 10.2 
PPP1R1C 2.87E-02 2.28E-01 -1.7 16.3 45.5 13.6 51.5 
MVP 2.35E-03 1.97E-01 -1.7 4.3 15.5 4.9 14.8 
NCF4 5.86E-04 1.85E-01 -1.7 7.3 24.1 7.2 24.3 
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SAMSN1 1.01E-02 2.19E-01 -1.8 36.7 131.1 39.9 130.7 
QTRT1 1.30E-01 2.66E-01 -1.8 5.9 13.4 3.7 19.5 
RASSF4 7.80E-04 1.85E-01 -1.8 14.7 52.5 15.6 53.0 
B4GALT5 1.25E-03 1.87E-01 -1.8 3.0 10.9 3.4 11.3 
DUSP10 7.60E-03 2.08E-01 -1.8 3.5 15.1 4.6 13.8 
IRF1 3.61E-03 2.08E-01 -1.8 11.4 40.8 11.0 39.9 
IL4I1 2.00E-02 2.25E-01 -1.9 3.0 12.0 3.7 12.2 
B4GALT6 2.49E-01 3.19E-01 -1.9 4.8 18.8 3.0 9.8 
STAT1 5.60E-04 1.85E-01 -1.9 19.5 75.3 20.9 73.6 
SLAMF1 2.24E-02 2.25E-01 -1.9 9.5 36.3 9.7 34.4 
SLAMF7 2.90E-03 2.07E-01 -1.9 2.6 10.3 2.9 9.9 
ZNF33B 7.59E-02 2.49E-01 -1.9 8.2 37.8 10.2 30.4 
TXLNB 3.07E-02 2.29E-01 -1.9 12.4 41.4 9.5 41.4 
HLA-E.f 2.38E-01 3.13E-01 -1.9 6.8 21.5 1.6 10.6 
ADAMDEC1 3.23E-02 2.32E-01 -1.9 2.5 11.4 3.4 11.5 
BCL2A1 8.53E-03 2.10E-01 -2.0 63.1 245.0 65.9 254.1 
ICAM1 4.59E-02 2.37E-01 -2.0 14.0 58.3 14.5 52.2 
ATF3 1.09E-03 1.87E-01 -2.0 3.3 13.0 3.2 13.0 
LMNA 6.88E-02 2.47E-01 -2.0 8.4 36.8 8.5 31.2 
FABP6 6.19E-02 2.42E-01 -2.0 10.1 43.6 9.8 37.6 
IL7R 2.63E-02 2.26E-01 -2.1 1.9 11.2 4.0 13.5 
RASGEF1B 1.26E-02 2.23E-01 -2.1 7.2 35.0 9.5 35.9 
PDE4DIP 9.60E-02 2.55E-01 -2.1 6.3 25.8 7.5 33.2 
TMEM120A 1.55E-01 2.77E-01 -2.1 5.5 17.7 4.7 26.2 
GOPC 1.25E-03 1.87E-01 -2.1 10.5 49.7 12.1 48.6 
SAMD9L 6.08E-03 2.08E-01 -2.1 2.6 13.1 3.6 13.8 
GPR137B 9.45E-02 2.55E-01 -2.1 5.1 19.7 5.1 24.9 
TRAF1 2.77E-02 2.28E-01 -2.1 8.5 38.1 9.9 42.4 
BCL2 1.08E-02 2.21E-01 -2.2 4.5 20.0 4.3 19.2 
AL132671.2 2.13E-02 2.25E-01 -2.2 9.5 43.6 9.8 46.2 
TDRD7 2.90E-03 2.07E-01 -2.2 5.0 25.2 5.9 25.6 
EPSTI1 3.37E-03 2.08E-01 -2.3 54.3 259.8 51.6 259.4 
FLNB 3.76E-01 3.72E-01 -2.3 2.6 19.9 2.7 6.0 
BCL2L1 1.74E-03 1.88E-01 -2.3 55.5 292.8 61.6 289.9 
CLIC2 2.96E-03 2.07E-01 -2.3 6.0 34.9 8.3 36.9 
NFKBIZ 1.28E-02 2.23E-01 -2.4 5.5 31.9 7.3 35.2 
GADD45B 6.17E-02 2.41E-01 -2.4 2.8 15.4 2.7 13.2 
NFKBIA 4.21E-03 2.08E-01 -2.4 31.0 168.3 34.3 175.1 
MGLL 4.15E-02 2.36E-01 -2.4 2.2 10.1 1.8 11.5 
SLFN5 6.81E-04 1.85E-01 -2.5 2.5 14.3 2.8 14.8 
NUS1 4.45E-02 2.37E-01 -2.5 4.4 25.6 5.1 29.2 
FCRL4 2.51E-03 2.03E-01 -2.6 1.9 12.7 2.5 13.2 
CRIP1 5.03E-02 2.37E-01 -2.6 24.8 157.8 33.9 188.6 
GBP1 4.14E-02 2.36E-01 -2.6 3.6 24.3 5.0 28.6 
NCF2 1.45E-03 1.87E-01 -2.7 8.2 59.1 11.0 61.7 
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TFEC 4.16E-03 2.08E-01 -2.7 17.5 126.9 22.8 135.2 
IFI44L 7.36E-02 2.48E-01 -2.7 9.6 58.9 10.4 72.0 
ZBTB10 5.56E-02 2.38E-01 -2.7 5.3 41.7 6.4 35.4 
AL928654.4 1.92E-03 1.92E-01 -2.7 143.5 1108.0 198.4 1148.9 
ZNF782 4.91E-01 3.73E-01 -2.7 1.7 24.2 2.3 2.3 
INSIG1 2.81E-02 2.28E-01 -2.8 26.7 178.6 23.1 162.3 
ACSBG1 2.02E-02 2.25E-01 -2.8 1.7 17.3 2.8 15.1 
KDM2B 1.23E-02 2.23E-01 -2.9 9.1 65.2 9.0 67.4 
CLDN12 4.41E-01 3.73E-01 -2.9 2.0 29.2 2.4 4.7 
LGALS1 1.96E-03 1.92E-01 -3.1 12.1 133.7 19.3 127.7 
TRIP10 1.07E-01 2.58E-01 -3.1 9.8 84.7 7.1 61.8 
PTK2B 2.64E-03 2.04E-01 -3.3 7.4 79.4 8.6 77.0 
CD83 3.38E-02 2.32E-01 -3.5 21.6 275.7 26.1 247.3 
ESR1 4.37E-01 3.73E-01 -3.5 0.6 2.7 1.3 18.3 
TNFAIP3 8.44E-02 2.52E-01 -3.6 11.4 186.1 16.2 144.1 
MYEOV 6.74E-03 2.08E-01 -3.6 0.9 11.7 1.1 12.3 
CCR7 1.35E-02 2.23E-01 -3.7 3.7 47.9 4.1 50.3 
IL32 1.70E-02 2.25E-01 -3.7 1.7 21.0 1.5 19.7 
LNX1 2.34E-02 2.25E-01 -3.8 1.2 15.7 1.1 14.6 
LAMP3 2.58E-02 2.25E-01 -3.9 0.8 14.2 1.1 12.9 
CCL22 2.62E-02 2.26E-01 -3.9 1.0 18.1 1.6 20.2 
MTSS1 2.10E-02 2.25E-01 -4.0 1.4 27.8 2.2 30.6 
TTC39A 1.70E-02 2.25E-01 -4.0 1.2 21.2 1.4 20.0 
NRG4 1.78E-03 1.88E-01 -4.0 3.5 60.8 3.8 60.8 
EBI3 3.52E-03 2.08E-01 -4.1 2.9 58.2 4.0 57.9 
TPCN2 3.75E-02 2.33E-01 -4.2 0.7 11.0 0.5 9.8 
SRGN 1.23E-03 1.87E-01 -4.5 33.2 816.3 37.7 804.9 
UBD.e 5.42E-02 2.37E-01 -4.8 2.7 72.7 2.3 61.6 
UBD.b 7.10E-02 2.48E-01 -5.1 3.6 186.8 6.6 149.4 
IFI27 2.81E-02 2.28E-01 -5.1 1.2 41.8 1.2 38.3 
CXCL10 1.20E-02 2.23E-01 -5.2 2.9 118.9 3.7 124.1 
TNFRSF9 4.18E-02 2.36E-01 -5.3 0.3 14.3 0.5 16.3 
IFI27.b 3.22E-02 2.32E-01 -5.4 1.2 49.3 1.2 54.5 
GRIA4 1.91E-02 2.25E-01 -5.6 0.5 30.3 0.8 32.4 
AP003071.5 1.29E-01 2.65E-01 -6.2 0.2 18.2 0.2 12.1 
TNFAIP6 3.48E-02 2.33E-01 -7.2 0.1 10.6 0.1 9.5 
SERPINB10 9.20E-03 2.18E-01 -7.3 0.1 12.1 0.1 11.7 
ZC3H12C 2.50E-02 2.25E-01 -7.6 0.1 11.9 0.1 12.9 
Table 15: Upregulated genes in the presence of LMP1-induction found via RNA Seq 
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Mass Spectrometry Data 
 
Table Mass Spectrometry No LMP1 Group 
Gene Unique 
Peptides 
Sequence 
Coverage 
Control 
MS Count 
No LMP1 
MS Count 
N=1 
No LMP1  
MS Count 
N=2 
KIFC1 36 55.6 0 57 44 
MORC2 27 29.6 0 45 41 
TRIP12 30 20.3 0 45 26 
RTCB 17 39.2 0 25 38 
OAS3 25 25 0 38 24 
MAP4 26 16.1 0 29 27 
WIZ 18 21.5 0 21 23 
C14orf166 8 39.3 0 22 17 
HCFC1 13 8.6 0 18 19 
ATP5B 14 39.5 0 20 17 
RCC1 15 54.6 0 24 12 
SKIV2L2 17 18.2 0 18 15 
CDC27 1 24.8 0 18 14 
EBNA1BP2 9 31.9 0 21 11 
MED23 16 12.7 0 18 12 
FAM98B 6 25.6 0 14 14 
ABCF1 13 19.7 0 14 13 
KIF2C 12 21.8 0 13 14 
MED24 11 17.7 0 16 8 
ZC3H11A 12 18.6 0 12 12 
DDX50 13 27.7 0 14 10 
HMMR 10 22 0 8 14 
RPP30 8 35.8 0 12 10 
EXOSC2 8 36.9 0 11 11 
SYMPK 13 14.5 0 10 11 
FEN1 8 29.7 0 10 11 
TRIM25 13 28.1 0 8 13 
CENPV 7 37.1 0 9 12 
DTX3L 11 21.9 0 13 7 
C2orf49 7 41.8 0 8 12 
CMAS 9 27.6 0 13 6 
SNIP1 7 22.7 0 10 8 
CDKN2AIP 9 23.1 0 9 9 
EXOSC9 7 22.7 0 8 9 
MED14 9 9.7 0 8 9 
ERCC2 11 20 0 12 4 
EXOSC6 5 29 0 6 10 
MORF4L1 8 25.6 0 4 11 
DRG1 8 29.2 0 8 7 
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EXOSC4 5 26.5 0 8 7 
WDR33 7 9.9 0 7 7 
CCNK 4 11.2 0 9 5 
CPSF3 6 11.1 0 5 9 
EXOSC7 7 34.7 0 10 4 
CGGBP1 5 34.1 0 7 6 
PSPC1 6 22.9 0 3 10 
EXOSC5 4 19.1 0 6 7 
EXOSC3 5 28.7 0 8 4 
RRBP1 12 10.9 0 3 9 
MED12 6 3.9 0 7 4 
ACTL6A 6 22.1 0 10 1 
KPNB1 5 8 0 6 5 
CDC23 8 21.3 0 9 2 
TPX2;HCA90 6 10.2 0 4 7 
PARP9 7 13.9 0 5 5 
MED16 6 9.4 0 7 3 
GTF2F1 5 13.9 0 2 8 
MED4 6 27.8 0 6 4 
NCAPD3 8 7 0 9 1 
AKAP17A 7 11.9 0 9 1 
ARHGEF2 6 8 0 4 6 
SCHIP1;IQCJ-
SCHIP1;IQCJ 2 5.6 0 5 4 
PHB2 4 19.9 0 7 2 
GTF2H2C;GTF2H2 5 13.9 0 6 3 
CDC16 6 17.5 0 5 4 
GTF2H4 5 15.8 0 6 3 
HDGFRP2 4 9.7 0 4 5 
EED 5 14.8 0 6 2 
RPL15 6 32.2 0 7 1 
LSM14A 4 12.8 0 4 4 
SERBP1 3 10.9 0 5 3 
FAM98A 5 20.8 0 5 3 
HEATR1 5 2.7 0 5 2 
PXK 4 8.1 0 3 4 
CPSF4 3 25.1 0 5 2 
CWC22 5 6.5 0 6 1 
MLLT1 5 11.4 0 1 6 
FRG1 2 25 0 5 2 
ANAPC5 4 7.7 0 3 4 
EBF1 3 9.4 0 6 1 
MED17 3 4.6 0 3 4 
OSBPL1A 3 51.2 0 4 2 
RTEL1 1 1.4 0 4 2 
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MAGOH;MAGOHB 1 54.8 0 5 1 
MED22 2 22.5 0 3 3 
TADA2B 3 9.5 0 5 1 
PPP1R18 2 2.4 0 2 4 
CDCA5 3 9.8 0 2 4 
RNF40 5 9.9 0 5 1 
MED15 1 4.1 0 1 5 
ZC3H15 4 13.4 0 2 4 
BOD1L1 5 2.2 0 2 4 
MPHOSPH6 3 23.9 0 3 3 
PHF5A 4 40.9 0 5 1 
PHB 3 17.5 0 5 1 
RPP38 5 18.7 0 3 3 
CBX3 4 30.1 0 4 2 
CDK13 3 5 0 3 3 
NELFB 2 4.3 0 3 2 
TBL3 1 7.2 0 4 1 
MED21 2 20.1 0 3 2 
HM13 2 6.6 0 4 1 
SLC25A3 3 10.5 0 3 2 
RBMX2 3 10.2 0 3 2 
DHX37 3 3.8 0 2 3 
RPP40 2 23.9 0 4 1 
RSRC1 4 21 0 4 1 
CCHCR1 2 4.4 0 1 4 
PRDM2 3 2.7 0 3 2 
SLC25A4 3 28.9 0 3 2 
CACNA1A 2 4.1 0 4 1 
ANAPC1 4 2.5 0 2 3 
CPSF2 4 7.5 0 2 3 
CDK19;CDK8 2 10 0 2 2 
WDR3 1 1.1 0 2 2 
KLF12 2 7 0 2 2 
PBRM1 3 2.3 0 3 1 
CD2BP2 2 6.5 0 3 1 
MED20 3 17 0 2 2 
ALKBH5 3 12.7 0 1 3 
INTS3 3 6.4 0 3 1 
MED6 3 16.9 0 2 2 
NIPBL 3 1.2 0 2 2 
EP400 4 1.7 0 3 1 
RBMXL1 3 28.5 0 1 3 
NFIA;NFIX 2 7.1 0 3 1 
GTF2F2 2 9.6 0 1 3 
RFX5 2 11.5 0 3 1 
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RRP12 1 1.3 0 3 1 
CDC27 1 26.9 0 1 2 
TRMT6 2 9.3 0 1 2 
NELFA;WHSC2 1 6.7 0 2 1 
ENY2 2 27.1 0 2 1 
ANAPC4 2 4.9 0 2 1 
PUF60 0 49.6 0 2 1 
CBX4 1 3.2 0 2 1 
FAM76A 3 12.5 0 2 1 
MNAT1 1 6 0 1 2 
CDC26 1 14.1 0 1 2 
WHSC1L1 2 3.9 0 2 1 
ANAPC10 1 11 0 1 2 
EXOSC1 3 20.5 0 1 2 
GTF2E2 1 7.1 0 2 1 
ANAPC2 2 4 0 2 1 
TRRAP 38 12.4 0 48 9 
EXOSC10 22 35.2 0 32 24 
DNMT1 51 38.5 0 93 60 
DDX49 14 34.6 0 24 20 
MED1 19 20.3 0 21 18 
DDX1 20 34.3 0 31 34 
NDNL2 13 43.1 0 24 9 
PRC1 14 27.9 0 23 13 
CPSF1 17 15 0 11 13 
NSMCE2 6 32.6 0 11 12 
XRCC1;FOXH1 7 15.2 0 10 8 
MINA 7 19.8 0 10 5 
NSMCE1 6 27.4 0 10 3 
GTPBP1 10 17.9 0 9 11 
AFF4 7 7.7 0 9 9 
ATRIP 12 20.7 0 9 6 
DDB1 8 9.6 0 9 3 
GAPDH 5 26.3 0 9 2 
NSMCE4A 7 24.2 0 14 6 
CDK12 3 4.8 0 7 5 
MMTAG2 4 25.9 0 7 2 
SMC6 29 35.7 0 44 20 
KNOP1 9 26.6 0 11 5 
MDC1 4 3.6 0 5 1 
VRK1 16 47.7 0 34 22 
NOP14 3 3.2 0 4 3 
BUD31 5 32.2 0 7 5 
C10orf12 3 3.7 0 7 3 
PCBP1 4 21.6 0 10 10 
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SETX 7 3.4 0 3 5 
CENPU;MLF1IP 4 11.7 0 3 5 
UPF3B 4 14 0 3 4 
APRG1 1 5.3 0 5 7 
RSBN1 7 13.8 0 5 5 
KTN1 3 2 0 5 3 
ATR 66 34.9 0 86 75 
SMC5 31 29.1 0 43 29 
DDX18 21 40.6 0 43 22 
HNRPLL;HNRNPLL 6 34.4 0 15 17 
RFC1 24 27.5 0 44 29 
RBM26 12 18.5 0 13 13 
RSBN1L 10 15.5 0 12 7 
SMCHD1 81 46 0 199 100 
TCOF1 0 20.5 0 49 35 
YBX1;YBX3 11 43.8 0 18 22 
ATAD5 6 4.5 0 4 3 
NCAPG2 12 13.8 0 12 3 
RIF1 6 4.2 0 4 3 
APEX1 16 67.3 0 37 18 
NOP2 18 25.7 0 22 17 
DIDO1 23 13.4 1 31 20 
THOC6 13 59.8 1 19 15 
ATP5A1 11 31.4 1 18 6 
ERCC3 11 21 1 11 9 
VDAC2 8 32.5 1 14 8 
THOC7 7 42.2 1 8 11 
SRP68 7 18.5 1 4 8 
POLDIP3;PDIP46 7 23.3 1 10 2 
THOC3 8 35.3 1 5 6 
SNRPG;SNRPGP15 2 20.3 1 6 2 
CTR9 5 6.1 1 3 5 
CANX 4 8.4 1 6 2 
NKAP 3 14.5 1 3 4 
SNRPF 3 39.5 1 3 2 
FAM133B;FAM133A 3 35.2 1 3 2 
ACSL1 12 20.8 1 14 8 
H2AFV;H2AFZ 3 31.2 1 6 3 
PSIP1 15 29.4 1 35 26 
RBM15 14 21.1 1 14 12 
ZNF638 16 11.7 1 19 11 
SFSWAP 7 11.5 1 5 7 
IGF2BP1 6 18.5 1 15 7 
POP1 18 24.4 1 29 25 
IK 11 28.5 1 13 3 
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CCAR1 25 30 1 48 14 
THOC2 39 31 2 74 47 
THOC5 22 34 2 33 26 
THOC1 21 36.1 2 34 24 
TMPO 22 42.2 2 31 23 
HSPA5 14 28.7 2 17 12 
SLC25A5 5 32.6 2 15 12 
NOLC1 7 12 2 8 12 
HELLS 10 14.7 2 14 6 
SNRNP27 4 29.7 2 9 8 
MFAP1 4 15.3 2 8 4 
DYNLL1;DYNLL2 3 49.4 2 7 5 
MKI67 116 46 2 206 153 
THRAP3 12 17.8 2 20 24 
SRP72 12 23.7 2 12 10 
RAD21 10 31.1 2 19 5 
DKC1 12 32.9 2 14 11 
PDS5B 29 28.2 2 51 21 
SNRPA 3 20.2 3 5 4 
RRP1B 24 40.3 3 34 28 
HIST1H1C 3 39.9 3 43 20 
SRSF9 7 33.5 3 16 7 
MYEF2 9 16.8 3 7 5 
SAFB 13 30.3 3 28 18 
RBBP6 13 9.2 3 8 11 
VDAC1 10 43.5 4 12 12 
DDX3X;DDX3Y 9 19 4 12 9 
SF3B5 3 43 4 8 7 
SNRPE 2 25 4 6 7 
BRD2 14 29.7 4 28 17 
PRPF19 14 39.5 5 27 9 
SNRNP40 13 48.7 5 24 10 
FIP1L1 10 26.2 5 10 11 
SREK1 12 27.1 5 26 14 
BRD3 8 28.2 5 12 12 
SLTM 16 19.1 5 31 30 
SNRPD1 3 37.8 5 7 10 
SMU1 14 33.5 5 19 12 
CDC5L 23 41.1 5 33 11 
NFKB1 6 10.5 6 7 7 
RUVBL2 17 39.1 6 22 13 
SYNCRIP 21 46.2 6 48 53 
DDX41 19 35.3 7 24 14 
BRD4 12 15.6 7 33 30 
DDX17 17 39.5 7 48 19 
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BUB3 12 48.6 7 15 16 
RCC2 28 64.2 7 83 70 
PUF60 1 52.8 8 44 34 
BCLAF1 13 23.8 8 18 16 
ZFR 19 23.5 8 20 14 
PRPF38B 15 32.8 8 28 23 
NPM1 12 49.8 8 15 13 
PDS5A 43 42.3 9 93 35 
PPIG 11 14.5 9 19 15 
XRN2 11 15.2 10 28 12 
SRSF10 12 58.2 10 24 12 
U2AF2 12 42.9 11 36 29 
HNRNPA1;HNRNPA1L2 18 54.1 12 43 66 
ACIN1 25 24.9 15 68 21 
NUMA1 42 27.2 16 63 34 
ILF2 17 51.3 16 45 26 
LUC7L2 0 32.1 16 29 17 
HNRNPA2B1 23 66.3 16 66 90 
SRRM1 1 23.4 16 66 35 
DDX21 38 51.5 20 106 60 
IFI16 22 53.9 21 102 97 
HNRNPU 45 50.1 29 170 149 
HNRNPC;HNRNPCL1 8 40.8 30 63 59 
STRBP 26 47.7 30 46 41 
DDX23 30 38.8 35 55 41 
DDX46 42 43.5 38 60 54 
HNRNPR 2 48 42 109 107 
SRRM2 68 30.7 44 153 58 
EFTUD2 48 62.4 48 108 57 
SF3B1 43 39.2 49 69 63 
DDX5 26 51.1 52 106 93 
PRPF8 96 47.7 85 206 107 
Table 16: The 293 specific proteins found in the group No LMP1 from Mass Spectrometry 
pull-down during DNA Affinity chromatography  
 
 
Table Mass Spectrometry LMP1 Group 
Gene Unique 
Peptides 
Sequence 
Coverage 
Control 
MS Count 
LMP1 
MS 
Count 
N=1 
LMP1 
MS 
Count 
N=2 
SUPT6H 25 18.8 0 35 5 
TBL2 13 43.1 0 22 1 
RBM12B 6 7 0 11 11 
ZNF106 12 17.9 0 18 4 
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USF2 4 26.1 0 13 8 
CHD1L 11 18.7 0 11 8 
TXLNA 10 22 0 17 2 
NACA 3 59.2 0 12 6 
NOL6 11 12.9 0 16 2 
SDAD1 10 19.2 0 14 4 
IRF2 5 50.4 0 9 8 
URB1 13 8.1 0 14 2 
RPL10 8 39.7 0 8 8 
LLPH 2 13.2 0 7 8 
AKAP8L 3 4.6 0 9 5 
GTF2B 7 26.9 0 12 1 
PURB 5 18.3 0 5 8 
RARA;RARB 2 5.4 0 6 6 
MTA2 8 19.9 0 11 1 
MDN1 4 0.8 0 7 4 
RPL29 3 20.8 0 7 4 
DDX51 6 11.7 0 7 2 
ZBTB7B 4 6.5 0 6 3 
PRRC2B 2 1.7 0 6 2 
BTF3 3 29.6 0 7 1 
COPA 4 4 0 2 6 
LOC102288414 3 23.2 0 5 3 
ZBTB48 3 5.7 0 6 2 
FER1L4 1 1 0 5 2 
THAP1 4 21.1 0 5 2 
CRAMP1L 4 4.4 0 6 1 
CHAMP1 4 4.8 0 5 2 
NOP16 3 24.2 0 4 3 
ZNF800 3 4.5 0 5 2 
MYNN 3 14.7 0 3 4 
ZHX1 3 3.8 0 4 2 
EBI3 2 8.3 0 5 1 
PARP14 6 5.5 0 5 1 
LARP4B 2 3.1 0 4 2 
ABI1 2 5.8 0 4 2 
ELF1 1 5 0 3 2 
PHAX 3 8.1 0 4 1 
ZNF770 3 30.3 0 3 2 
PRDM15;ZNF298 3 2.7 0 3 2 
RRP7A 2 8.6 0 4 1 
MYSM1 3 3.6 0 4 1 
NCAPH 1 2 0 3 2 
RREB1 2 1.1 0 2 3 
ZCRB1 3 24.4 0 4 1 
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TNRC18 3 1.2 0 3 2 
MAK16 3 11.7 0 4 1 
CCDC106 2 8.6 0 2 3 
ZBTB7A 2 6.7 0 1 4 
SUPT4H1 2 30.3 0 3 1 
KIAA1429 1 1 0 3 1 
COPB2 4 7.3 0 1 3 
ZNF668 1 2.1 0 2 2 
TOP3A 2 6 0 2 2 
RPL34 2 12.8 0 3 1 
ZNF91;ZNF595 2 2.6 0 3 1 
CPB1 1 3.4 0 2 2 
CWF19L2 2 3.2 0 1 3 
BCL11A 3 5.4 0 2 2 
ZNF93 3 7.5 0 3 1 
SHOC2 2 4.3 0 3 1 
ZNF286A;ZNF286B 2 5.1 0 2 2 
ZFP62 2 3 0 3 1 
ZNF24 1 3.5 0 2 2 
RPL26L1 1 44.1 0 2 1 
CHRAC1 2 46.4 0 2 1 
ZBTB17 3 16.6 0 2 1 
ZNF687 2 1.4 0 1 2 
ZNF593 3 40.3 0 1 2 
REST 2 2.3 0 1 2 
NOL12 2 10.3 0 2 1 
HIRIP3 5 17.3 0 21 8 
RPL8 5 19.5 0 22 8 
STK10 11 15.5 0 10 4 
ABT1 6 20.6 0 10 4 
FAM60A 4 33.9 0 10 3 
RPL32 6 42.1 0 9 3 
RBM19 6 6.4 0 17 6 
NOC3L 4 7.6 0 7 1 
ZNF768 6 13.2 0 13 10 
NEIL1 6 22.8 0 6 3 
RRP15 2 6.7 0 6 3 
RPL13 4 31.7 0 6 2 
VRK3 3 7.1 0 5 2 
HBS1L 14 39.8 0 20 1 
USP42 2 2.5 0 4 1 
HOXB4 6 18.3 0 12 12 
ERI1 5 21.2 0 6 2 
ZNF652 4 6.6 0 3 2 
TRIM4 1 5.4 0 3 1 
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SMNDC1 2 13.9 0 3 1 
 2 17.8 0 7 4 
NOC2L 19 23.9 0 45 30 
TREX1 12 39.1 0 20 17 
RPL27A 8 39.9 0 27 34 
RPL23 10 72.9 0 41 15 
RPL36A;RPL36AL;RPL36A-
HNRNPH2 6 29.6 0 12 13 
PPAN 17 38.5 0 44 12 
CEBPZ 28 29.1 0 57 32 
CTCF 17 21 0 45 37 
BANF1 11 80.9 0 31 21 
RPL35 6 35.8 0 20 27 
YY1;YY2 10 21 0 29 20 
RPL17 9 47.4 0 25 13 
WDR76 19 32.3 0 33 19 
UHRF2 9 14 0 12 6 
CPSF3L 2 4.4 0 6 6 
NCKAP1L 10 10.8 0 17 6 
RPL26;KRBA2;RPL26L1 1 60.7 0 25 53 
PDCD11 72 39.3 0 225 168 
WBP11 2 15.5 0 10 11 
DDX27 15 18.7 0 30 12 
HOXC4 5 22.3 0 8 4 
MYBBP1A 13 12 0 13 4 
SUPT5H 19 23.5 0 28 15 
ZNF629 10 13.9 0 19 11 
REL 13 26.6 0 24 14 
RPL22 5 62.1 0 4 7 
RPL23A 14 44.3 0 55 61 
FTSJ3 13 17.5 0 34 9 
RPF2 4 17.6 0 5 3 
RBM28 26 31.5 0 42 21 
ISG20L2 5 19.3 0 11 5 
RPL7L1 11 37.4 0 20 10 
CMSS1 17 53.3 0 45 26 
SP110 4 9.9 1 4 3 
CHD1 9 5.5 1 13 10 
MAP4K4;TNIK;MINK1 7 9.2 1 7 3 
CDK11A;CDK11B 5 5.4 1 6 3 
HJURP 5 9.6 2 3 3 
RPS9 10 37.6 2 12 7 
RPL39P5;RPL39 3 23.5 2 7 7 
RPL38 7 57.1 3 32 23 
HSPB1 6 31.7 4 22 14 
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RPS26;RPS26P11 3 31.3 4 13 6 
TOP1 53 53.6 4 217 225 
RPS23 3 16.1 5 11 11 
TOP2B 34 46.4 7 57 40 
RPS6 14 41 9 45 30 
RPS4X 16 55.5 11 40 16 
UBTF 45 47 14 133 156 
Table 17: The 144 specific proteins found in the group LMP1 from Mass Spectrometry 
pull-down during DNA Affinity chromatography 
 
